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Abstract
Metastasis is responsible for 90% of cancer-related deaths. An important early step in the
metastatic process is epithelial-to-mesenchymal transition (EMT) of tumor cells.
Stimulated by TGFβ signaling, cells that undergo EMT have increased migratory and
invasive potential, resulting in metastasis and the development of tumors at a secondary
site. The TGFβ type 3 receptor (TβR3) has been implicated in modulating TGFβ signaling,
yet its functional outcomes remain unclear. My findings demonstrated that TβR3 silencing
does not alter TGFβ-dependent Smad2 phosphorylation in neither H1299, not A549 nonsmall cell lung carcinoma cells but reduces Smad2 expression in H1299 cells. Interestingly,
although TβR3 knockdown did not alter mRNA expression of EMT markers, it resulted in
the reduction of TGFβ-dependent EMT protein markers. Finally, inhibition of EMT
attenuated cellular invasion while enhancing chemotactic migration. Together, these
results suggest that TβR3 has a distinct role in modulating EMT and cellular motility in a
Smad-independent manner.

Keywords
Transforming growth factor beta (TGFβ), Smad signaling, transforming growth factor
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Introduction
1.1
1.1.1

Lung Cancer
Disease Process

Lung cancer is separated into two main categories based on cellular size: small cell lung
carcinoma and non-small cell lung carcinoma (NSCLC). First characterized by Watson and
Berg (1962), small cell lung carcinoma represents 15% of all lung cancer diagnoses and,
despite being responsive to initial chemotherapeutic treatments, is more aggressive than
non-small cell lung carcinoma. The remaining 85% of lung cancers are non-small cell lung
carcinomas, which include histological subtypes such as adenocarcinoma, squamous cell
carcinoma, and large cell carcinoma (Riihimaki, 2014). Since NSCLC is less responsive to
chemotherapy and represents the majority of lung cancer diagnoses, this thesis will focus
on investigating non-small cell lung carcinomas.
Riihimaki et al. (2014) observed that the most prevalent histological subtype of cancer in
its cohort was adenocarcinoma, representing 43% of all lung cancer diagnoses. While no
significant sex difference was found, 80% of all lung cancer diagnoses were made in
patients who were 60 years of age or older. This year, only 750 Canadians under the age
of 50 are expected to be diagnosed with NSCLC, whereas 28,000 diagnoses are expected
among those who are 50 years of age or older (Canadian Cancer Society, 2017). Survival
is also reduced as the age of diagnosis increases. Patients diagnosed under the age of 40
have the highest five-year survival rate of 45%, while patients diagnosed at 80+ have the
lowest at 10% (Canadian Cancer Society, 2017).
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Smoking tobacco is associated with 85% of all cases of lung cancer in Canadian patients
(Canadian Cancer Society, 2017). Other risk factors include inhalation of radon, asbestos
or air pollution, in addition to genetic predisposition. Despite the associated health
concerns, approximately 15% of Canadian men and women remain daily smokers
(Statistics Canada, 2015).
Epithelial in origin, lung cancer is responsible for approximately 20, 000 deaths in Canada
annually, accounting for 26% of cancer-related deaths and 8% of all deaths (Canadian
Cancer Society, 2017). Behind prostate cancer in males, breast cancer in females, and
nonmelanoma skin cancer, lung cancers account for one of the most prevalent cancer
subtypes (Canadian Cancer Society, 2017). The discrepancy between incidence and
mortality rate of lung cancer reinforces its severity and aggressiveness. Furthermore,
survival rates of patients diagnosed with lung cancer are poor, with more than 50% of
patients dying within 1 year of initial diagnosis (U.S. National Institutes of Health, 2016).
The five-year survival rate of lung cancer is 55% when diagnosis shows a localized tumor
(U.S. National Institutes of Health, 2016).

1.1.2

Lung Cancer Metastasis

Metastasis involves the migration of tumor cells away from the primary tumor, local
invasion, transport through the bloodstream and/or lymphatic system, and relocation into
the secondary location. Metastatic processes are an important target for cancer research, as
the prevention of metastasis drastically improves prognoses and treatment outcomes. The
seed and soil hypothesis, first described by Paget (1889), expressed the idea that cancer
cells migrated throughout the body, and would only form a secondary tumor after reaching
a fertile tissue that promotes development. However, the advancement of recent genetic
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technologies has led to studies that counter this view by suggesting cancer cells are preprogrammed to target specific regions of the body as secondary tumor sites (Bloom et al.,
2004). Common locations of secondary tumors arising from primary lung carcinomas
include brain (39%), bone (34%), and liver (20%), although metastasis to the liver or bone
yields worse prognoses than to nervous system tissue. Riihimaki et al. (2014) showed that
various types of lung cancer have different preferred locations of secondary tumor
development. For example, adenocarcinomas tend to metastasize to bone or liver tissue,
while squamous cell lung cancers develop secondary tumors primarily in the nervous
system and liver. Tumor metastasis occurs prior to diagnosis in 84% of cases, reducing a
patient’s five-year survival rate to 4% (U.S. National Institutes of Health, 2016).
Additionally, the average survival rate of patients exhibiting metastatic lesions is reduced
from 13 to 5 months when compared to patients with localized lung tumors (U.S. National
Institutes of Health, 2016; Riihimaki et al., 2014).

1.1.3

Epithelial to Mesenchymal Transition and Metastasis

In response to the TGFβ signaling cascade, epithelial-to-mesenchymal transition (EMT)
involves the transition of adherent epithelial cells to mesenchymal cells, which possess an
enhanced ability to migrate, invade, and resist apoptosis (Gunaratne & Di Guglielmo, 2013;
Kalluri & Neilson, 2003). Although EMT is necessary during normal embryogenesis,
fibrotic wound healing, and organ development, it is commandeered by epithelial tumor
cells to metastasize to secondary sites in the body (Kalluri & Weinberg, 2009).
Epithelial-to-mesenchymal transition (Figure 1.1) involves the reduced expression of
epithelial markers including E-cadherin, claudins, and occludins, which are necessary in
establishing cell-to-cell junctions (Kalluri & Weinberg, 2009). Alterations in epithelial
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Figure 1.1 Characterization of cellular epithelial-to-mesenchymal transition (EMT):
an early metastatic process.
Epithelial cells express several cell-cell adhesions, including E-cadherin and ZO-1 to form
tight junctions (orange), adherens junctions (green), and desmosomes (blue) which limit a
cells migratory potential (1). Facilitated by transcription factors Snail, Slug, Zeb1, Zeb2,
and Twist, epithelial cells lose cellular contacts, undergo changes in polarity, and develop
an enhanced ability to migrate and invade (2). A reduction in epithelial markers is matched
by an upregulation of mesenchymal markers, which include N-cadherin and vimentin. It is
important to note that EMT is a reversible process, and mesenchymal cells can reacquire
epithelial phenotype through a mesenchymal-to-epithelial transition (MET).
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protein expression results in morphological changes such as the dissociation of tightjunctions, adherens-junctions, desmosomes, and the loss of apical-basal polarity (Zhang et
al., 2016; Angadi & Kale, 2015). Complementarily to the loss of epithelial markers is the
increased expression of mesenchymal markers, including N-cadherin, vimentin, and αsmooth muscle actin (Angadi & Kale, 2015). Cellular transformation into a more
mesenchymal phenotype promotes front-back polarity and cytoskeletal reorganization. In
epithelial cells, actin is primarily cortical but it is rearranged through EMT to create stress
fibers, thus bolstering migratory and invasive potential (Thiery, 2002). This invasive
potential is exacerbated by the upregulation of matrix metalloproteinases, with their ability
to degrade components of the extracellular matrix (Angadi & Kale, 2015).
E-cadherin is a traditional marker of epithelial cells, as its high expression level is
indicative of established cell-cell junctions (Baum & Georgiou, 2011). These cellular
connections are modulated via the cytoplasmic domain of E-cadherin, which interacts with
various components of adherens junctions including p120 and β-catenin (Harris & Tepass,
2010). The maintenance of epithelial integrity is important in preventing metastatic
dispersion of cancer cells.
Epithelial-to-mesenchymal shift is an early process involved in tumor metastasis (Figure
1.2). Cells undergoing EMT develop increased migratory and invasive potential, leading
to local invasion of their surrounding stroma and intravasation into the bloodstream. Bodily
dissemination occurs, followed by extravasation of cancer cells into secondary sites of
micrometastasis. It is important to note that EMT is a reversible process, and cells undergo
mesenchymal-to-epithelial transition (MET) to reacquire epithelial characteristics after
reaching a targeted body region. Supplementary to distant metastasis, cells that have locally
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Figure 1.2 Processes involved in tumor metastasis.
Cancerous cells dissociate from a primary tumor and locally invade after undergoing EMT
(1; EMT is denoted by the colour shift). Cells can then intravasate into the bloodstream (2)
or reacquire an epithelial phenotype to locally recur (3). Once in the bloodstream, tumor
cells disseminate (4) to a secondary location, where they adhere to endothelial cells and
extravasate into surrounding tissues (5). Finally, cellular phenotype is reversed via
mesenchymal-to-epithelial transition (demonstrated by a change in colour) and a
secondary, micrometastatic tumor is developed (6).
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invaded have the potential to reversibly shift back from a mesenchymal to an epithelial
state. Thus, the initiation of EMT promotes both metastasis to a secondary location, as well
as local recurrence after treatment (Kalluri & Weinberg, 2009; Thompson & Haviv, 2011).

1.2
1.2.1

TGFβ Signaling
TGFβ in Cancer

Under normal physiological conditions, transforming growth factor-beta (TGFβ) signaling
acts as a tumor suppressor by controlling cell growth, proliferation, and differentiation
(Kalluri & Weinberg, 2009). However, dysregulation of the TGFβ signaling pathway in
tumor cells results in the promotion of cancerous characteristics. Late stage tumors often
upregulate the expression of TGFβ ligands, which possess context-specific tumor
promoting effects such as angiogenesis, evasion of immune defenses, and epithelial-tomesenchymal transition (Elliot & Blobe, 2005; Rahimi & Leof, 2007; Xu et al., 2009).
Activity of the TGFβ signaling pathway is elevated in tumor cells, establishing a target for
chemotherapeutic treatments.

1.2.2

TGFβ Family of Ligands and Receptors

Pathway activation is initiated via ligand binding to TGFβ receptors, which triggers a
downstream signaling cascade. TGFβ1, TGFβ2, and TGFβ3 are tightly regulated cytokines
that are synthesized and secreted as precursor proteins that remain in a latent state until
pro-peptide N-terminal regions are cleaved by MMP2, MMP9, or thrombospondin
(Flanders et al., 2016; Konrad et al., 2007; Yu & Stamenkovic, 2000; Schultz-Cherry &
Murphy-Ullrich, 1993). All three forms of TGFβ are highly conserved, with 80% amino
acid sequence homology (Robertson & Rifkin, 2013). Despite genetic similarity, structural
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variation influences ligand function. For example, TGFβ3 possesses a more flexible
structural conformation than the rigid TGFβ1, resulting in difference in binding affinity for
different receptors (Huang et al., 2014; Konrad et al., 2007).
There are three main receptors involved in the TGFβ signaling pathway, termed TGFβ type
1 (TβR1), type 2 (TβR2), and type 3 (TβR3) receptors. The genes that encode TβR1 and
TβR2 contain multiple splice variants with different exons in sequences corresponding to
the extracellular domain. However, alternative splicing does not occur during TβR3 mRNA
maturation, resulting in a single protein isoform (Konrad et al., 2007). Each of these three
receptors possesses an extracellular, transmembrane, and cytoplasmic domain, yet the
functionality of each region varies among receptor types (Figure 1.3). Since TβR1 lacks a
canonical extracellular ligand binding site, TGFβ signaling relies on ligand association
with TβR2 to transform external stimuli into intracellular communication. While both
TβR1 and TβR2 transduce signaling via intracellular serine/threonine kinase domains, that
of TβR2 is constitutively active and phosphorylated. The cytoplasmic region of TβR1 also
incorporates a 20-amino acid glycine-serine rich (GS) pocket which, when
unphosphorylated, is occupied by FKBP12. This binding pocket is phosphorylated by
TβR2 and undergoes a conformational change to dissociate from FKBP12 and open the
domain to R-Smad interactions (Wrana et al., 1994).
TβR1 and TβR2 are internalized via clathrin-dependent and clathrin-independent
mechanisms. Following ligand binding, the TβR1/2 heteromeric complex is internalized
via clathrin-coated pits to facilitate TGFβ signaling from the early endosome. However,
cell surface receptor levels are also regulated by clathrin-independent endocytosis. When
present in lipid-raft membranes, clathrin-independent internalization of TβR1/2 into
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Figure 1.3 Structure of membrane bound TGFβ receptors I, II, and III.
The type III TGFβ receptor (TβR3) facilitates TGFβ signaling by binding and presenting
TGFβ ligand to the type II TGFβ receptor (TβR2) (1), and by binding and relocating
TβR1/2 receptors in membrane domains (2). Additionally, membrane bound TβR3 can be
cleaved at sites recognized by plasmin and matrix metalloproteinases into soluble factors,
which bind and sequester TGFβ ligand from interacting with TβR1/2 (3).
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caveolin-1

positive

vesicles

causing

Smurf2-mediated

ubiquitination

and

proteasomal/lysosomal degradation (Di Guglielmo et al., 2003).
Mutations in TβR1 or TβR2 often arise in epithelial tissues, interfering with TGFβdependent apoptosis. Furthermore, inactivating mutations in TβR2 occur more frequently
than TβR1, primarily in the cytoplasmic kinase domain responsible for phosphorylating
TβR1 (de Caestecker et al., 2000).
TGFβ receptor level is regulated through mechanisms that involve post-translational
changes. An inhibitory-Smad, Smad7, recruits an E3-ubiquitin ligase, Smurf2, to associate
with TβR1 and TβR2, inducing ubiquitin-dependent proteolysis (Kavsak et al., 2000). Like
TβR1 and TβR2, TβR3 internalization is a ligand-independent process. Furthermore,
modifications to the glycosaminoglycan region of TβR3 has no effect on receptor
internalization or degradation (Finger et al., 2008a). In addition, the short cytoplasmic tail
of TβR3 is critical for docking of β-arrestin2, which initiates receptor endocytosis through
intracellular processes (Finger et al., 2008a). TβR3 endocytosis is important for both Smaddependent and Smad-independent signaling. A decrease in the phosphorylation of Smad2
and p38 MAP kinase, following blockade of TβR3 internalization by nystatin, suggests that
TβR3 has specific functions dependent on endocytosis (Finger et al., 2008a).
While TβR2 is restricted to binding TGFβ1 and TGFβ3, TβR3 is able to bind all three
forms of TGFβ ligand (Finger et al., 2008a). Thus, TβR3 possesses the unique ability to
induce TGFβ signaling of TGFβ2. In addition to TβR3 uniquely binding TGFβ2, it also
binds with greater affinity than either TGFβ1 or TGFβ3 (Mendoza et al., 2009). TβR1 is
unable to bind any TGFβ ligand isoform as it does not possess an extracellular ligand
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binding domain (Finger et al., 2008a). Notably, regardless of ligand subtype, TβR2 binds
more strongly to TGFβ that is being presented by TβR3 than it does to free ligand (LopezCasillas et al., 1993). Binding affinity of certain ligands is also dependent on receptor
interactions. When TβR1 is not physically associated with TβR2, TβR2 possesses low
affinity for TGFβ1 (Lopez-Casillas et al., 1994). However, formation of a receptor complex
with TβR1 increases TβR2 binding affinity for TGFβ1, while the affinity for TGFβ2
remains low. Additionally, cells become more responsive to TGFβ stimulation following
expression of exogenous TβR3 (Lopez-Casillas, 1993).
Although the TGFβ1, TGFβ2, and TGFβ3 have similar functions in vitro, genetic
inactivation of individual ligands in mice reveals distinctly different phenotypical
outcomes. Further in vivo research has revealed unique roles that are performed by
specific TGFβ subtypes. For example, wound healing during embryogenesis is associated
with high levels of TGFβ3, but not TGFβ1 or TGFβ2 (Whitby & Ferguson, 1991).

1.2.3

SMAD Function and Regulation

Smad proteins, named after shared similar genetic sequences with Sma and Mad proteins,
function as downstream effectors of TGFβ signaling by acting as receptor substrates (Liu
et al., 1996). Of the eight Smad proteins involved in TGFβ signaling, only five, Smad-1, 2, -3, -5, and -8, act as substrates for type 1 receptor activation, and are therefore referred
to as receptor-regulated Smads (R-Smads). Smad4, a common-Smad (Co-Smad), is not a
substrate for type 1 receptor phosphorylation, and instead forms complexes with R-Smads
prior to nuclear localization. Finally, inhibitory-Smads (I-Smads), Smad6 and Smad7,
repress TGFβ signaling by interfering with R-Smad interactions with Co-Smad or activated
receptors (Massague, 1998).
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Approximately 500 amino acids long, R- and Co-Smad proteins are comprised of an Nterminal Mad-homology 1 domain (MH1), a central linker region, and a C-terminal MH2
domain. Interestingly, the MH1 domain is absent in I-Smads. Additionally, although a Cterminal MH2 domain is conserved among all Smad proteins, functionality of this domain
differs between Smad subtypes. When unphosphorylated, Smad2 and Smad4 exist as
homotrimers (Wu et al., 2001b). However, upon Smad2 phosphorylation, Smad2/4 form a
heterodimer, or a heterotrimer (2 R-Smads, 1 Co-Smad) via binding of MH2 domains (Wu
et al., 2001a). R-Smad interaction with receptor kinases is dependent on the connection
between loop 3 domain in the carboxy-terminal region of R-Smads with a loop 1 domain
of the receptor. Co-Smads do not possess a loop 3 domain, and are therefore unable to bind
to, or be phosphorylated by, activated type 1 receptors (Massague, 1998). Receptor kinases
are responsible for phosphorylation of R-Smad C-terminal S-S-X-S domain (Wrana, 2000).
Specifically, TβR1 and activin type 1 receptors target Smad2 and Smad3 for
phosphorylation, while BMP type 1 receptors are primarily associated with Smad1, Smad5,
and Smad8.
MH1 and MH2 domains are separated by a proline rich central linker region, which in
Smad1, Smad2, and Smad3 is phosphorylated by serine/threonine MAP kinases Erk1 and
Erk2 to impede Smad nuclear localization and TGFβ signaling (Wrana, 2000; Kretzschmar
et al., 1999).
Ski and Sno are oncogenes without catalytic function. However, interactions with the
Smad2/4 complex negatively regulates canonical TGFβ signaling. Ski and Sno have been
shown to simultaneously bind to Smad2 and Smad4, hindering their ability to modulate
gene transcription. Specifically, Ski has been shown to competitively bind Smad4 MH2
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domain, preventing its association with phosphorylated Smad2 (Wu et al., 2002).
Additionally, when interacting with Smad2/4 complexes, Ski and Sno act as corepressors
by binding promoter regions and inhibiting gene transcription (Akiyoshi et al., 1999;
Stroschein et al., 1999).
Inactivating mutations in the MH2 domains inhibit Smad2/4 complex formation and are
evident in cancer cells (Wu et al., 2001b). Mutations can occur in the MH2 domain of
Smad2, Smad3, and Smad4, most frequently in the binding sites responsible for
heteromeric complex formation (Fleming et al., 2012). Missense mutations are more
common than nonsense, and Smad4 is generally more prone to genetic mutations than RSmads (Fleming et al., 2012; de Caestecker et al., 2000).
Hairpin loops of Smad4 MH1 domains bind to Smad binding elements (SBE) in the
promoter regions of target genes (Shi et al., 1998). Smad2/4 weakly binds to DNA on its
own and relies on interactions with other co-activators, co-repressors, or transcription
factors to induce transcriptional change (Wrana, 2000).

1.2.4

Canonical and Non-Canonical TGFβ Signaling

Canonical Transforming Growth Factor-beta (TGFβ) signaling (Figure 1.4) is responsible
for the regulation of many cellular processes, including cellular apoptosis, differentiation,
and growth (Kalluri & Weinberg, 2009). Two ubiquitously expressed, membrane bound
serine/threonine kinase receptors initiate TGFβ signaling upon ligand binding: TGFβ Type
1 Receptor and TGFβ Type 2 Receptor. Upon ligand binding, two constitutively
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Figure 1.4 Schematic displaying the canonical TGFβ signaling pathway.
TGFβ ligand binding to the serine/threonine kinase TGFβ type II receptor (TβR2) induces
the transphosphorylation of the TGFβ type I receptor (TβR1) (1). After the TβR1/2
complex is internalized into an early endosome, Smad anchor for receptor activation
(SARA) recruits intracellular signaling protein to be phosphorylated by TβR1 (2). After
phosphorylation, Smad2 dissociates from the TβR1, forms a complex with Smad4 to
translocate into the nucleus, and facilitates gene transcription (3).
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phosphorylated type 2 receptors interact with two type 1 receptors. This heterotetrameric
complex is internalized into the early endosome, where downstream signaling processes
are

initiated.

Following

endocytosis,

constitutively

phosphorylated

TβR2

transphosphorylates TβR1. TβR1 then phosphorylates intracellular proteins Smad2 and
Smad3 at C-terminal residues. Smad2/3 are referred to as receptor-activated Smads (RSmad) since they are responsive to external stimuli (Siegel & Massague, 2003; Finger et
al., 2008b; Zhang et al., 2016). This association of TβR1 and Smad2 is mediated by Smad
anchor for receptor activation (SARA) (Di Guglielmo et al., 2003). SARA has been shown
to enhance Smad2 interaction with activated TβR1 by retaining Smad2 localization near
the plasma membrane and increasing its proximity to the receptor (Tsukazaki et al., 1998).
Once phosphorylated, Smad2 is released from the TβR1/2 complex into the cytoplasm and
forms a complex with a common-mediated Smad, Smad4 (Massague, 1998; Wrana, 2000).
Smad2/4 complexes undergo constant shuffling between the cytoplasm and the nucleus,
which is dependent on the phosphorylation of Smad2 (Xu & Massague, 2004). The
accumulation of Smad2/Smad4 complex in the nucleus facilitates transcription factor
binding to DNA, initiating the transcription of genes that inhibit cell growth and
proliferation in non-cancerous cells (Massague, 1998).
However, while TGFβ signaling acts as a tumor suppression in healthy cells, TGFβ activity
in tumor cells is tumor promoting. An intact TGFβ signaling pathway crosstalks with other
signaling pathways including the MAPK, receptor tyrosine kinase (RTK), Wnt, and Notch
pathways, exacerbating tumorigenic processes (Terai et al., 2011; Principe et al., 2014;
Zavadil et al., 2004). Previous research has investigated the role of Type I and II receptors
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on metastatic potential, yet the contributions of a third type of TGFβ receptor, the TGFβ
Type III receptor remain unclear (Docea et al., 2012; Zhang et al., 2014).
In an atypical fashion, TGFβ signaling has been linked to integrin-linked kinase (ILK)
expression. Studies have demonstrated that ILK forms complexes with TβR2 and protects
the receptor from ubiquitination and degradation (Vi et al., 2015). Furthermore, ILK
expression may be necessary for Smad2 phosphorylation and for the facilitation of
downstream TGFβ-dependent transcriptional responses (Vi et al., 2011). Li et al. (2003)
have shown that ILK expression is involved in EMT processes including cadherin shift,
migration, and invasion, which can be abrogated by ILK inhibition via HGF.
TGFβ1-induced signaling can occur independent of both Smad2 phosphorylation and ILK.
Non-canonical, or Smad-independent, TGFβ signaling through RhoA (a small GTPase)
and its downstream kinase, ROCK, has been implicated in actin reorganization and cell
migration, two necessary characteristics of epithelial-to-mesenchymal transition (Masszi
et al., 2003; Bhowmick et al., 2001). However, RhoA activation was not observed to
disturb cell-cell adherens junctions (Kaartinen et al., 2002). While both pathways are
dependent upon TGFβ ligand for activation, their parallel function influence EMT
separately.
Furthermore, TGFβ ligand triggers TβR1 phosphorylation of ShcA, which, after forming a
complex with Grb2 and Sos, induces Ras activation and the downstream activation of
Erk1/2 via tyrosine phosphorylation (Roskoski, 2012). Increased Erk activation through
the MAP kinase signaling pathway has been shown to enhance EMT in a TGFβ dependent
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manner, through a reduction in E-cadherin and an increase in N-cadherin expression
(Grande et al., 2002).

1.2.5

Regulation of EMT

The expression of epithelial and mesenchymal markers during EMT is regulated at both a
transcriptional and post-translational level. Regulation of E-cadherin expression at a
transcriptional level is repressed by several E-box binding transcription factors, including
Snail, Slug, ZEB1, and ZEB2 (Peinado et al., 2007). Through a separate means of
interaction, the helix-loop-helix transcription factor Twist also represses E-cadherin
expression, facilitating EMT (Peinado et al., 2007). Once translated, these proteins are
translocated to the nucleus, where the 5’ promoter region E-cadherin is bound, and
transcription is repressed (Peinado et al., 2007). However, the action of these EMT
regulating molecules may be dependent on cell-context. For instance, while it is well
established that transcription factor Snail is necessary for mediation of E-cadherin
expression, EMT in renal cells is Snail-independent (Li et al., 2003).
E-cadherin expression is also regulated post-translationally via tyrosine phosphorylation
or ubiquitination, promoting protein endocytosis and weakening cellular adhesions (Fujita
et al., 2002). In addition to transcriptional and post-translational methods of modulating Ecadherin expression, the degradative powers of matrix metalloproteinases (MMPs) have
also been linked to E-cadherin repression. While MMPs have classically been
characterized as tools used to remodel the extracellular matrix, recent studies have shown
E- and N-cadherin to be alternative substrates for MMP proteolytic cleavage. Furthermore,
cadherin cleavage by MMPs appears to be dependent on the makeup of surrounding
extracellular matrix, with collagen I and IV providing a microenvironment that was more

18

prone to degradation of both E- and N-cadherin by MMP14 when compared to fibronectin
(Covington et al., 2005).
microRNAs are single-stranded, non-coding oligomeric nucleotides, 20-25 nucleotides in
length, that bind to transcribed mRNA (Esquela-Kerscher & Slack, 2006). Once bound,
microRNAs have two separate regulatory functions: reduce mRNA stability or inhibit
protein translation (Esquela-Kerscher & Slack, 2006). Recently, microRNAs have been
investigated with regards to their ability to alter EMT. The downregulation of two families
of microRNA that share consensus seed sequences — miR-200 (miR-200a, -200b, -200c,
-141, -429) and miR-30 (miR-30a-5p, -30a-3p, -30e, -30e-3p) — have been linked to
enhanced epithelial-to mesenchymal transition and tumor metastasis (Schliekelman & Liu,
2014). Furthermore, a reduction in miR-200 family members has been correlated with
shortened survival of cancer patients (Mlcochova et al., 2016; Tang & Xu, 2015).
Specifically, miR-200 family microRNAs target and repress the translation of mRNA
encoding E-cadherin repressors ZEB1/2 (Mlcochova et al., 2016). In essence, these
microRNAs act as repressors of E-cadherin transcriptional repressors. Furthermore, a
double-negative feedback loop exists between expression of ZEB1 and the miR-200
family, as ZEB1 is able to bind to the promoter region of miR-200 genes and inhibit
transcription (Schliekelman & Liu, 2014). Treatment with miR-200 family members has
been shown rescue TGFβ-dependent E-cadherin repression, and the suppression of EMT
(Mlcochova et al., 2016; Zhang et al., 2012). Correspondingly, it is suggested that EMT
may be suppressed in cancer patients via the upregulation of these microRNAs, or
therapeutic treatment with exogenous oligomers that mimic microRNA sequences.
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EMT can also be modulated independent of TGFβ signaling. Expression of other ligands,
including HGF and BMP-7, has been shown to inhibit EMT by preventing and even
reversing TGFβ1-dependent cadherin shift both in vitro and in vivo (Yang & Liu, 2001;
Zeisberg et al., 2003). In contrast, EMT processes can also be enhanced by the activation
of other signaling cascades. EMT has been promoted by bFGF2 initiation of the FGF
signaling pathway (Strutz et al., 2002). Additionally, phosphorylation of Erk1/2 via the
MAP kinase cascade has been implicated in EMT progression (Schramek et al., 2003). Wnt
and notch, and their ligands β-catenin and Jagged-1 respectively, have also been
established as drivers of EMT (Ye & Weinberg 2016).

1.2.6

TGFβ, EMT, and Autophagy

In addition to TGFβ signaling, EMT progression has recently been linked to autophagic
processes. Autophagy is a mechanism through which cells degrade and process cellular
proteins in response to stress (Parzych & Klionski, 2014). Through the formation of protein
complexes involving ULK1 kinase, Atg13, and Atg17, double-membraned vesicles called
autophagosomes are employed to facilitate endocytosis (Degenhardt et al., 2006).
Following autophagosome formation, autophagic proteins Atg5, Atg12, and Atg16 are
responsible for the recruitment of LC3B1 (Matsushita et al., 2007), which undergoes
proteolytic cleavage by Atg4 to generate LC3B2 and is incorporated into the
autophagosomal membrane (Satoo et al., 2009). Next, fusion with lysosomes facilitates the
degradation of cellular components. Since LC3B remains integrated in the autophagosome
until lysosomal fusion is completed, LC3B is the gold-standard as a marker of autophagy.
Recently published studies have demonstrated that chemical inhibition of autophagy by
Bafilomycin-A1 or chloroquine-di-phosphate inhibits TGFβ-induced EMT in cells from
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retinal pigment epithelium, hepatocellular carcinoma, and NSCLC. (Alizadeh et al., 2018;
Dash et al., 2018; Wu et al., 2018). Furthermore, knockdown of autophagic complex
proteins Atg5 and Atg7 has been shown to inhibit EMT by reducing the protein expression
of mesenchymal markers vimentin, Snail, and Slug (Jiang et al., 2018, Dash et al., 2018).
Additionally, an increase in TGFβ- or rapamycin-induced autophagy simultaneously
exacerbated epithelial-to-mesenchymal transition in both a time- and concentrationdependent manner (Wu et al., 2018).
In 2014, Nitta et al. found that TGFβ-induced cellular invasion was significantly hindered
by autophagy inhibition, establishing a functional link between autophagy, EMT, and
metastasis to supplement previously studied changes in cellular morphology.
A study by Pang et al. (2016) demonstrated that autophagosome formation was necessary
to induce E-cadherin degradation via the autophagosome-lysosomal degradation pathway.
From their observations, an established mechanism displayed Src activation in response to
autophagy, resulting in β-catenin phosphorylation and association with phosphorylated
Smad2. This β-catenin/Smad2 complex translocates to the nucleus and initiates
transcriptional upregulation of ILK, which has been implicated in EMT processes (Pang et
al., 2016). In addition to its role as a structural component of adherens junctions by binding
to the cytoplasmic domain of E-cadherin, β-catenin also regulates E-cadherin expression
by stabilizing Smad2 DNA binding as a co-activator of gene transcription (Kim et al.,
2009). As such, the relationship between the expression of LC3B, an autophagic marker,
and ILK, an EMT facilitator, is positive.

21

1.2.7

Matrix Metalloproteinases

Matrix metalloproteinases (MMPs) are a group of 23 enzymes that carry out several
functions, one of which is to degrade and remodel specific components of the extracellular
matrix (ECM) and are classified into different groups based on structure or substrate.
MMP1, MMP13, and MMP14 are collagenases, primarily responsible for degrading
collagen I, II, and III, while MMP2 and MMP9 digest gelatin, collagen IV and collagen V
(Lu et al., 2011). Under normal physiological conditions, MMPs play a vital role in
embryogenesis and wound healing (Cepeda et al., 2017). However, their ability to degrade
and remodel components of the extracellular matrix (ECM) promotes the migration and
invasion of tumor cells.
The expression patterns of MMPs varies widely and are present in both tumor cells and the
surrounding stroma (Okada et al., 1995; Sato et al., 1994). Membrane-bound MMP-14 has
been characterized in cancer-associated fibroblasts, tumor-associated macrophages, and
endothelial cells (Chun et al., 2004; Sakamoto & Seiki, 2009) However, MMP-15 and -16
are primarily expressed in endothelial cells. MMP14 expression is high in mesenchymal
cancers and sarcomas, facilitating invasion of tumor cells through microenvironments that
are rich in collagen (Apte et al., 1997).
MMP activity is tightly regulated. Translated as inactive zymogens, MMPs are only
activated following N-terminal proteolytic cleavage (Cepeda et al., 2017). Plasmin is a
common activator of collagenase MMPs, including MMP-1, -3, -8, -10, and -13 (Lu et al.,
2011). However, MMPs that possess a transmembrane domain (MMP-14, -15, -16, -24) or
have cytoplasmic C-termini anchored to glycosylphosphatidylinositol (GPI) (MMP-17,
MMP-25), are activated only by furin (Lu et al., 2011; Sohail et al., 2008). Furin binds a
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specific recognition site in the pro-peptide region, situated at the N-terminal end of the
catalytic domain (Pei & Weiss, 1995). Interestingly, certain gelatinase pro-MMP
zymogens must be activated by other MMPs. MMP-2 and MMP-9 are each activated by a
plethora of MMPs that can specifically interact with one of the two gelatinases, but not
both. Notably, all membrane-bound MMPs cleave pro-MMP-2, while pro-MMP-9 is
activated by the secreted MMPs of MMP-3, -10, and -13. Once activated, MMP-2 also has
the proteolytic potential to activate the zymogen of its fellow gelatinase MMP-9. (Lu et al.,
2011).
Additionally, a group of four tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, -4)
can selectively restrict the functional capabilities of specific MMPs. Dysregulation of
zymogen cleavage or TIMP expression by cancer cells can result in aberrant ECM
degradation, facilitating tumor metastasis (Jackson et al., 2017). In a stoichiometric 1:1
ratio, TIMPs reversibly insert an intrinsic cysteine disulfide bridge into the active domain
of MMPs, inhibiting their catalytic function (Jackson et al., 2017; Brew & Nagase, 2010).
The regulation of MMP activity by TIMPs in a stoichiometric fashion is important to
control not only degradation of the extracellular membrane, but also downstream cell
signaling (Cepeda et al., 2017; Frantz et al., 2010; Hynes & Naba, 2012). This is especially
relevant to membrane-bound MMPs that possess a cytoplasmic C-terminus. Thus, these
MMPs possess the intrinsic capability to modulate intercellular communication and
intracellular signaling by acting as a scaffold to promote cytoplasmic protein association.
Membrane-bound MMP14 can form a complex with TIMP-2 facilitating MAPK signaling
and phosphorylating downstream effector Erk1/2 (Pahwa et al., 2014; Sounni et al., 2010)
MMP14 has also been shown to induce NF-κB transcription (Cepeda et al., 2017).
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EMT transcription factors such as Snail, Zeb1/2, and Twist, have been shown to increase
membrane-bound MMP transcription in addition to repressing E-cadherin (Ota et al., 2009;
Huang et al., 2009; Liu et al., 2016). These EMT transcription factors influence metastasis
on two separate levels: releasing cell-cell junctional connections and promoting the
expression of proteolytic enzymes to degrade the extracellular matrix.

1.3
1.3.1

Transforming Growth Factor β Type 3 Receptor
TβR3 in Cancer

Transforming Growth Factor Type 3 receptor (TβR3), also referred to as betaglycan, is the
most abundantly expressed TGFβ receptor in normal epithelial cells and is ubiquitous
(Zhang et al., 2016). However, many cancer types have abnormally low expression levels
of TβR3, including breast, prostate, lung, and ovarian cancers, and reduction is further
enhanced as cancers develop into more advanced grades and later stages (Finger et al.,
2008a). These cancer types demonstrate that TβR3 expression is an active suppressor of
tumorigenicity, invasiveness, and progression (Zhang et al., 2016; Dong et al., 2007;
Turley et al., 2007; Finger et al., 2008b; Hempel et al., 2008). However, the reduction of
TβR3 is not due to aberrations in transcriptional, translational, or degradational processes.
Rather, loss of the chromosomal locus of TβR3, 1p31-32, has been demonstrated in
cancerous tumors (Dong et al., 2007, Turley et al., 2007). In lung cancer specifically, TβR3
mRNA and protein expression are both reduced due to loss of heterozygosity (Finger et al.,
2008b). Zhang et al. (2016) found that TGFβ1 stimulation suppresses both the mRNA and
protein expression of TβR3, in a dose-dependent manner (Hempel et al., 2008). However,
the mechanism by which this occurs is currently unclear.
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Conflicting literature has suggested that overexpression or silencing of TβR3 in various
cell types results in TβR3 acting as either a tumor promoter or suppressor (Criswell et al.,
2008; Finger et al., 2008b). In colon cancer cells, TβR3 acts as a tumor promoter, and
knockdown has been shown to inhibit cell viability, while reducing cell migration and
invasion (Liu et al., 2013). On the contrary, overexpression of TβR3 has been shown to
suppress migratory and invasive potential in non-small-cell lung carcinoma and
hepatocellular carcinoma (Finger et al., 2008b; Zhang et al., 2016). Additionally,
exogenous TβR3 following knockdown has been shown to inhibit invasion, and metastasis
both in the presence and absence of TGFβ (Dong et al., 2007; Turley et al., 2007, Sun et
al., 1997). Abnormally repressed TβR3 expression in late stage malignant cancers suggests
a possible involvement in suppressing cell migration, invasion, and in vivo tumorigenesis
(McLean & Di Guglielmo, 2010; Zhang et al, 2016; Criswell et al., 2008; Finger et al.,
2008b).
Additionally, the administration of TGFβ increased the migratory potential of
hepatocellular carcinoma cells. This suggests a link between the reduction in TβR3 and
cellular migration (Zhang et al., 2016).

1.3.2

Structure of TβR3

Genetic coding for TβR3 is made of a 225 kbp sequence on chromosome 1p33-p32
(Zakrzewski et al., 2016). Divided into 18 exons, TβR3 transcription is primarily regulated
by the more proximal of its two separate upstream promoter regions (Hempel et al., 2007;
Zakrzewski et al., 2016). The core protein of TβR3 is 851 amino acids in length, comprised
of a 766 amino acid extracellular region, transmembrane domain, and short, 42 amino acid
cytoplasmic tail, and exhibits a molecular weight of 100 kDa (Lopez-Casillas et al., 1994).
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The core molecular weight of TβR3 is 100 kDa, however specific composition of bound
extracellular chondroitin sulfate glycosaminoglycans (GAGs) may increase the molecular
weight to between 180 and 300 kDa (Zhang et al., 2016, Lopez-Casillas et al., 1994).
However, while modifications to GAG does not alter TβR3 internalization, functional
characteristics are impaired (Finger et al., 2008a). Importantly, ligand interaction with
TβR3 is weakened, suppressing downstream TGFβ signaling (Deng et al., 1999)
TGFβ Type 3 Receptor (Figure 1.3) is a membrane-anchored, heparin sulfate proteoglycan
that possesses a short cytoplasmic C-terminal tail (Finger et al., 2008a; Gatza et al., 2010).
The short cytoplasmic tail of TβR3 contains a PDZ binding motif, which is necessary for
binding to the constitutively phosphorylated site of TβR2 (Blobe et al, 2001a; LopezCasillas et al., 1991; Blobe et al., 2001b). This interaction is released following the
association of TβR1 to TβR2 (Blobe et al., 2001a). Tazat et al. (2015) also established that
TβR3 can bind TβR1 or TβR2 independent of one another or form a heterotrimer
containing all three TGFβ receptors. This cytoplasmic tail can also be phosphorylated at
its threonine 841 residue by TβR2, promoting the association of β-arrestin, and TβR3
endocytosis (Finger et al., 2008a). Independent of ligand, TβR3 can be internalized via
clathrin-dependent or -independent mechanisms. Notably, endocytosis of a βarrestin2/TβR2/TβR3 complex through a clathrin-independent sequence facilitates TβR3
degradation and suppresses both canonical and atypical routes of TGFβ signaling (Finger
et al., 2008a; Chen et al., 2003). Additionally, this tail may be responsible for anchoring
TβR3 to clathrin-mediated membranes, or lipid-raft membranes through clathrin and
flotillin, respectively (Finger et al., 2008a).
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However, TβR3 lacks the Ser/Thr kinase abilities of TGFβ Type 1 and 2 receptors, or any
other intrinsic enzymatic capabilities (Finger et al., 2008a, Zhang et al., 2016). As such, it
is unable to phosphorylate Smad2 and induce TGFβ signaling on its own. The facilitation
of TGFβ signaling is reliant upon the TβR1/2 complex, to which TβR3 presents TGFβ
ligand.
TβR3 differs from its TβR1 and TβR2 counterparts in more ways than simply lacking an
intracellular kinase domain. The extracellular domains of TβR1 and TβR2 are shorter than
that of TβR3 and are primarily constructed of cysteine residues (Attisano et al., 1993). On
the contrary, the N-terminal ectodomain of TβR3 is folded into two ligand binding regions,
separated by a linker region (Wang et al., 1991; Lopez-Casillas et al., 1991; Lopez-Casillas
et al., 1994; Mendoza et al., 2009). Together, these binding sites allow dual, independent
action of the receptor which are modulated by receptor cleavage (Gatza et al., 2010).
In addition to membrane-bound TβR3, the receptor can undergo ectodomain shedding by
proteolytic cleavage at two separate sites of the extracellular domain. This cleavage is
mediated by two membrane-bound matrix metalloproteinases, MT1-MMP (MMP14) and
MT3-MMP (MMP16), and plasmin (Velasco-Loyden et al., 2004; Zakrzewski et al., 2016).
MMP cleavage occurs at an extracellular site proximal to the transmembrane domain, while
plasmin cleavage is present in the more distal linker region that separate the two
extracellular binding domains of TβR3 (Figure 1.3). Ectodomain shedding released a
soluble form of TβR3, which can be detected in both the serum and the extracellular
domain (Gatza et al., 2010). Interestingly, the two forms of TβR3 possess different and
opposite actions with regards to TGFβ signaling. Interestingly, the invasive capabilities of
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NSCLC cells have been inhibited following culture in conditioned media containing
soluble TβR3 (Finger et al., 2008a).
TβR3 resembles certain structural components of Endoglin in each of its distal
extracellular, transmembrane, and intracellular domains (Lopez-Casillas et al., 1994). Like
TβR3, endoglin is a glycoprotein coreceptor of TGFβ, whose primary function is to induce
angiogenesis among endothelial cells (Burrows et al., 1995; Cheifetz et al., 1992).
Interestingly, despite these structural similarities, endoglin is only able to bind TGFβ1 and
TGFβ3 ligands but is unable to mimic the ability of TβR3 to bind TGFβ2 (Cheifetz et al.,
1992). Thus, TβR3 possesses unique binding capabilities that cannot be explained by
structural similarities with other receptors.

1.3.3

Modulation of TGFβ Signaling

TβR3 influences TGFβ signaling in three distinct ways (Figure 1.3). Two of these
functions act to promote TGFβ stimulation and response, while the third acts as a protective
neutralizer of excessive TGFβ signaling. Firstly, TβR3 facilitates TGFβ signaling by
binding either TGFβ1, TGFβ2, or TGFβ3 and presenting the ligand to TβR2 (LopezCasillas et al., 1993). From there, the canonical TGFβ signaling pathway can proceed as
previously described. Since TβR3 has the ability to bind TGFβ2, unique among TGFβ
receptors, TβR3 can initiate TGFβ-dependent processes that would otherwise not occur.
TβR3 further propagates TGFβ signaling by extending the half-life of TβR1 and TβR2
(Figure 1.5). Normally, TβR1 and TβR2 can be internalized in either a clathrin-mediated
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Figure 1.5 Complex role of TβR3 in TGFβ signaling.
In addition to facilitating or inhibiting TGFβ ligand association with the TβR1/2 complex,
TβR3 extends the half-life of TβR1/2 receptors. Normally internalized into caveolin-1
positive vesicles and ubiquitinated by Smurf2 for degradation (3), TβR1/2 can be relocated
out of lipid-raft membranes after binding to TβR3 (2). Thus, activation of the TGFβ
signaling pathway is prolonged (1).
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manner or through lipid-raft endocytosis (Finger et al., 2008a); distinct trafficking routes
that serve opposing functions. TβR1/2 complexes found in lipid raft membranes are
degraded through caveolae internalization and ubiquitination. Once endocytosed into
caveolin-1 positive vesicles, Smurf2, an E3 ubiquitin ligase, is responsible for tagging
TβR1 and TβR2 with ubiquitin, which targets the receptors for proteasomal/lysosomal
degradation (McLean & Di Guglielmo, 2010; Kavsak et al., 2000). TβR3 has also been
shown to bind and relocate TβR1/2 from lipid rafts to clathrin-coated pits, extending
receptor complex half-life (McLean & Di Guglielmo, 2010). This relocation may occur by
TβR3 binding TβR1 or TβR2 independently, in the absence or presence of TGFβ ligand
(McLean & Di Guglielmo, 2010). Furthermore, the relocation of these receptors has been
shown to reduce trafficking of TβR2 into caveolin-1 positive vesicles, while increasing
endocytosis into the early endosome. Extension of TβR1 and TβR2 half-life suggests that
TβR3 expression heightens basal levels of TGFβ signaling (McLean & Di Guglielmo,
2010)
Downstream signaling is propagated by the presentation of TGFβ ligand by TβR3 to
TβR1/2 complex, yet also reduced by inhibiting receptor complex formation by binding
and sequestering ligand from binding to the TβR1/2 complex (Siegel & Massague, 2003;
Zhang et al., 2016). Membrane-bound and soluble TβR3 possess different and opposite
actions with regards to TGFβ signaling. While membrane-bound TβR3 facilitates
canonical TGFβ signaling by increasing TGFβ ligand affinity for TβR2, soluble TβR3
binds TGFβ and interferes with ligand access to TβR2. Thus, ectodomain shedding of
TβR3 acts as a negative feedback mechanism to neutralize excessive TGFβ signaling,
suppressing uncontrollable cell proliferation (Mendoza et al., 2009). Additionally, Tazat et
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al. (2015) found that the ability of TβR3 to bind TβR1 or TβR2 competed with TβR1 and
2 from binding each other, thus reducing TGFβ signaling.

1.3.4

TβR3 Modulation of Other Signaling Pathways

TβR3 is not limited to binding the three TGFβ ligands. It also binds inhibin, and BMP-2, 4, and -7 through ligand binding sites. TβR3 also binds inhibin A, whose binding sites
overlap with those of TGFβ. Once bound, the TβR3/inhibin A complex interacts with, and
inhibits activin and BMP type 2 receptor signaling (Mendoza et al., 2009, Finger et al.,
2008a). TβR3 also interacts with basic fibroblast growth factor 2 (bFGF2), by way of GAG
modifications (Finger et al., 2008a), thus implying that TβR3 is involved in a number of
different signaling pathways, other than the one after which it was named.
Additionally, silencing of TβR3 has been shown to promote the phosphorylation of Akt
kinase, facilitating downstream pro-tumorigenic influences (Zhang et al., 2016). Akt is an
established anti-apoptotic factor, inactivating Bad and pro-caspase 9 through
phosphorylation, downregulating p53, and activating NF-κB (Downward, 2004; Pommier
et al., 2004; Mayo & Donner, 2002; Zhou & Hung, 2002).
The overexpression of TβR3 has been shown to suppress the viability of nasopharyngeal
carcinoma cells through the induction of apoptosis. TβR3 was demonstrated to increase the
intracellular concentration of divalent calcium, a known inducer of apoptosis. As a
mediator of apoptosis, TβR3 expression also activates apoptotic signaling through the
protein upregulation of Bad and Bax, the downregulation of Bcl-2 expression, and
inhibition of Bad phosphorylation. Together, these results suggest TβR3 acts as a tumour
suppressor through the anti-proliferative effect of apoptosis (Zheng, 2013).
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1.4

Rationale, Hypothesis, and Objectives

Previous studies have demonstrated that the tumor suppressive capabilities of TβR3 are
lost in late stage tumors due to a reduction in receptor expression. Primarily, TβR3
modulates the TGFβ signaling pathway by presenting TGFβ ligand to, and extending the
half-life of, the TβR1/2 receptor complex, in addition to soluble TβR3 sequestering
overabundant TGFβ to prevent excessive signaling. As such, it is of interest to investigate
the sensitivity and longevity of TGFβ-dependent signaling in the absence of TβR3.
Furthermore, examining the transcriptional expression of TGFβ-responsive genes could
elucidate the multi-layered regulatory nature of TβR3 on TGFβ signaling.
Although EMT is regulated through many pathways, an important driver of this premetastatic process is the TGFβ signaling cascade. Exploring the effect of TβR3 silencing
on EMT through alterations in epithelial and mesenchymal markers may reveal TGFdependent and -independent influences on EMT.
TGFβ signaling and EMT are established promoters of cell migration and invasion, which
are both phenotypical characteristics of cancerous tumors. Thus, studying the migratory
and invasive capabilities of TβR3 silenced non-small-cell lung cancer cells can reveal a
functional process that is regulated by TβR3.
Based on these studies, since TβR3 is posited to facilitate TGFβ signaling, thereby inducing
EMT and enhancing cellular migratory and invasive potential, I hypothesize that silencing
TβR3 will suppress TGFβ signaling, shifting cells into a more epithelial phenotype and
inhibiting migration and invasion.
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Based on this hypothesis, my overall objectives are to:
1) Determine how TβR3 influences TGFβ signaling in NSCLC cells.
2) Assess the role of TβR3 in regulating TGFβ-dependent epithelial-to-mesenchymal
transition of NSCLC cells.
3) Investigate the downstream functional implications of TβR3 on cell migration and
invasion.
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Materials and Methods

2.1

Antibodies, Primers, and Reagents

The following antibodies, primers, and reagents were used in applicable western blotting
and qPCR analyses.
Table 2.1 Primary and secondary antibodies used for western blotting.
Target

Supplier

Product Number

Dilution

E-Cadherin (mouse)

BD Biosciences

610182

1:1000

GAPDH (rabbit)

Cell Signaling

2118S

1:2000

LC3B1/2 (rabbit)

Cell Signaling

2775S

1:1000

N-Cadherin (mouse)

BD Biosciences

610921

1:1000

Smad2 (mouse)

BD Biosciences

610843

1:1000

pSmad2 (rabbit)

Cell Signaling

3101

1:1000

TGFBR3 (goat)

R&D Systems

AF-242-PB

1:1000

Tubulin (mouse)

Sigma

T4026

1:2000

Goat HRP from donkey Santa Cruz

Sc-2020

1:25 000

Mouse HRP from goat

Pierce

PI31430

1:25 000

Rabbit HRP from goat

Pierce

PI31460

1:25 000
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Table 2.2 Primer sequences used for qPCR.
Primers were designed to correspond with human proteins using Integrated DNA
Technologies Realtime PCR tool and supplied by Invitrogen. All sequences are 5’ to 3’.
Target
Gene

Protein

Forward

Reverse

Coding
Sequence

TGFBR3

TβR3

CGGGAGATATGGATGAAGGAG

CATGTTGAAGGTGATGTTTCCG

CCDS55614.1

SNAI1

Snail

AATCGGAAGCCTAACTACAGCG

GTCCCAGATGAGCATTGGCA

CCDS13423.1

SNAI2

Slug

ATACCACAACCAGAGATCCTCA

GACTCACTCGCCCCAAAGATG

CCDS6146.1

SERPINE1

PAI-1

CATCCCCCATCCTACGTGG

CCCCATAGGGTGAGAAAACCA

CCDS5711.1

SMAD7

Smad7

GTGTTGCTGTGAATCTTACGG

TCGGGTATCTGGAGTAAGGAG

CCDS59317.1

CDH1

E-Cadherin

CCCACCACGTACAAGGGTC

CTGGGGTATTGGGGGCATC

CCDS82005.1

CDH2

N-Cadherin

CCCAAGACAAAGAGACCCAG

GCCACTGTGCTTACTGAATTG

CCDS11891.1

ARRB2

Β-Arrestin2

AATCTTCCATGCTCCGTCAC

CGAATCTCAAAGTCTACGCCG

CCDS58504.1

MET

MET

GACTCCTACAACCCGAATACTG

ATAGTGCTCCCCAATGAAAGTAG

CCDS47689.1

PRICKLE1

Prickle1

TGAGACCAGAGCAGATCCAG

AAAGACTGGCAATACCGTACC

CCDS8742.1

SMAD2

Smad2

GATCCTAACAGAACTTCCGCC

CACTTGTTTCTCCATCTTCACTG

CCDS11934.1

TGFBR1

TβR1

ACATGATTCAGCCACAGATACC

GCATAGATGTCAGCACGTTTG

CCDS47998.1

TGFBR2

TβR2

GAGCTCCAATATCCTCGTGAAG

TATCTTGCAGTTCCCACCTG

CCDS33727.1

MMP1

MMP1

GCACAAATCCCTTCTACCCG

AACAGCCCAGTACTTATTCCC

CCDS8322.1

MMP14

MMP14

TGCCTACCGACAAGATTGATG

ATCCCTTCCCAGACTTTGATG

CCDS9577.1

HPRT

HPRT

TGGCGTCGTGATTAGTGATG

AACACCCTTTCCAAATCCTC

CCDS14641.1
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Table 2.3 Reagents used for cell processing and data collection.
Reagent

Supplier

Product Number

Application

Clarity™ Western ECL
Substrate

BioRad

170-5060

Western blotting

DC™ Protein Assay

BioRad

Protein Assay

Reagent A

500-0113

Reagent B

500-0114

Reagent C

500-0115

E.N.Z.A.® Total RNA
Kit I

OMEGA bio-tek R6834-01

RNA Isolation

iScript™ Reverse
BioRad
Transcription Supermix
for RT-qPCR

1708841

Reverse Transcription

Lipofectamine®
RNAiMAX

Invitrogen

13778-150

Transfection

Matrigel Matrix

BD Biosciences

356237

Transwell Invasion

BLUeye Prestained
Protein Ladder

FroggaBio

PM007-0500

Western blotting

siRNA medium GC
content Control

Ambion

siRNA against

Ambion

439240

Transfection

Bioline

BIO-98020

qPCR

Transfection

TGFBR3
SensiFAST™ SYBR
No-ROX Kit
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2.2
2.2.1

Cell Culture and Transfection
Cell Culture

NCI-H1299 (hereafter termed H1299) non-small-cell lung carcinoma cells (ATCC® CRL5803™) were cultured in RPMI-1640 medium with L-glutamine and sodium bicarbonate
(Sigma R7858-500ML) and supplemented with 10% fetal bovine serum (FBS). A549
NSCLC cells (ATCC® CCL-185™) were cultured in Kaighn’s modification of F-12 Ham
nutrient mixture with L-glutamine and sodium bicarbonate (F12K; Sigma N3520-10X1L)
medium containing 10% FBS. All cells were maintained at 37°C in a humidified
atmosphere containing 5% CO2.

2.2.2

Cell Transfection

H1299 and A549 cells were plated and transfected using Lipofectamine® RNAiMAX
reagent (Invitrogen) as per manufacturer’s recommendations. Specifically, 100 µL of
OptiMEM medium was used as a diluent for appropriate volumes of each Lipofectamine®
RNAiMAX and siRNA in separate 1.5 mL microcentrifuge tubes. The volumes of
Lipofectamine® RNAiMAX and siRNA corresponded to a 3:1 ratio. After vortexing,
solutions containing OptiMEM and siRNA were pipetted into their paired tube containing
appropriate volumes of OptiMEM and Lipofectamine® RNAiMAX and mixed by
pipetting. Solutions were incubated at room temperature for five minutes, then pipetted in
a drop-wise fashion into their corresponding cell plates. Cells were incubated for 48 hours
with the transfection agents prior to downstream applications.
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2.3

TGFβ Administration

For experiments that required TGFβ1 (hereby referred to as TGFβ) administration, cells
were rinsed three times with phosphate buffered saline (PBS) and serum-starved in growth
media containing 0.2% FBS (low-serum) overnight. The following morning, TGFβ ligand
was diluted to a specific concentration (as indicated in individual experiments) in culture
medium containing 0.2% FBS and vortexed. Spent media was aspirated, cells were washed
with PBS, and fresh medium supplemented with TGFβ was added. All control cells were
cultured in low-serum medium lacking TGFβ.
When investigating TGFβ sensitivity and longevity, cells were incubated with a specific
concentration of TGFβ (dose response – 0 pM, 1 pM, 2.5 pM, 5 pM, and 10 pM; time
course – 250 pM) at 37°C for 30 minutes. Experiments using a concentration gradient were
then lysed. To assess a signaling time course, media containing 250 pM TGFβ1 was
aspirated and one set of cell plates, one control and one TβR3 silenced, were lysed as a 30minute timepoint. Remaining plates were rinsed three times with PBS. Culture media
containing 0.2% FBS was added to cells, which were incubated at 37°C and lysed either 1
hour, or 4 hours later.
When investigating protein markers of EMT, following transfection and serum-starvation,
cells were incubated with 250 pM TGFβ in a reverse manner. In this regard, cells to be
treated with TGFβ for 48 hours were initially supplemented with TGFβ, while remaining
plates were cultured in media containing low-serum media without TGFβ. Twenty-four
hours later, fresh low-serum media including 250 pM TGFβ was added to plates designated
for 24- and 48-hour exposures to TGFβ. After an additional 24 hours, all cells, including a
48-hour low-serum condition, were lysed.
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All experiments examining transcriptional response to TGFβ involved cells that were
treated with 250 pM TGFβ in low-serum media for 24 hours, after undergoing transfection
and overnight serum-starvation.

2.4

Cell Lysis and Protein Assay

Following appropriate incubations, cells were rinsed with PBS. Next, a lysis buffer
comprised of 50 mM Tris pH 7.5, 1 mM EDTA, 0.5% Triton X-100, 150 mM sodium
chloride was used in conjunction with phosphatase and protease inhibitors 2.5 mM sodium
fluoride, 10 mM sodium pyrophosphate, 50 µM PMSF, and 1 mg/mL pepstatin A. This
solution was pipetted onto the cells and rocked at 4°C for 20 minutes. Cells were scraped,
and lysates were pipetted into individual 1.5 mL microcentrifuge tubes to be centrifuged at
4°C for 10 minutes at 15 000 rcf. Supernatants were transferred to separate tubes and
sample prep buffer (30% glycerol, 10% 1.5M Tris pH 6.8, 1.2% sodium dodecyl sulfate,
0.018% bromophenol blue, 15% β-mercaptoethanol) and stored at -20°C.
Using the DC™ Protein Assay system (BioRad) as per manufacturer’s instructions,
concentrations of protein samples were determined prior to the addition of sample prep
buffer. A Beckman Coulter DU® 730 Life Science UV/Vis Spectrophotometer was used
to measure absorbance values relative to a standard curve and to calculate protein
concentration.

2.5

SDS-PAGE and Western Blotting

For SDS-PAGE, separating gels containing 10% acrylamide (15% to separate LC3B1 from
LC3B2) were used in conjunction with 5% acrylamide stacking gels. Following gel
polymerization and the setup of a running apparatus, samples were heated at 90°C for 5
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minutes. A BLUeye Prestained Protein Ladder (FroggaBio) was used as a reference in
comparison to separation of total protein. Next, volumes corresponding to 50 µg of protein
sample were loaded and electrophoresed at 120 V. Following protein separation, a wet
transfer technique was employed to transfer proteins from SDS-acrylamide gels onto
nitrocellulose membranes at a constant amperage of 350 mA for 2 h. Nitrocellulose
membranes were then stained using Ponseau S (15% acetic acid, 4 mg/mL Ponseau S) to
visualize total protein. Membranes were then cut at appropriate protein sizes and Ponseau
S was removed using tris-buffered saline-tween 20 (TBST; 50 mM Tris, 150 mM sodium
chloride, 0.05% Tween-20, pH7.5).
As a method of blocking non-specific antibody binding, membranes were rocked at room
temperature for 1 hour in 5% skim milk in TBST. After blocking, membranes were
incubated overnight at 4°C on a rocker, in appropriate primary antibodies diluted in TBST.
The next day, primary antibody solutions were removed, and membranes were washed with
TBST three consecutive times for 10 minutes each. Next, membranes were incubated in
appropriate secondary antibodies, conjugated to horseradish peroxidase, rocking at room
temperature for 1 hour. An additional round of three 10-minute washes with TBST
preceded membrane coating with Clarity™ Western ECL Substrate (BioRad) per
manufacturer’s instructions. A VersaDoc Imaging System (BioRad) was used to visualize
luminescent proteins, and densitometry was completed via QuantityOne 1-D Analysis
Software (BioRad).

2.6

RNA Isolation and cDNA Synthesis

Following TGFβ incubations, an E.N.Z.A.® Total RNA Kit I (OMEGA bio-tek) was used
per manufacturer’s instructions to isolate total RNA, and eluted RNA was stored at -80°C.
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Prior to reverse transcription, the concentration and purity of isolated RNA was assessed
using a NanoDrop 2000 spectrophotometer (ThermoFisher Scientific). Next, 1 µg of RNA
was mixed with iScript™ Reverse Transcription Supermix for RT-qPCR (BioRad) per
manufacturer’s instructions, and reverse transcription was performed in a DNA Engine
(BioRad) with parameters of 25°C for 5 minutes, then 46°C for 20 minutes, and 95°C for
1 minute to generate cDNA. cDNA was then stored at -20°C.

2.7

Quantitative Polymerase Chain Reactions

For qPCR, master mixes comprised of 0.6 µL 10 mM forward primer, 0.6 µL 10 mM
reverse primer, 4.3 µL nuclease-free water, and 7.5 µL SensiFAST™ SYBR (Bioline) were
added to 2 µL of sample cDNA, per reaction, depending on the number of genes or samples
being studied. Quantitative polymerase chain reactions were performed by a CFX96™
Real-Time System and C1000 Touch™ Thermal Cycler (BioRad), with PrimePCR
parameters optimized for SYBR. Samples were initially denatured at 95°C for 2 minutes.
Next, samples were cycled forty times through a denaturing step at 95°C for 5 seconds and
primer annealing at 60°C for 30 seconds. After forty cycles, samples were incubated at
95°C for five seconds. The efficiency and amplification factor of each primer set was
determined using a standard curve and calculated using Thermofisher Scientific qPCR
Efficiency Calculator.

2.8
2.8.1

Transwell Assays
Cell Migration

Following transfection, cells to be seeded in Transwell chambers were serum-starved using
culture media with 0.2% FBS for 4 hours. Transwell® Permeable Supports (Corning; 6.5
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mm Insert, 24 Well Plate, 8.0 µm Polycarbonate Membrane, REF#3422) were placed in
24-well plates with culture media containing either 0.2% or 10% FBS in the lower
chamber. After serum starvation, cells were lifted following cleavage of adhesion proteins
by Trypsin, counted, and diluted to a concentration of 250 000 cells/mL using low-serum
media. Next, 200 µL of cell suspension (corresponding to 50 000 cells) was pipetted into
the upper Transwell chamber and incubated for 24 hours at 37°C with 5% CO2.
The next day, cotton swabs soaked in PBS were inserted into the upper chamber and were
used to gently remove any adherent cells from the upper side of the membrane. Washes
with PBS removed any remaining non-adherent cells from the upper membrane and
cleaned cells that were adherent to the lower side of the membrane. Cells were then fixed
by 4% paraformaldehyde (PFA) for 10 minutes at room temperature, washed 5 times with
PBS, and permeabilized with 0.25% Triton X-100. Following 3 additional PBS washes, a
razorblade was used to precisely cut the Transwell membrane out of the supporting
apparatus. Excised membranes were then incubated in DAPI (1 µg/mL) in the dark for 5
minutes. One final wash with PBS prepped the membranes for mounting between a glass
slide and coverslip. When handling membranes, care was taken to not rub the underside of
the membrane and accidentally remove migrated adherent cells.
Visualization of migrated cells (5 fields/experimental condition) was completed using an
Olympus IX81 motorized inverted research microscope and InVivo software
(MediaCybernetics; Version 3.2.2 Build 45, 2007). Finally, the number of migrated cells
per field of view was quantified using ImageJ software (Version 1.51n).
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2.8.2

Cell Invasion

Cellular invasion was investigated using the same procedure as Transwell migration above,
with one addition: Prior to cell trypsinization and seeding, 50 µL of ice cold 1.02 mg/mL
Matrigel Matrix (BD Biosciences) diluted in low-serum culture media was added to the
upper chamber of each Transwell apparatus and incubated at 37°C. After allowing the
matrix to gel for 30 minutes, cells were trypsinized and the protocol described above was
performed.

2.9

Microarray Analysis

Following transfection of H1299 cells, total RNA was isolated using the E.N.Z.A. Total
RNA Kit (OMEGA bio-tek) as per the manufacturer’s instructions. Next, samples were
diluted to a concentration of 100 ng/µL and sent to the London Regional Genomics Center
(Robarts Research Institute, London, Ontario, Canada) for processing. Once received, the
use of an Agilent 2100 Bioanalyzer (Aligent Technologies) and an RNA 6000 Nano kit
(Caliper Life Sciences) evaluated RNA quality. Upon validation, single-stranded
complimentary DNA (sscDNA) was generated from 200 ng of total RNA via the Ambion
WT Expression Kit for Affymetrix GeneChip Whole Transcript WT Expression Arrays
(Applied Biosystems), and the Affymetrix GeneChip WT Terminal Labeling kit and
Hybridization User Manual (Affymetrix). Total RNA was then converted to cDNA and in
vitro transcription resulted in cRNA. Through this process, 5.5 µg of single stranded cDNA
was synthesized, end-labeled, and hybridized to Human GeneChip 2.0 arrays for 16 hours
at 45°C. To reduce human error, all steps involving liquid transfer were performed by a
GeneChip Fluidics Station 450 (Affymetrix). Next, GeneChips were scanned using a
GeneChip Scanner 3000 7G (Affymetrix) and probe level data was analyzed using
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Affymetrix Command Console v1.1. Partek Genomics Suite v6.5 was used to convert
probe data to gene level information, and an ANOVA was performed to determine
significance. Gene fold-change represents the average of two separate experiments
comparing gene expression in TβR3 silenced cells to control cells. A fold-change of ±1.75
was considered the cutoff for further investigation. Microarray False Discovery Rate and
multiple comparison tests were carried out using Partek Genomics Suite v6.5. Gene
ontology analyses were performed using PANTHER v13.1.

2.10

Statistical Analyses

Statistical analysis for a minimum of three biological replicates was conducted using
GraphPad Prism® 6 for Windows (Version 6.01). Unpaired t-tests, one-way ANOVA, or
two-way ANOVA analyses were performed, followed by Tukey’s post-hoc tests. Values
were considered to be statistically significant when p<0.05, which is denoted by asterisks
as specified in the figures below.
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Results

3

Results

3.1

The effect of TβR3 on TGFβ-dependent Smad2
phosphorylation in A549 and H1299 cells

To determine how TβR3 influences TGFβ signaling in NSCLC cells, I first assessed Smad2
phosphorylation. However, I first confirmed the expression of TβR3 in two NSCLC cell
lines, H1299 and A549 cells, and the knockdown efficiency of siRNA-mediated TβR3
silencing. I observed that H1299 cells indeed expressed TβR3 and interestingly, significant
TβR3 knockdown was observed even at the lowest concentrations of siTβR3 when
compared to equivalent concentration of scrambled negative control siRNA (siControl)
(Figure 3.1). Cells treated with 12.5 nM siTβR3 expressed 47% TβR3 when compared to
siControl. However, since I observed that 25 and 37.5 nM of both siTβR3 and siControl
resulted in approximately 25% of cell detachment from the culture dishes (data not shown),
this suggested that increased volumes of Lipofectamine might be toxic to the cells. In
contrast to H1299 cells, low basal expression of TβR3 in A549 cells prevented the
quantification of knockdown of the western blots (Figure 3.2a). Therefore, qPCR was
performed on mRNA extracted from both A549 and H1299 cells treated with 12.5 nM
siTβR3 or 12.5 nM siControl using primers for TβR3 (Table 2.2). Consistent with H1299
cells, A549 cells had significantly reduced TβR3 mRNA levels (Figure 3.2b). Based on
the western blotting and qPCR results, a concentration of 12.5 nM siTβR3 was used in all
following experiments investigating TβR3 expression in H1299 or A549 cells.
I first investigated the impact of TΒR3 knockdown on TGFβ signaling by measuring
Smad2 phosphorylation. First, sensitivity to different concentrations of TGFβ was
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Figure 3.1 Knockdown of TβR3 in H1299 cells by siRNA
a) H1299 cells were transfected with increasing concentrations of either siTβR3 or
siControl and incubated at 37°C for 48 hours. Cell lysates were then subjected to western
blotting for TβR3 or GAPDH (loading control).
b) Three separate experiments were carried out as described in panel a, imaged and
quantitated using the BioRad QuantityOne software. (Mean ± SD; One-way ANOVA with
Tukey’s post-hoc, *p<0.05)
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Figure 3.2 Knockdown of TβR3 in A549 cells by siRNA
a) A549 cells were transfected with increasing concentrations of either siTβR3 or siControl
and cultured at 37°C for 48 hours. Cell lysates were then subjected to western blotting for
TβR3 or GAPDH (loading control).
b) Relative mRNA expression of TβR3 in A549 and H199 cells transfected with 12.5 nM
siTβR3 or siControl and cultured at 37°C for 48 hours. RNA was isolated and subjected to
reverse-transcription qPCR analysis to assess TβR3 transcript levels. (Two-way ANOVA;
Mean ± SEM; N=3; Tukey’s post-hoc ****p<0.0001)
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measured by relative phosphorylation of Smad2. In both cell lines, TβR3 knockdown did
not significantly alter the increase of Smad2 phosphorylation in response to an increase in
TGFβ concentration (Figures 3.3, 3.4). Second, the maintenance of Smad2
phosphorylation was assessed using a time-course protocol. Briefly, following
administration of 250 pM TGFβ for 30 minutes, TGFβ was washed-out, replaced with
TGFβ free media, and lysed at various time points to determine the maintenance of
signaling following ligand removal. Both H1299 and A549 cells responded to 250 pM
TGFβ following 30 minutes, demonstrated by increased Smad2 phosphorylation (Figures
3.5, 3.6). Both cell lines also displayed similar levels of TGFβ signaling following TGFβ
washout, with Smad2 phosphorylation decreasing over time. Therefore, based on my
results, I conclude that neither A549 nor H1299 cells displayed altered TGFβ-dependent
Smad2 signaling sensitivity (amplitude of signal), nor longevity (time course of signaling),
following TβR3 knockdown. Interestingly, total Smad2 expression was insignificantly
reduced following TβR3 knockdown in H1299 cells when compared to matched controls
(Figure 3.5). However, a similar reduction in total Smad2 expression was not seen in A549
cells. Although the fraction of expressed Smad2 that had been phosphorylated was not
altered following TβR3 knockdown, there was a reduction in Smad2 phosphorylation when
compared to time- and concentration-matched controls. Thus, TβR3 knockdown may
reduce TGFβ signaling through suppressed Smad2 expression, rather than by regulating
phosphorylation processes. To investigate this possibility, I assessed downstream effects
of TGFβ signaling, the E-to-N cadherin shift that is observed during TGFβ-dependent
EMT.
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Figure 3.3 The effect of TβR3 knockdown on TGFβ-dependent Smad2
phosphorylation in H1299 cells
a) H1299 cells transfected with 12.5 nM siTβR3 or siControl were treated with the
indicated concentrations of TGFβ in serum-free media for 30. Cell lysates were then
subjected to western blotting for TβR3, phosphorylated Smad2 (pSmad2), Smad2 or
GAPDH (loading control).
b) Three separate experiments were carried out as described in panel a, imaged and
quantitated using the BioRad QuantityOne software, and expressed as phosphorylated
Smad2/total Smad2 (Relative pSmad2). (Two-way ANOVA; Mean ± SD; N=3; Tukey’s
post-hoc)
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Figure 3.4 The effect of TβR3 knockdown on TGFβ-dependent Smad2
phosphorylation in A549 cells
a) A549 cells transfected with 12.5 nM siTβR3 or siControl were treated with the indicated
concentrations of TGFβ in serum-free media for 30. Cell lysates were then subjected to
western blotting for phosphorylated Smad2 (pSmad2), Smad2 or GAPDH (loading
control).
b) Three separate experiments were carried out as described in panel a, imaged and
quantitated using the BioRad QuantityOne software, and expressed as phosphorylated
Smad2/total Smad2 (Relative pSmad2). (Two-way ANOVA; Mean ± SD; N=3; Tukey’s
post-hoc)
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Figure 3.5 Time course of Smad2 phosphorylation in H1299 cells following TβR3
knockdown
a) H1299 cells were transfected with 12.5 nM siTβR3 or siControl, incubated for 48 hours
at 37°C, and serum-starved overnight. Following incubation with 250 pM TGFβ for 30
minutes, media was replaced with serum-free media and cells were lysed at various time
points. Cell lysates were then subjected to western blotting for TβR3, phosphorylated
Smad2 (pSmad2), Smad2 or GAPDH (loading control).
b) Three separate experiments were carried out as described in panel a, imaged and
quantitated using the BioRad QuantityOne software, and expressed as phosphorylated
Smad2/total Smad2 (Relative pSmad2). (Two-way ANOVA; Mean ± SD; N=3; Tukey’s
post-hoc)
c) H1299 cells were transfected with 12.5 nM siTβR3 or siControl, incubated for 48 hours
at 37°C, and serum-starved overnight. Following incubation with 250 pM TGFβ for 30
minutes, media was replaced with serum-free media and cells were lysed at various time
points. Cell lysates were then subjected to western blotting for Smad2 or GAPDH (loading
control). The relative total Smad2 protein expression was normalized and graphed. (Twoway ANOVA; Mean ± SD; N=3; Tukey’s post-hoc)
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Figure 3.6 Time course of Smad2 phosphorylation in A549 cells following TβR3
knockdown
a) A549 cells were transfected with 12.5 nM siTβR3 or siControl, incubated for 48 hours
at 37°C, and serum-starved overnight. Following exposure to 250 pM TGFβ for 30
minutes, media was replaced with serum-free media and cells were lysed at various time
points. Cell lysates were then subjected to western blotting for phosphorylated Smad2
(pSmad2), Smad2 or GAPDH (loading control).
b) Three separate experiments were carried out as described in panel a, imaged and
quantitated using the BioRad QuantityOne software, and expressed as phosphorylated
Smad2/total Smad2 (Relative pSmad2). (Two-way ANOVA; Mean ± SD; N=3; Tukey’s
post-hoc)
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3.2
The effect of TβR3 silencing on TGFβ-dependent EMT
markers
As described by Kalluri & Weinberg (2009), hallmarks of EMT include reduced Ecadherin and increased N-cadherin protein expression when treated with TGFβ.
Investigating genes such as SNAI1 (Snail), SNAI2 (Slug), SERPINE1 (PAI-1), and Smad7
would demonstrate a mechanism by which TβR3 expression influences gene transcription
in a TGFβ-dependent manner. Interestingly, TβR3 knockdown did not significantly alter
gene transcription in the absence of TGFβ, in either cell line (Figure 3.7). However,
following TGFβ stimulation, a significant increase in expression of Smad7 mRNA was
found in the absence of TβR3 in both cell lines. This result was not demonstrated when
TGFβ was administered to control cells. Furthermore, the significant increase in SNAI1 in
response to TGFβ in control A549 cells was diminished when TβR3 was silenced. In
contrast, SNAI1 mRNA expression did not significantly increase in H1299 control cells
following TGFβ administration but did in TβR3 silenced cells.
I next carried out qPCR analysis to investigate E-cadherin and N-cadherin mRNA levels
in both cell lines. Following TβR3 knockdown, a significant increase in CDH1 (Ecadherin) expression was observed in A549 cells, but not in H1299 cells, regardless of
TGFβ administration (Figure 3.8), suggesting that the altered E-cadherin levels might be
post-translational. In contrast, A549 N-cadherin expression was significantly increased in
the presence of TGFβ (Figure 3.8b), yet no difference was seen between control and
knockdown conditions. Interestingly, I observed an additive effect between TβR3
knockdown and TGFβ administration in H1299 N-cadherin expression (Figure 3.8a).
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a)
a)

b)
b)
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Figure 3.7
Figure 3.7 TGFβ-dependent transcription in response to TβR3 knockdown
H1299 (a) and A549 (b) cells were transfected with 12.5 nM siTβR3 or siControl,
incubated for 48 hours at 37°C, and serum-starved overnight. Cells were then treated with
250 pM TGFβ for 24 hours and total RNA was isolated. qPCR analysis was carried out as
described in the materials and methods section and graphed. (One-way ANOVA; Mean ±
SEM; N=3; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001)
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a)

b)

Figure 3.8 Expression of cadherin mRNA in the absence of TβR3
Relative mRNA expression of E- and N-cadherin. H1299 (a) and A549 (b) cells were
transfected with 12.5 nM siTβR3 or siControl, incubated for 48 hours at 37°C, and serumstarved overnight. Cells were then treated with 250 pM TGFβ for 24 hours and total RNA
was isolated. qPCR analysis was carried out as described in the materials and methods
section and graphed. (One-way ANOVA; Mean ± SEM; N=3; *p<0.05, **p<0.01,
****p<0.0001)
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Therefore, while N-cadherin transcription was not found to be TGFβ dependent in control
H1299 cells, N-cadherin mRNA levels were significantly increased following TGFβ
administration in TβR3 knockdown cells.
Since TGFβ signaling has been shown to modulate EMT protein markers, we next explored
the expression of E-cadherin and N-cadherin to determine whether TβR3 expression
influences downstream phenotypic changes. Following supplementation with 250 pM
TGFβ for 0, 24, or 48 hours, A549 cells showed a canonical E- to N- cadherin shift.
However, knockdown of TβR3 dampened the TGFβ-dependent cadherin shift (Figure
3.10). Surprisingly, H1299 cells demonstrated an increase in both E-cadherin and Ncadherin over time (Figure 3.9). However, as seen with the A549 cells, TβR3 knockdown
interfered with TGFβ-dependent alteration in E- and N-cadherin levels. TβR3 silenced cells
did not exhibit and increase in N-cadherin protein levels in response to TGFβ, although
control cells did. Together, these results suggest that the knockdown of TβR3 dampens the
ability of TGFβ to induce an E to N cadherin shift in both A549 and H1299 cells, which is
consistent with the hypothesis that TβR3 promotes TGFβ-signaling.
When comparing E-cadherin protein expression to mRNA expression, basal expression
was observed to be consistently increased in TβR3 knockdown cells. Corresponding to
protein expression, mRNA levels were also reduced following TGFβ exposure in A549
cells and increased in H1299 cells. However, inconsistencies were present when examining
these relationships with N-cadherin. Protein expression level was reduced in response to
TGFβ stimulation, while mRNA expression was significantly increased in both cell lines.
The disconnect between mRNA and protein expression of N-cadherin in the presence of
TGFβ suggests a complex interplay between mRNA and protein expression, so I further
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a)
a)
a)

b)

b)

Figure 3.9 TβR3 knockdown on TGFβ-dependent cadherin shift in H1299 cells
a) H1299 cells were transfected with 12.5 nM siTβR3 or siControl, incubated for 48 hours
at 37°C, and serum-starved overnight. Cells were then treated with 250 pM TGFβ for the
indicated time points and lysed. Cell lysates were then subjected to western blotting for Ecadherin, N-cadherin or GAPDH (loading control).
b) Three separate experiments were carried out as described in panel a, imaged and
quantitated using the BioRad QuantityOne software. (Two-way ANOVA; Mean ± SD;
N=3; Tukey’s post-hoc *p<0.05, **p<0.01)
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a)
a)

b)

b)

Figure 3.10 TβR3 knockdown on TGFβ-dependent cadherin shift in A549 cells
a) A549 cells were transfected with 12.5 nM siTβR3 or siControl, incubated for 48 hours
at 37°C, and serum-starved overnight. Cells were then treated with 250 pM TGFβ for the
indicated time points and lysed. Cell lysates were then subjected to western blotting for Ecadherin, N-cadherin or GAPDH (loading control).
b) Three separate experiments were carried out as described in panel a, imaged and
quantitated using the BioRad QuantityOne software. (Two-way ANOVA; Mean ± SD;
N=3; Tukey’s post-hoc *p<0.05)

60

mined the microarray data for microRNAs that may alter EMT processes. Specifically,
microRNAs targeting E-cadherin repressors SNAIL, ZEB1/2, or E-cadherin directly,
would have the ability to modulate E-cadherin mRNA levels. However, the expression of
an important subset of EMT-regulating microRNAs, including the mir200 and mir30
families, were unaffected by TβR3 knockdown (Appendix Table 5).
As described in the introduction, the processes of autophagy and epithelial-tomesenchymal transition are related and positively correlated; i.e., as autophagy is induced,
so is EMT. As such, I used the autophagy protein LC3B as a marker of EMT and observed
that its expression is markedly reduced in both A549 and H1299 cells following TβR3
knockdown. A significant decrease was found in LC3B1 in A549 cells, regardless of TGFβ
administration (Figure 3.12). Similar results were found in H1299 cells, with TβR3
knockdown reducing expression of both LC3B1 and LC3B2 (Figure 3.11). However,
significance was only seen following 48 hours of TGFβ incubation.
Based on my observations that EMT markers were affected by TβR3 silencing, I next
investigated if this would result in altered cell migration or invasion.
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a)

b)

Figure 3.11 LC3B expression in H1299 cells following TβR3 knockdown
a) H1299 cells were transfected with 12.5 nM siTβR3 or siControl for 48 hours, serumstarved overnight, and treated with 250 pM TGFβ. Cell lysates were then subjected to
western blotting for LC3B or tubulin (loading control).
b) Three separate experiments were carried out as described in panel a. LC3B1 and LC3B2
were imaged and quantitated using the BioRad QuantityOne software. (Two-way
ANOVA; Mean ± SD; N=3; Tukey’s post-hoc *p<0.05)

62

a)

b)

Figure 3.12 LC3B expression in A549 cells following TβR3 knockdown
a) A549 cells were transfected with 12.5 nM siTβR3 or siControl for 48 hours, serumstarved overnight, and treated with 250 pM TGFβ. Cell lysates were then subjected to
western blotting for LC3B or tubulin (loading control).
b) Three separate experiments were carried out as described in panel a. LC3B1 and LC3B2
were imaged and quantitated using the BioRad QuantityOne software. (Two-way
ANOVA; Mean ± SD; N=3; Tukey’s post-hoc **p<0.01, ****p<0.0001)
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3.3

Cell migration and invasion in the absence of TβR3

Since cellular EMT was reduced in both A549 and H1299 cells following TβR3
knockdown, it was expected that the invasive potential of these cells would
correspondingly be reduced. Transwell assays were coated with Matrigel to measure
H1299 cell invasion. Following seeding and a 24-hour incubation period, cellular invasion
through Matrigel was significantly decreased in TβR3 knockdown cells when compared to
control cells (Figure 3.13).
We next sought to determine whether the role of TβR3 in TGFβ signaling and cadherin
shift could also reduce phenotypic changes in cell migration. Cell migration was
investigated using transwell assays. Contrary to my expectations, A549 and H1299 cells
exhibited a significantly greater migratory ability following TβR3 knockdown (Figure
3.14). Additionally, a greater number of H1299 cells migrated when compared to A549
cells. Since H1299 cells had previously metastasized to the lymph node, they may be more
mesenchymal than A549 cells and possess a greater migratory potential.
The diametrically opposite effect of TβR3 silencing on cell migration vs. invasion
suggested that a complex interplay of gene expression could be regulating effects. I
therefore assessed this via microarray analysis.
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a)

b)

Figure 3.13 The number of H1299 cells that invaded through Matrigel following TβR3
knockdown
(a) H1299 cells were transfected with 12.5 nM siTβR3 or siControl, incubated for 48 hours,
and serum-starved for 4 hours. Following trypsinization, 50,000 cells were seeded into
Transwell chambers (24-well, 8 µm pores) coated with 50 µL Matrigel (0.9 µg/µL) for 30
mins at 37°C. Media containing 0.2% FBS (SF) was placed in the upper chamber, and
either 0.2% or 10% FBS (S) in the lower chamber. Following 24 hours of incubation at
37°C, the cells were fixed with 4% PFA, permeabilized with 0.25% Triton X-100, and
stained using DAPI. Scale bar = 100 µm.
b) The number of cells that migrated through the filter was counted using ImageJ using 5
representative fields per cover slip and graphed. (Unpaired t-test; Mean ± SEM; N=3;
***p<0.001)
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a)

b)

c)

c
)

Figure 3.14 The number of A549 and H1299 cells that migrated following TβR3
knockdown
A549 (a) or H1299 (b) cells were transfected with 12.5 nM siTβR3 or siControl, incubated
for 48 hours, and serum-starved for 4 hours. Following trypsinization, 50,000 cells were
seeded into Transwell chambers (24-well, 8 µm pores). Media containing 0.2% FBS (SF)
was placed in the upper chamber, and either 0.2% (SF) or 10% FBS (S) in the lower
chamber. Following 24 hours of incubation at 37°C, the cells were fixed with 4% PFA,
permeabilized with 0.25% Triton X-100, and stained using DAPI. Scale bar = 100 µm.
c) The number of migrated cells was counted using ImageJ using 5 representative fields
per cover slip and graphed. (Unpaired t-test; Mean ± SEM; N=3; ***p<0.001)
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3.4
3.4.1

Changes in mRNA expression
Microarray Analysis

The disconnect between cellular migration and invasion following TβR3 knockdown
motivated the assessment of gene transcription on a wider scale. RNA isolated from H1299
cells following TβR3 knockdown was then analyzed by microarray gene chip analyses
(Figure 3.15). The most upregulated gene encoded matrix metalloproteinase 1 (MMP1),
with cells expressing +7.59-fold more MMP1 mRNA following TβR3 knockdown when
compared to control (Figure 3.15a). Notable genes of interest, including prickle planar cell
polarity protein 1 (PRICKLE1, +3.98), hepatocyte growth factor receptor (MET, +3.43),
and the notch receptor ligand jagged 1 (JAG1, +2.85), were also significantly upregulated.
In addition to MMP1, MMP14 was the only other matrix metalloproteinase to exhibit
significant alteration, with a fold-change of +1.78. Notably, the transcription of genes
involved in TGFβ signaling (Smad2, Smad4, Smad7) and EMT (E-cadherin, N-cadherin,
Snail, Slug) did not demonstrate significant changes. Numerous genes involved in cell
cycling and DNA replication were significantly downregulated, including cyclins E2
(CCNE2, -3.82), A2 (CCNA2, -3.00), and B2 (CCNB2, -2.53), in addition to various cell
division cycle proteins (CDC25C, CDC45, CDCA2) and cyclin-dependent kinases (CDK1,
CDK14). ZEB2, a Smad-binding transcriptional repressor of E-cadherin displayed a foldchange of -1.81, but curiously, the expression of its paralog, ZEB1, was unchanged. qPCR
was employed to validate the accuracy of the microarray, which was confirmed as no
significant change was seen between mRNA expression levels between the two techniques
(Figure 3.15b).

67

a)

b)

Figure 3.15 mRNA expression of selected genes from H1299 microarray analysis
Selected genes (most up- and downregulated genes, as well as the genes of TGFβ signaling
members) from (a) Affymetrix Human GeneChip 2.0 Microarray mRNA analysis (N=2)
and (b) validation by qPCR (Mean ± SEM; N=3) of H1299 cells transfected with 12.5 nM
siTβR3 or siControl and incubated at 37°C for 48 hours. Black dashed line denotes ±1.75
fold-change. Total RNA was isolated and microarray technique was performed by London
Regional Genomics Center.
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Quantitative polymerase chain reactions were also performed on mRNA isolated from both
A549 and H1299 cells following TβR3 knockdown and stimulation with TGFβ. Measuring
the mRNA expression of MMP1 and MMP14 would both validate microarray findings, as
well as determine the effect of TGFβ ligand on the upregulation of these genes. MMP1
mRNA expression was significantly upregulated in both cell lines, following TβR3
knockdown and incubation with exogenous TGFβ (Figure 3.16). MMP14 also
demonstrated a significant increase in both basal and stimulated mRNA expression.
Furthermore, TβR3 knockdown and TGFβ presence displayed an additive effect on the
expression of MMP1 and MMP14 in A549 cells. However, this relationship was
synergistic in nature in H1299 cells.

3.4.2

Gene Ontology Analysis

Using a subset of genes that exhibited a minimum microarray fold-change of +2.00 (Figure
3.17a) or -2.00 (Figure 3.17b), separate gene ontology analyses were performed using the
PANTHER Classification System to reveal cellular processes. The group of up-regulated
genes displayed greatest affinity for the pathways of cardiac right ventricle morphogenesis
and regulation of chromatin binding, demonstrating fold enrichments of 48.86 and 38.68,
respectively. Mirroring findings from the microarray analysis, pathways involving mitotic
and DNA regulation emerged from the group of genes that were significantly downregulated.
Interestingly, two relevant pathways were revealed when analyzing the cohort of upregulated genes: Regulation of chemotaxis and regulation of locomotion. These pathways
possessed fold enrichments of 10.37 and 3.98, respectively, and supported transwell
migration results. Inquiry into specific genes involved in these pathways yielded MET
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a)

b)

Figure 3.16 MMP1 and MMP14 mRNA expression following TβR3 knockdown
H1299 (a) and A549 (b) cells were transfected with 12.5 nM siTβR3 or siControl,
incubated for 48 hours at 37°C, and serum-starved overnight. Cells were then treated with
250 pM TGFβ for 24 hours and total RNA was isolated. qPCR was carried out for MMP1
or MMP14. (Two-way ANOVA; +/- SEM; N=3; *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001)
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a)

b)

Figure 3.17 Gene ontology analysis of microarray mRNA expression
Pathways involving genes that exhibited a fold-change of +2.00 or greater (a), and -2.00 or
less (b) as determined by microarray analysis of H1299 cells.
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being involved in both regulation of chemotaxis and locomotion, while JAG1 is important
in only the regulation of locomotion (Figure 3.18; Table 3.1; Table 3.2).
In this thesis, my results have demonstrated that the knockdown of TβR3 did not alter the
phosphorylation of Smad2 in response to a gradient of TGFβ concentrations, nor over time.
Additionally, TGFβ-dependent transcription was altered following TβR3 silencing, and
cadherin expression was suppressed, along with LC3B expression, in both A549 and
H1299 cells. Phenotypically, a greater number of cells migrated through Transwell assays
in the absence of TβR3, while fewer cells invaded through a Matrigel plug. Finally,
Microarray and qPCR analyses revealed the upregulation of MMP1 and MMP14, while
gene ontology analysis reported the upregulation of genes involved in the regulation of
chemotaxis and locomotion.
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Figure 3.18 Specific upregulated genes that regulate locomotion and chemotaxis
Fold-change of genetic hits involved in chemotactic and locomotion pathways reported in
gene ontology analysis.
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Table 3.1 Regulation of Chemotaxis
Gene

Protein

Average Microarray
Fold-change

THBS1

Thrombospondin-1

+2.03

SCG2

Secretogranin-2

+2.37

PTPRO

Receptor-type tyrosine-

+2.95

protein phosphatase O
EFNB2

Ephrin-B2

+2.13

CXCL1

Growth-regulated alpha

+2.30

protein
MET

Hepatocyte growth factor

+3.43

receptor
Table 3.2 Regulation of Locomotion (including above)
Gene

Protein

Microarray Fold-change

DPYSL3

Dyhydropyrimidinase-

+2.00

related protein 3
PTPRG

Receptor-type tyrosine-

+2.14

protein phosphatase gamma
HAS2

Hyaluronan synthase 2

+2.05

JAG1

Jagged-1

+2.85

SEMA3C

Semaphorin-3C

+2.38
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Discussion

4

Discussion

4.1

TGFβ-dependent Smad2 signaling after knockdown of TβR3

Despite previous studies that demonstrated the role of TβR3 modulating TGFβ signaling
(Figure 1.5), neither H1299 nor A549 cells exhibited a change in relative Smad2
phosphorylation in response to a gradient of TGFβ ligand (Figures 3.3, 3.4). Thus, TβR3
silencing may not alter the ability of TβR2 to associate with the TGFβ ligand. Additionally,
the knockdown of TβR3 was predicted to induce a faster return to basal Smad2
phosphorylation as measured by a washout time-course (Figures 3.5, 3.6). However, the
relative phosphorylation of Smad2 following TGFβ washout was not significantly different
when comparing TβR3 knockdown to control in A549 or H1299 cells.
Interestingly, when investigating Smad2 phosphorylation in H1299 cells over time, a
reduction in the expression of Smad2 was seen in both the presence and absence of TGFβ
ligand when compared to control (Figure 3.5). A reduction in Smad2 protein in H1299
suggests TβR3 expression may protect Smad2 linker regions from phosphorylation and
downstream degradative pathways. Erk1/2 is active in phosphorylating serine residues in
the linker region of Smad2 (Xu et al., 2012), which recruits E3 ubiquitin ligases to
ubiquitinate Smad2 and promote proteasomal degradation. MMP14 has been implicated in
activating Erk1/2 through the MAPK signaling cascade (Cepeda et al., 2017). An increased
MMP14 expression following TβR3 silencing may therefore facilitate Erk1/2 activation,
Smad2 linker phosphorylation, and subsequent degradation. Additionally, PI3K signaling
has been shown to modulate Smad2 degradation. Yu et al. (2015) demonstrated that PI3K
phosphorylation of specific tyrosine residues of the Smad2 linker region recruits ubiquitin
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ligase Nedd4L. Thus, although the fraction of total Smad2 that is phosphorylated remains
unchanged in response to TβR3 silencing, the reduction in absolute Smad2 phosphorylation
may suppress downstream TGFβ signaling and functional processes. Furthermore, TβR3
was more highly expressed in H1299 cells than in A549 cells, so protein knockdown may
have had a more significant physiological impact in H1299 cells than in A549. Thus,
silencing of TβR3 in H1299 cells may be more impactful on Smad2 expression than in
A549 cells. As such, a knockdown of this receptor may have a greater impact on Smaddependent TGFβ signaling in H1299 cells by reducing absolute Smad2 phosphorylation
through suppressed Smad2 expression, rather than by regulating kinase activity.
Contrary to my predictions, these results support the null hypothesis that the relative Smad2
phosphorylation level was not altered following TβR3 silencing. However, a reduction in
Smad2 protein via linker phosphorylation and degradation in H1299 cells may hinder
absolute Smad2 phosphorylation and suppress TGFβ signaling. This finding supports my
hypothesis, yet through the modulation of Smad2 expression rather than altering Smad2
phosphorylation.

4.2

TGFβ-dependent EMT marker analysis

First, steady-state mRNA expression of TGFβ responsive genes assessed transcriptional
changes in A549 and H1299 cells following TβR3 silencing. Notably, TβR3 silencing in
A549 cells prevented a significant increase in SNAI1 expression as was seen in control
cells, and induced a significant increase in Smad7 expression, in response to TGFβ in A549
cells (Figure 3.7b), suggesting that TβR3 silencing regulates transcription of different
genes in different ways. However, in H1299 cells, a significant increase was seen in SNAI1
in TβR3 silenced cells treated with TGFβ (Figure 3.7a). Thus, TβR3 silencing exhibits
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differential regulation of transcriptional response to TGFβ in a cell specific manner. Since
mRNA expression is altered in both cell lines, together with unchanged TGFβ-dependent
Smad2 phosphorylation, it can be concluded that both cell lines retain intact TGFβ
signaling cascades despite TβR3 silencing.
Interestingly, differential TGFβ response holds true for the CDH1 gene (E-cadherin).
When examining mRNA expression of EMT markers, a significant increase in E-cadherin
expression in A549 but not H1299 cells suggests TβR3 silencing shifts the cellular
phenotype to a more epithelial state in certain cell contexts (Figure 3.8). A comparative
increase in E-cadherin protein expression suggests a link between transcriptional and
translational or degradative regulation of E-cadherin by TβR3 (Figures 3.9, 3.10).
Therefore, silencing TβR3 enhances E-cadherin steady-state mRNA levels, which results
in increased E-cadherin protein generated by functional translational machinery.

In

addition to greater basal expression, E-cadherin responds to TGFβ in a traditional manner,
with both mRNA and protein expression decreasing in response to TGFβ, following
canonical EMT progression simply from a more epithelial baseline.
Interestingly, A549 cells expressed more E-cadherin protein than H1299 cells (Figure 3.9,
3.10). While A549 cells were removed from an adenocarcinoma primary tumor, localized
in the lung, H1299 cells were excised from lymph node (Giard et al., 1973; Giaccone et
al., 1992). Thus, H1299 cells have previously undergone metastatic processes, and may not
be as epithelial as A549 cells. As a result, A549 cells may display changes in phenotypical
EMT markers more clearly than H1299 cells.
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Similar changes in the expression of both E-cadherin protein and mRNA suggests TβR3
primarily influences E-cadherin expression on a transcriptional level, and that downstream
protein levels are adjusted accordingly. The expression of E- and N-cadherin is tightly
regulated through separate and distinct processes. Since E-cadherin expression is
suppressed by transcription factors including Zeb1, Zeb2, Snail, and Slug, a reduction in
repressor protein expression may increase the basal and TGFβ-induced expression of Ecadherin. The transcription factor ZEB2 represses the transcription of E-cadherin in
response to TGFβ signaling by binding the promoter region of CDH1 (Peinado et al., 2007).
As observed by microarray analysis, the mRNA expression of ZEB2 was reduced
following TβR3 silencing (Figure 3.15a). Mining of microarray data for microRNAs that
repress E-cadherin transcription directly, or indirectly through transcription factors,
yielded no significant change in expression (Appendix Table 5). Future studies
investigating protein expression of repressive transcription factors may elucidate a
mechanism by which TβR3 influences E-Cadherin transcription.
Autophagy processes have been linked to EMT and E-cadherin expression (Alizadeh et al.,
2018; Dash et al., 2018). In support of a suppressed epithelial-to-mesenchymal transition,
and increased expression of E-cadherin, LC3B expression was significantly reduced
following TβR3 silencing (Figures 3.11, 3.12). Furthermore, the general reduction in
LC3B expression, rather than the inhibition of LC3B1 cleavage to LC3B2, suggests that
TβR3 silencing has an important upstream regulatory role in autophagy, independent of
Atg4 cleavage of LC3B1 specifically. LC3B mRNA expression has been linked with
Erk1/2 activation, demonstrating a regulatory pathway that is following atypical TGFβ
signaling (Kim et al., 2014). Since Pang et al. (2016) demonstrated that autophagosome
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formation was necessary to degrade E-cadherin, a broad downregulation of LC3B may
suppress this degradation pathway, leading to the increase in E-cadherin protein expression
exhibited after TβR3 silencing.
From this, the influence of TβR3 on E-cadherin expression may be two-fold. My results
showing increased E-cadherin mRNA expression following TβR3 knockdown, in
conjunction with a reduction in the formation of autophagosomes, which have been shown
to degrade E-cadherin (Pang et al., 2016), may result in elevated E-cadherin levels.
However, my observations assessing the relationship between N-cadherin mRNA and
protein expression was weaker. In A549 cells, N-cadherin mRNA was significantly
increased in TβR3 silenced conditions when treated with TGFβ, equal to or greater than
expression in control cells (Figure 3.8). However, a significant increase in N-cadherin
mRNA expression was observed in TβR3 silenced H1299 cells treated with TGFβ, which
was not seen in control cells. Together, these results demonstrate an inconsistency between
transcriptional regulation of TβR3 with respect to specific genes and between cell lines. In
stark contrast, N-cadherin protein expression remained consistent between the cell lines,
with TβR3 silencing resulted in reduced TGFβ-dependent induction (Figures 3.9, 3.10).
A clear disconnect is between N-cadherin mRNA and protein expression suggests TβR3
may be involved in modulating N-cadherin translation or degradation.
Although the transcriptional regulation of E-cadherin is well established, the
characterization of N-cadherin control is unclear. A study by Alexander et al. (2006) found
that the nuclear accumulation of transcription factor Twist1 resulted in its association with
an E-box element in the promoter region of CDH2, the gene encoding N-cadherin, and
enhanced its transcription. Thus, Twist1 is not only an important regulator of E-cadherin
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repression, but also induces N-cadherin expression. However, Twist1 mRNA expression
was not altered following TβR3 silencing and the role of other EMT-regulating
transcription factors like Snail, Slug, Zeb1, and Zeb2, in N-cadherin regulation is unknown
at this time.
Interestingly, Cardenas et al. (2014) demonstrated that TGFβ signaling facilitates global
changes in DNA methylation during EMT. TGFβ-dependent expression and activity of
DNA methyltransferases (DNMT) has been shown to alter mRNA expression of genes
associated with EMT, including COL1A1. Additionally, the methylation of histone H3 has
been implicated in repressing the transcription of CDH1 (Cao et al., 2008). Furthermore,
the pattern of DNA methylation is reversed following withdrawal of TGFβ ligand
(Cardenas et al., 2014). Thus, Smad-independent TGFβ signaling may influence Ncadherin mRNA expression through altered DNA methylation and would be an interesting
future study.
Recently, regulation of N-cadherin protein has also been linked to PI3K/PKCζ/mTOR
signaling pathway, independent from transcriptional changes (Palma-Nicolas & LopezColome, 2013). Furthermore, Twist1 expression is transcriptionally regulated by PI3K
activity, which suggests an overarching pathway that regulates N-cadherin transcription
and translation through separate downstream events (Hao et al., 2012). Furthermore, Ncadherin protein can be targeted for proteolysis via plasmin and matrix metalloproteinase
activity (Paradies & Grunwald, 1993). A study by Takino et al. (2014) showed that MMP14
expression reduces N-cadherin adhesion, and Covington et al. (2006) have also established
that MMP14 expression is involved in N-cadherin cleavage. Therefore, opposing roles of
PI3K in promoting N-cadherin translation, and upregulated MMP expression in degrading
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N-cadherin, may result in unaltered N-cadherin protein expression in response to TGFβ
despite significantly increased mRNA levels.
While studies investigating N-cadherin mRNA and protein expression yielded significant
differences in both cell lines, E-cadherin only exhibited significant changes in A549 cells
at the mRNA level. Thus, TβR3 silencing may have a greater influence on the expression
of N-cadherin than E-cadherin. Additionally, E-cadherin protein expression may be so
tightly regulated that altering mRNA levels by knocking down TβR3 may not result in
wide-spread phenotypical changes.
Prickle1, which encodes Prickle Planar Cell Polarity Protein 1, has been implicated in βcatenin-independent Wnt signaling (Daulat et al., 2012). Prickle1 is a homolog of planar
cell polarity (PCP) proteins, which include the traditional Wnt signaling components of
Frizzled and Dishevelled. PCPs, including Prickle1, are essential for the maintenance of
epithelial apical-basal polarity, a characteristic that serves as a phenotypical epithelial
marker to assess EMT (Tao et al., 2009). Since the mRNA expression of Prickle1 was
found by microarray to be highly upregulated in H1299 cells following TβR3 silencing,
this observation supports the enhanced epithelial state of TβR3 knockdown cells
demonstrated by increased E-cadherin expression (Figure 3.15). Additionally, Prickle1
homolog Prickle4 was found to be upregulated (+2.00) by microarray, as was tight junction
protein Claudin1 (+2.70) (Appendix Table 1). While H1299 cells do not demonstrate a
significant increase in E-cadherin expression, the upregulation of other epithelial markers
may serve to maintain an epithelial phenotype.

81

Together, a potential reduction of E-cadherin proteasomal degradation through autophagic
processes, the upregulation of E-cadherin mRNA, and the heightened expression of
Prickle1, Prickle4, and Claudin1 all suggest the maintenance of an epithelial phenotype.
The increase in epithelial marker expression corresponded with a reduction in the protein
level of mesenchymal marker N-cadherin, further supporting my hypothesis. However, the
mechanism behind these phenotypic changes remains unclear.

4.3

Interplay between cell migration and invasion

As predicted following a phenotypic shift towards a more epithelial state, fewer H1299
cells invaded through a Matrigel plug (Figure 3.13). However, the cellular migratory
potential in H1299 cells did not match the inhibited invasion exhibited following TβR3
knockdown (Figure 3.14). Thus, TβR3 may influence these functional characteristics via
different mechanisms of action.
Cellular invasive potential is dependent on two qualities: the ability of a cell to degrade the
surrounding extracellular matrix, and its capacity to move after ECM degradation. For a
tumor cell to successfully invade, both its degradative and motile capabilities must be
heightened. In my studies, since fewer cells were able to invade Matrigel plugs yet
exhibited an enhanced ability to migrate when unobstructed, the inability to invade could
be a result of reduced degradative function. Interestingly, this is countered by an increase
in MMP1 and MMP14 steady-state mRNA levels in both cell lines when TβR3 is silenced,
both basally and in the presence of TGFβ (Figure 3.16). However, despite greater mRNA
expression, a lack of increased MMP protein expression would still not explain MMP
functional activity, nor a reduction in cell invasion, as a maintenance of similar enzyme
abundance should correspond with a similar number of cells that can invade.
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However, a reduction in MMP activity would impede extracellular matrix degradation.
Normally activated via proteolytic cleavage and inhibited by TIMPs, functionally active
MMP levels may be regulated by TβR3. Thus, repression of invasion may be a result of
reduced MMP activation by plasmin, furin, or other MMPs, or by an upregulation of TIMPs
to aberrantly block MMP-dependent ECM degradation. However, no significant changes
in mRNA expression were found by microarray with regards to proteins that regulate MMP
activity (Appendix Table 4). Additionally, a downregulation of MMP protein expression
despite increased mRNA levels could implicate TβR3 in a mechanistic pathway that
controls MMP proteolysis. As a secreted enzyme (Lu et al, 2011), the ability of MMP1 to
interact with its substrates and perform its functional ability relies upon an intact secretory
pathway. Thus, impairment of the secretory pathway by which MMP1 is exocytosed could
result in the suppression of extracellular matrix degradation, leaving a robust obstacle
through which cells are unable to transverse.
Although MMP expression and activity are necessary for cells to invade, the ability of
MMPs to carry out their functions are limited to the substrates with which they interact.
Specifically, MMP1 and MMP14 are collagenases, primarily responsible for degrading
collagens I, II, and III (Lu et al., 2011). Matrigel is mainly composed of laminin and
collagen IV (Corning). As such, formation of a Matrigel plug may create a barrier that is
unable to be degraded by upregulated MMP1 and MMP14. Interestingly, recent studies
have demonstrated that MMP14 expression is inversely proportional to invasive potential,
finding that cancer cells expressing lower levels of MMP14 invaded 3D cultures at a
greater rate than cells expressing higher levels of MMP14 (Cepeda et al., 2016; Yamamoto
et al., 2008). Thus, the overexpression of MMP14 following TβR3 silencing may actually
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hinder the ability of H1299 cells to invade through a Matrigel plug. As such, matrix
metalloproteinases may have addition roles in modulating cell signaling through the
proteolysis of other non-extracellular membrane components.
TβR3 has also been shown to inhibit the NF-κB signaling pathway (Criswell et al., 2008),
which is known to facilitate MMP1 expression (Nguyen et al., 2015). Thus, the silencing
of TβR3 could permit NF-κB signaling to increase MMP1 transcription. Additionally, βarrestin2 has also been implicated in NF-κB regulation. β-arrestin2 is a scaffolding protein
that can bind the cytoplasmic C-terminal tail of TβR3 and induce its internalization.
Interestingly, following TβR3 silencing, the mRNA expression of β-arrestin2 was
downregulated (Figure 3.15). In addition to its role as a scaffolding protein, β-arrestin2 is
also involved in modulating intracellular signaling cascades. β-arrestin2 has been shown
to inhibit Traf6 signaling and the activation of its downstream targets, including NF-κB
(Wang et al., 2006; Xiao et al., 2015). Since β-arrestin2 mRNA expression was reduced,
inhibition of Traf6 may be absent resulting in the enhancement of NF-κB signaling. Thus,
TβR3 may promote β-arrestin2 expression, or protect it from degradation, as a way to
suppress NF-κB. In either case, the reduction in TβR3 and β-arrestin2 expression can
enhance NF-κB signaling and promote MMP1 upregulation.
However, MMP14 transcriptional regulation is not mediated by NF-κB activation, but
elevated MMP14 activity has been shown to promote Erk1/2 phosphorylation and
downstream NF-κB activation (Cepeda et al., 2017). From these observations, an increase
in MMP14 expression may initiate cell signaling processes to upregulate its fellow
collagenase MMP1. Importantly, MMP14 transcription relies upon a promoter region that
is distinct from that of other MMPs, as it lacks a conventional TATA-box domain. A

84

binding site for SP-1 transcription factor is vital for MMP14 transcription and provides a
unique mechanism of MMP14 regulation in which TβR3 may be involved (Lohi et al.,
2000). Furthermore, a transcription factor involved in the repression of E-cadherin, Snail,
has been shown to collaborate with SP-1 to induce the transcription of MMPs. Since TβR3
silencing significantly upregulated Snail expression (Figure 3.7), its interaction with SP-1
may act as a facilitator of increased MMP1 and MMP14 expression. Finally, microRNA
expression of oligomers that are responsible for regulating MMP expression was found to
remain unchanged following TβR3 silencing (Appendix Table 3).
In contrast to my results, Gordon et al. (2009) proposed a mechanism by which TβR3
expression suppressed cellular invasion through inhibiting Smad1 phosphorylation. Smad1
is a substrate of the activin type 2 receptor in the BMP signaling pathway which is
modulated by TβR3. However, when BMP-2, -4, or -7 ligand expressions are increased,
TβR3 expression in reduced and Smad1 may be phosphorylated. Smad1 then translocates
to the nucleus and enhances the expression of MMP2, which degrades the extracellular
matrix to promote invasion. Thus, TβR3 involvement in BMP signaling may play a role in
receptor expression, MMP activity, and downstream regulation of EMT and invasion.
Contrary to a suppressed invasive capability of H1299 cells following TβR3 silencing, both
H1299 and A549 knockdown cells exhibited greater migratory potential than control cells
(Figure 3.14). Examination of microarray data and subsequent gene ontology analyses
revealed two interesting genes that were upregulated and involved in the regulation of
chemotaxis and locomotion: MET and JAG1 (Figure 3.18)

85

MET, also referred to as the hepatocyte growth factor receptor (HGFR), is a receptor
tyrosine kinase that is an established promoter of cell migration (Piater et al., 2015). The
binding of HGF to MET initiates a phosphorylation of tyrosine residues and initiates the
Ras/MAPK signaling pathway, culminating in Erk1/2 phosphorylation and the promotion
of migration (Gonzalez et al., 2017). Furthermore, the upregulation of both Met protein
and mRNA expression have been implicated in cell migration and tumor budding (Bradley
et al., 2016). JAG1 codes for the protein Jagged1, a ligand for Notch receptors which is
upregulated in various late stage cancers (Dai et al., 2014). Upon ligand-receptor
association, cleavage of the Notch intracellular domain (NICD) by γ-secretase induces
nuclear accumulation and progression of prostate, breast, and head and neck cancers (Dai
et al., 2014). As such, the elevated expression of Jagged1 and Notch receptors promotes
Notch signaling and has been implicated in the promotion of cell migration (Tang et al.,
2017). Together, the upregulation of MET and JAG1 following TβR3 silencing may
influence the increase in cellular migratory potential.
Thus, the invasive and migratory potential of A549 and H1299 cells is clearly influenced
by TβR3 silencing. However, the inconsistencies between migration and invasion suggests
the interplay of additional, non-canonical TGFβ signaling pathways.

4.4

Summary of observations

In this thesis, I observed that TβR3 knockdown did not alter relative Smad2
phosphorylation in response to TGFβ in the H1299 or A549 NSCLC cell lines, although
total Smad2 expression was insignificantly reduced in H1299 cells. When examining Ecadherin mRNA and protein levels, significant change was only found in the increased
mRNA expression in A549 cells. However, in both cell lines, N-cadherin mRNA
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expression was significantly increased in response to TGFβ, but protein levels were
unaffected. Correlating with suppressed EMT transition, autophagic marker LC3B
expression was reduced in both A549 and H1299 cells following TβR3 knockdown.
Functionally, the invasive potential of H1299 cells was reduced, while more A549 and
H1299 cells migrated through transwell assays.
Together, these results suggest that epithelial to mesenchymal transition, cell migration,
and cell invasion, may be altered by atypical TGFβ signaling. These processes have been
shown to be regulated via mechanisms involving the PI3K, MAPK, and NF-κB pathways,
which are each modulated by TGFβ ligand in a Smad-independent manner. TβR3
expression may protect the integrity of the Smad signaling pathway and following receptor
knockdown, cells may access non-canonical TGFβ cascades. Activation of various
pathways may serve a purpose in modulating downstream processes independently, and in
suppressing canonical Smad signaling by phosphorylating Smad linker regions to facilitate
ubiquitination and degradation. Clearly, TβR3 expression is involved in controlling
multiple signaling pathways, and its specific functions in modulating EMT transition, cell
migration, and cell invasion are complex.

4.5

Limitations and Future Directions

In this study, TβR3 was transiently reduced by siRNA, thus limiting the length of time
cellular processes could be monitored before TβR3 expression was reacquired. Developing
stable cell lines that expressed shRNA against TβR3 would allow for long-term
experiments to be conducted. The use of CRISPR-Cas9 gene editing technologies could
also permanently remove TβR3 from each cell line for future testing.
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Reducing TβR3 in cells that highly express TβR3, such as H1299, is an effective way to
reveal specific processes with which it may be involved. However, the efficiency of the
knockdown may not be sufficient to cause physiological changes in the event that the
reduced expression level of TβR3 remains sufficient to perform its normal roles.
Furthermore, reducing protein levels in cell lines that have low levels of receptor may not
uncover small changes in signaling potential. Therefore, future studies investigating the
overexpression of TβR3 in cells that express low basal receptor levels would be beneficial
to demonstrate specific functions in a direct way. Furthermore, overexpression of mutant
TβR3 that alter their interaction with TGFβ (other TGFβ receptors) may shed light on the
mechanism of this system.
The transition of A549 and H1299 cells from an epithelial state to a mesenchymal
phenotype was investigated via the measurement of E-cadherin and N-cadherin expression
at a protein and mRNA level. Although these proteins represent the gold-standard of EMT
markers, the use of additional epithelial markers, including ZO-1 and cytokeratin; and the
mesenchymal markers, vimentin and α-smooth muscle actin (αSMA), would further
reinforce the cadherin shift demonstrated by E- and N-cadherin.
My research primarily examined the protein and mRNA expression of EMT markers in
response to TGFβ over time, but cellular morphology was not investigated. Next, it would
be worthwhile to examine cytoskeletal organization of actin in response to TGFβ. In
epithelial cells, actin is normally structured in a cortical fashion (Thiery et al., 2002).
However, during EMT, actin is rearranged to form stress fibers and promote a migratory
phenotype (Thiery et al., 2002). Fluorescence microscopy using Phalloidin, a polymerized
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actin stain, could be employed to investigate any morphological changes exhibited in cells
following TβR3 knockdown.
Although LC3B expression was studied to determine a connection between TβR3, the
autophagic processes, and EMT, further experiments examining TβR3 knockdown on other
autophagic markers, such as Atg5, Atg7, Beclin1, or p62 should be conducted. Together
with electron microscopic techniques to visualize the formation of autophagosomes,
altered expression of these markers would hone in on specific autophagic stages that are
influenced by TβR3.
Functional analysis of cell migration was limited to transwell assays, which measure the
ability of a cell to sense a chemotactic agent and migrate across a physical barrier. Thus,
only amoeboid, chemotactic motility was investigated and measured the number of cells
that were able to migrate a pre-established distance. As a result, the total distance traveled,
velocity, and direction by which the cells migrated was not determined. Therefore, the use
of single-cell tracking technologies to measure these outputs may provide greater insight
into the specific migratory processes that are altered by TβR3. Additionally, employing
wound-healing assays would take cell-cell signaling and contact into account when
measuring migrated distance as a physiologically relevant cancerous mass. Finally, the use
of µ-Slide Chemotaxis (Ibidi) would test the chemotaxis of a migrating cell sheet through
a channel, rather than single cells through a membrane, acting as a comprehensive measure
of cell migration, taking all the above factors into consideration.
To investigate how MMP1 and MMP14 upregulation impact cellular invasion, a number
of processes should be investigated. First, protein expression should be compared to the
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steady-state mRNA expression of the MMPs to confirm an upregulation of MMP zymogen.
Next, zymographic techniques should be performed to assess the activity of MMP1 and
MMP14 in degrading appropriate substrates (Leber & Balkwill, 1997). Finally, when
examining cellular invasion through a Transwell assay, establishing a barrier using
collagen I-III may place cells in a more appropriate physiological context with regards to
their MMP expression. Also, instead of using a plug, a hanging droplet apparatus may be
used to measure cellular invasion out of a spheroid of cells and matrix as a pseudo-in vivo
technique (Tung et al., 2011).
Quantitative polymerase chain reactions and microarray techniques compare the relative
steady-state mRNA expression of various genes. However, these analyses do not reveal
changes in gene transcription. Incorporating a sequence encoding a luciferase enzyme into
the promoter region of genes of interest would clarify the mechanism by which TβR3
influences mRNA expression. Finally, investigating the involvement of TβR3 expression
in non-canonical TGFβ signaling processes would reveal novel functions of the accessory
receptor previously solely associated with the TGFβ cascade.
Despite these limitations, my results suggest that TβR3 has a distinct role in modulating
EMT and cellular motility and will be of interest to the field of TGFβ cancer biology.
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Figure 4.1 Proposed mechanism of TβR3 influence on cell migration and invasion
Black boxes signify results found in this thesis. Arrows demonstrate a sequence of
processes, while dashed arrows suggest speculated mechanisms of action.
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Appendix
Appendix Table 1 Genes upregulated in Microarray analysis ≥ +1.75 fold-change (165
genes)
Gene Symbol

MMP1
PRICKLE1
MET
HMBOX1
SOCS1
PTPMT1
PTPRO
JAG1
SERPINB7
PIP4K2A
NRBF2
CLDN1
PYGO2
CRH
KLC1
CALU
HIST1H2BG
PTPN1
TSC22D2
SLC2A3
CHAF1B
HIST1H2BC
SPP1
GPAT3
OR2A42
SEMA3C
SOX4
SCG2

Assignment
NM_001145938 // RefSeq // Homo sapiens matrix metallopeptidase 1 (MMP1),
transcript var
NM_001144881 // RefSeq // Homo sapiens prickle homolog 1 (PRICKLE1),
transcript variant
NM_000245 // RefSeq // Homo sapiens MET proto-oncogene, receptor tyrosine
kinase (MET),
XM_005273635 // RefSeq // PREDICTED: Homo sapiens homeobox containing 1
(HMBOX1), trans
NM_003745 // RefSeq // Homo sapiens suppressor of cytokine signaling 1
(SOCS1), mRNA. /
NM_001143984 // RefSeq // Homo sapiens protein tyrosine phosphatase,
mitochondrial 1 (P
NM_002848 // RefSeq // Homo sapiens protein tyrosine phosphatase, receptor
type, O (PTP
NM_000214 // RefSeq // Homo sapiens jagged 1 (JAG1), mRNA. // chr20 // 100 //
92 // 23
NM_001040147 // RefSeq // Homo sapiens serpin peptidase inhibitor, clade B
(ovalbumin),
NM_005028 // RefSeq // Homo sapiens phosphatidylinositol-5-phosphate 4kinase, type II,
NM_001282405 // RefSeq // Homo sapiens nuclear receptor binding factor 2
(NRBF2), trans
NM_021101 // RefSeq // Homo sapiens claudin 1 (CLDN1), mRNA. // chr3 // 94
// 89 // 16
NM_138300 // RefSeq // Homo sapiens pygopus family PHD finger 2 (PYGO2),
mRNA. // chr1
NM_000756 // RefSeq // Homo sapiens corticotropin releasing hormone (CRH),
mRNA. // chr
ENST00000348520 // ENSEMBL // kinesin light chain 1
[gene_biotype:protein_coding transc
NM_001130674 // RefSeq // Homo sapiens calumenin (CALU), transcript variant
2, mRNA. //
NM_003518 // RefSeq // Homo sapiens histone cluster 1, H2bg (HIST1H2BG),
mRNA. // chr6
NM_001278618 // RefSeq // Homo sapiens protein tyrosine phosphatase, nonreceptor type
ENST00000361875 // ENSEMBL // TSC22 domain family, member 2
[gene_biotype:protein_codin
NM_006931 // RefSeq // Homo sapiens solute carrier family 2 (facilitated glucose
transp
XM_011529753 // RefSeq // PREDICTED: Homo sapiens chromatin assembly
factor 1, subunit
ENST00000314332 // ENSEMBL // histone cluster 1, H2bc
[gene_biotype:protein_coding tran
NM_000582 // RefSeq // Homo sapiens secreted phosphoprotein 1 (SPP1),
transcript varian
NM_001256421 // RefSeq // Homo sapiens glycerol-3-phosphate acyltransferase 3
(GPAT3),
NM_001001802 // RefSeq // Homo sapiens olfactory receptor, family 2, subfamily
A, membe
NM_006379 // RefSeq // Homo sapiens sema domain, immunoglobulin domain
(Ig), short basi
NM_003107 // RefSeq // Homo sapiens SRY (sex determining region Y)-box 4
(SOX4), mRNA.
NM_003469 // RefSeq // Homo sapiens secretogranin II (SCG2), mRNA. // chr2 //
100 // 68

Average FoldChange

7.587845
3.98391
3.43446
3.16948
3.099
2.975635
2.95122
2.84577
2.830065
2.7278
2.7113
2.70308
2.698445
2.682165
2.51896
2.51797
2.49148
2.472065
2.471215
2.429165
2.41733
2.417155
2.403515
2.396755
2.388755
2.382555
2.37484
2.366255
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EHBP1L1
CALB2
CNR1
PDIA4
ARL4C
CXCL1
CCND2
PGGT1B
LOC286437
DNER
WSB1
FLRT3
CYB5D1
FAM49B
LOC105373538
TDG
PTPN14
PTPRG
EFNB2
HOXB5
MYO10
RNU6-57P
MIR548A1
EYA3
IGFL4
MT1X
B3GALT1
MCL1
ANKRD52
HMBOX1
TMEM2
B4GALT1
HAS2
NABP1

NM_001099409 // RefSeq // Homo sapiens EH domain binding protein 1-like 1
(EHBP1L1), mR
NM_001740 // RefSeq // Homo sapiens calbindin 2 (CALB2), transcript variant
CALB2, mRNA
NM_001160226 // RefSeq // Homo sapiens cannabinoid receptor 1 (brain)
(CNR1), transcrip
NM_004911 // RefSeq // Homo sapiens protein disulfide isomerase family A,
member 4 (PDI
NM_001282431 // RefSeq // Homo sapiens ADP-ribosylation factor-like 4C
(ARL4C), transcr
NM_001511 // RefSeq // Homo sapiens chemokine (C-X-C motif) ligand 1
(melanoma growth s
NM_001759 // RefSeq // Homo sapiens cyclin D2 (CCND2), mRNA. // chr12 //
100 // 62 // 1
XM_005272020 // RefSeq // PREDICTED: Homo sapiens protein
geranylgeranyltransferase typ
NR_039980 // RefSeq // Homo sapiens uncharacterized LOC286437
(LOC286437), long non-cod
NM_139072 // RefSeq // Homo sapiens delta/notch-like EGF repeat containing
(DNER), mRNA
NM_015626 // RefSeq // Homo sapiens WD repeat and SOCS box containing 1
(WSB1), transcr
NM_013281 // RefSeq // Homo sapiens fibronectin leucine rich transmembrane
protein 3 (F
NM_144607 // RefSeq // Homo sapiens cytochrome b5 domain containing 1
(CYB5D1), mRNA. /
NM_001256763 // RefSeq // Homo sapiens family with sequence similarity 49,
member B (FA
XR_923158 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105373538 (LOC1053735
NM_003211 // RefSeq // Homo sapiens thymine DNA glycosylase (TDG),
mRNA. // chr12 // 10
NM_005401 // RefSeq // Homo sapiens protein tyrosine phosphatase, non-receptor
type 14
NM_002841 // RefSeq // Homo sapiens protein tyrosine phosphatase, receptor
type, G (PTP
NM_004093 // RefSeq // Homo sapiens ephrin-B2 (EFNB2), mRNA. // chr13 //
100 // 100 //
NM_002147 // RefSeq // Homo sapiens homeobox B5 (HOXB5), mRNA. // chr17
// 100 // 74 //
NM_012334 // RefSeq // Homo sapiens myosin X (MYO10), mRNA. // chr5 //
100 // 83 // 33
ENST00000411348 // ENSEMBL // RNA, U6 small nuclear 57, pseudogene
[gene_biotype:snRNA
NR_030312 // RefSeq // Homo sapiens microRNA 548a-1 (MIR548A1),
microRNA. // chr6 // 10
NM_001282560 // RefSeq // Homo sapiens EYA transcriptional coactivator and
phosphatase
ENST00000595006 // ENSEMBL // IGF-like family member 4
[gene_biotype:protein_coding tra
NM_005952 // RefSeq // Homo sapiens metallothionein 1X (MT1X), mRNA. //
chr16 // 100 //
NM_020981 // RefSeq // Homo sapiens UDP-Gal:betaGlcNAc beta 1,3galactosyltransferase,
NM_001197320 // RefSeq // Homo sapiens myeloid cell leukemia 1 (MCL1),
transcript varia
NM_173595 // RefSeq // Homo sapiens ankyrin repeat domain 52 (ANKRD52),
mRNA. // chr12
NM_001135726 // RefSeq // Homo sapiens homeobox containing 1 (HMBOX1),
transcript varia
NM_001135820 // RefSeq // Homo sapiens transmembrane protein 2 (TMEM2),
transcript vari
NM_001497 // RefSeq // Homo sapiens UDP-Gal:betaGlcNAc beta 1,4galactosyltransferase,
NM_005328 // RefSeq // Homo sapiens hyaluronan synthase 2 (HAS2), mRNA. //
chr8 // 100
ENST00000410026 // ENSEMBL // nucleic acid binding protein 1
[gene_biotype:protein_codi

2.362085
2.359335
2.35512
2.34272
2.32081
2.296395
2.282615
2.27886
2.25092
2.2351
2.23316
2.201595
2.196315
2.189425
2.165175
2.15107
2.14654
2.138735
2.12732
2.122855
2.110515
2.10814
2.10333
2.098615
2.098035
2.09164
2.09153
2.09069
2.083575
2.079915
2.0798
2.054165
2.048335
2.03921

107

THBS1
FAM217B
SPRY1
UNC13A
PLD5
LOC105376694
ANKRD1
PRICKLE4
DPYSL3
ZFP14
ZNF783
PPP2R1B
CDS1
TGFB2
GATSL2
SLC36A1
RRS1
STX12
RBPJ
FAM46A
TIAM1
MIR365A
MAPKAP1
MIR4655
CNR1
ZNF157
SBNO1
LOC105373538
AK4
FAM32A
BARX2
KDM7A
DDX58
SSFA2

NM_003246 // RefSeq // Homo sapiens thrombospondin 1 (THBS1), mRNA. //
chr15 // 100 //
NM_001190826 // RefSeq // Homo sapiens family with sequence similarity 217,
member B (F
NM_001258038 // RefSeq // Homo sapiens sprouty RTK signaling antagonist 1
(SPRY1), tran
NM_001080421 // RefSeq // Homo sapiens unc-13 homolog A (C. elegans)
(UNC13A), mRNA. //
NM_001195811 // RefSeq // Homo sapiens phospholipase D family, member 5
(PLD5), transcr
XR_931876 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105376694 (LOC1053766
NM_014391 // RefSeq // Homo sapiens ankyrin repeat domain 1 (cardiac muscle)
(ANKRD1),
ENST00000335515 // ENSEMBL // prickle homolog 4
[gene_biotype:protein_coding transcript
NM_001197294 // RefSeq // Homo sapiens dihydropyrimidinase-like 3
(DPYSL3), transcript
NM_001297619 // RefSeq // Homo sapiens ZFP14 zinc finger protein (ZFP14),
transcript va
XM_005249929 // RefSeq // PREDICTED: Homo sapiens zinc finger family
member 783 (ZNF783
NM_001177562 // RefSeq // Homo sapiens protein phosphatase 2, regulatory
subunit A, bet
NM_001263 // RefSeq // Homo sapiens CDP-diacylglycerol synthase
(phosphatidate cytidyly
NM_001135599 // RefSeq // Homo sapiens transforming growth factor, beta 2
(TGFB2), tran
NM_001145064 // RefSeq // Homo sapiens GATS protein-like 2 (GATSL2),
mRNA. // chr7 // 1
NM_001308150 // RefSeq // Homo sapiens solute carrier family 36 (proton/amino
acid symp
NM_015169 // RefSeq // Homo sapiens ribosome biogenesis regulator homolog
(RRS1), mRNA.
NM_177424 // RefSeq // Homo sapiens syntaxin 12 (STX12), mRNA. // chr1 //
100 // 68 //
NM_005349 // RefSeq // Homo sapiens recombination signal binding protein for
immunoglob
NM_017633 // RefSeq // Homo sapiens family with sequence similarity 46,
member A (FAM46
NM_003253 // RefSeq // Homo sapiens T-cell lymphoma invasion and metastasis
1 (TIAM1),
NR_029854 // RefSeq // Homo sapiens microRNA 365a (MIR365A), microRNA.
// chr16 // 100
NM_001006617 // RefSeq // Homo sapiens mitogen-activated protein kinase
associated prot
NR_039799 // RefSeq // Homo sapiens microRNA 4655 (MIR4655), microRNA.
// chr7 // 100 /
NM_001160226 // RefSeq // Homo sapiens cannabinoid receptor 1 (brain)
(CNR1), transcrip
NM_003446 // RefSeq // Homo sapiens zinc finger protein 157 (ZNF157), mRNA.
// chrX //
NM_001167856 // RefSeq // Homo sapiens strawberry notch homolog 1
(Drosophila) (SBNO1),
XR_923158 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105373538 (LOC1053735
NM_001005353 // RefSeq // Homo sapiens adenylate kinase 4 (AK4), transcript
variant 1,
NM_014077 // RefSeq // Homo sapiens family with sequence similarity 32,
member A (FAM32
NM_003658 // RefSeq // Homo sapiens BARX homeobox 2 (BARX2), mRNA. //
chr11 // 100 // 5
NM_030647 // RefSeq // Homo sapiens lysine (K)-specific demethylase 7A
(KDM7A), mRNA. /
NM_014314 // RefSeq // Homo sapiens DEAD (Asp-Glu-Ala-Asp) box
polypeptide 58 (DDX58),
NM_001130445 // RefSeq // Homo sapiens sperm specific antigen 2 (SSFA2),
transcript var

2.029965
2.02722
2.021935
2.018905
2.01615
2.012215
2.01199
2.009555
2.00606
2.00576
2.003635
1.989705
1.98269
1.977195
1.97662
1.97038
1.96967
1.965035
1.96131
1.954995
1.940475
1.938085
1.93674
1.934215
1.924605
1.924055
1.9178
1.91522
1.913045
1.912335
1.912105
1.898755
1.89858
1.89748
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GUSBP1
MIR4441
CYB561D1
GAS2L1
MRPL45
SPRY4
TCEB3
TMEM145
TNFRSF21
CUEDC1
PTPRZ1
BANF1
GOPC
MIR31HG
KRTAP2-3
FHOD1
CPPED1
PLSCR4
TRUB2
CLIP4
ZNHIT6
LIPH
LOC105374749
SNORD114-1
RHOB
RNF43
MAGEA6
INPP5F
VGLL4
MIR1587
C15orf48
GABPA
ERCC5
HIST2H2BF

NR_027026 // RefSeq // Homo sapiens glucuronidase, beta pseudogene 1
(GUSBP1), transcri
NR_039643 // RefSeq // Homo sapiens microRNA 4441 (MIR4441), microRNA.
// chr2 // 100 /
NM_001134400 // RefSeq // Homo sapiens cytochrome b561 family, member D1
(CYB561D1), tr
NM_001278730 // RefSeq // Homo sapiens growth arrest-specific 2 like 1
(GAS2L1), transc
NM_001278279 // RefSeq // Homo sapiens mitochondrial ribosomal protein L45
(MRPL45), tr
NM_001127496 // RefSeq // Homo sapiens sprouty RTK signaling antagonist 4
(SPRY4), tran
NM_003198 // RefSeq // Homo sapiens transcription elongation factor B (SIII),
polypepti
NM_173633 // RefSeq // Homo sapiens transmembrane protein 145 (TMEM145),
mRNA. // chr19
NM_014452 // RefSeq // Homo sapiens tumor necrosis factor receptor
superfamily, member
NM_001271875 // RefSeq // Homo sapiens CUE domain containing 1 (CUEDC1),
transcript var
NM_001206838 // RefSeq // Homo sapiens protein tyrosine phosphatase, receptortype, Z p
NM_001143985 // RefSeq // Homo sapiens barrier to autointegration factor 1
(BANF1), tra
NM_001017408 // RefSeq // Homo sapiens golgi-associated PDZ and coiled-coil
motif conta
NR_027054 // RefSeq // Homo sapiens MIR31 host gene (MIR31HG), long noncoding RNA. //
NM_001165252 // RefSeq // Homo sapiens keratin associated protein 2-3
(KRTAP2-3), mRNA.
NM_013241 // RefSeq // Homo sapiens formin homology 2 domain containing 1
(FHOD1), mRNA
NM_001099455 // RefSeq // Homo sapiens calcineurin-like phosphoesterase
domain containi
NM_001128304 // RefSeq // Homo sapiens phospholipid scramblase 4 (PLSCR4),
transcript v
NM_015679 // RefSeq // Homo sapiens TruB pseudouridine (psi) synthase family
member 2 (
NM_001287527 // RefSeq // Homo sapiens CAP-GLY domain containing linker
protein family,
NM_001170670 // RefSeq // Homo sapiens zinc finger, HIT-type containing 6
(ZNHIT6), tra
NM_139248 // RefSeq // Homo sapiens lipase, member H (LIPH), mRNA. // chr3
// 100 // 90
XR_925976 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105374749 (LOC1053747
NR_003193 // RefSeq // Homo sapiens small nucleolar RNA, C/D box 114-1
(SNORD114-1), sm
NM_004040 // RefSeq // Homo sapiens ras homolog family member B (RHOB),
mRNA. // chr2 /
NM_001305544 // RefSeq // Homo sapiens ring finger protein 43 (RNF43),
transcript varia
ENST00000412733 // ENSEMBL // melanoma antigen family A6
[gene_biotype:protein_coding t
NM_001243194 // RefSeq // Homo sapiens inositol polyphosphate-5-phosphatase
F (INPP5F),
NM_001128219 // RefSeq // Homo sapiens vestigial-like family member 4
(VGLL4), transcri
NR_039763 // RefSeq // Homo sapiens microRNA 1587 (MIR1587), microRNA.
// chrX // 100 /
NM_032413 // RefSeq // Homo sapiens chromosome 15 open reading frame 48
(C15orf48), tra
NM_001197297 // RefSeq // Homo sapiens GA binding protein transcription
factor, alpha s
NM_000123 // RefSeq // Homo sapiens excision repair cross-complementation
group 5 (ERCC
NM_001161334 // RefSeq // Homo sapiens histone cluster 2, H2bf (HIST2H2BF),
transcript

1.897305
1.89599
1.884945
1.880455
1.87827
1.87776
1.873875
1.86874
1.86786
1.866395
1.86588
1.862805
1.862395
1.86227
1.861415
1.85921
1.85535
1.85202
1.848545
1.84656
1.84486
1.843155
1.83801
1.83693
1.83475
1.83369
1.826145
1.82158
1.81722
1.817035
1.816345
1.81563
1.814955
1.8133
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THSD7A
MYH8
RCHY1
TNFRSF10D
PPP3CB
MAGEA12
SGK1
ARHGDIA
CEP170P1
MAP2
HIST1H2BD
RASSF8
B3GALT1
FBXL19-AS1
PPFIBP1
ZNF626
MMP14
CWC15
WDR83
LOC105376235
FOXP2
VAMP4
P3H2
MBTPS1
GPR155
KATNAL1
MIR548AM
EIF3B
OPHN1
PREPL
SCX
GPCPD1
H3F3AP4
RASA3

NM_015204 // RefSeq // Homo sapiens thrombospondin, type I, domain
containing 7A (THSD7
NM_002472 // RefSeq // Homo sapiens myosin, heavy chain 8, skeletal muscle,
perinatal (
NM_001009922 // RefSeq // Homo sapiens ring finger and CHY zinc finger
domain containin
NM_003840 // RefSeq // Homo sapiens tumor necrosis factor receptor
superfamily, member
NM_001142353 // RefSeq // Homo sapiens protein phosphatase 3, catalytic
subunit, beta i
NM_001166386 // RefSeq // Homo sapiens melanoma antigen family A12
(MAGEA12), transcrip
NM_001143676 // RefSeq // Homo sapiens serum/glucocorticoid regulated kinase
1 (SGK1),
NM_001185077 // RefSeq // Homo sapiens Rho GDP dissociation inhibitor (GDI)
alpha (ARHG
NR_003135 // RefSeq // Homo sapiens centrosomal protein 170kDa pseudogene 1
(CEP170P1),
NM_001039538 // RefSeq // Homo sapiens microtubule-associated protein 2
(MAP2), transcr
NM_021063 // RefSeq // Homo sapiens histone cluster 1, H2bd (HIST1H2BD),
transcript var
NM_001164746 // RefSeq // Homo sapiens Ras association (RalGDS/AF-6)
domain family (N-t
XM_005246931 // RefSeq // PREDICTED: Homo sapiens UDP-Gal:betaGlcNAc
beta 1,3-galactosy
NR_024348 // RefSeq // Homo sapiens FBXL19 antisense RNA 1 (head to head)
(FBXL19-AS1),
NM_001198915 // RefSeq // Homo sapiens PTPRF interacting protein, binding
protein 1 (li
NM_001076675 // RefSeq // Homo sapiens zinc finger protein 626 (ZNF626),
transcript var
NM_004995 // RefSeq // Homo sapiens matrix metallopeptidase 14 (membraneinserted) (MMP
NM_016403 // RefSeq // Homo sapiens CWC15 spliceosome-associated protein
(CWC15), mRNA.
NM_001099737 // RefSeq // Homo sapiens WD repeat domain 83 (WDR83),
transcript variant
XR_930270 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105376235 (LOC1053762
NM_001172766 // RefSeq // Homo sapiens forkhead box P2 (FOXP2), transcript
variant 5, m
NM_001185127 // RefSeq // Homo sapiens vesicle-associated membrane protein 4
(VAMP4), t
NM_001134418 // RefSeq // Homo sapiens prolyl 3-hydroxylase 2 (P3H2),
transcript varian
NM_003791 // RefSeq // Homo sapiens membrane-bound transcription factor
peptidase, site
NM_001033045 // RefSeq // Homo sapiens G protein-coupled receptor 155
(GPR155), transcr
NM_001014380 // RefSeq // Homo sapiens katanin p60 subunit A-like 1
(KATNAL1), transcri
NR_039762 // RefSeq // Homo sapiens microRNA 548am (MIR548AM),
microRNA. // chrX // 100
NM_001037283 // RefSeq // Homo sapiens eukaryotic translation initiation factor
3, subu
NM_002547 // RefSeq // Homo sapiens oligophrenin 1 (OPHN1), mRNA. // chrX
// 100 // 89
NM_001042385 // RefSeq // Homo sapiens prolyl endopeptidase-like (PREPL),
transcript va
NM_001080514 // RefSeq // Homo sapiens scleraxis bHLH transcription factor
(SCX), mRNA.
NM_019593 // RefSeq // Homo sapiens glycerophosphocholine phosphodiesterase
1 (GPCPD1),
NR_002315 // RefSeq // Homo sapiens H3 histone, family 3A, pseudogene 4
(H3F3AP4), nonNM_007368 // RefSeq // Homo sapiens RAS p21 protein activator 3 (RASA3),
mRNA. // chr13

1.811745
1.80751
1.801645
1.800885
1.7959
1.79377
1.792335
1.791955
1.78878
1.78864
1.788425
1.78679
1.7843
1.78243
1.7789
1.776355
1.776015
1.7755
1.77217
1.77159
1.769185
1.769
1.768995
1.76674
1.76206
1.760585
1.758735
1.756245
1.756205
1.755085
1.7548
1.754265
1.75039
1.75039
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Appendix Table 2 Genes downregulated in Microarray ≤ -1.75 fold-change (441 genes)
Gene Symbol

TGFBR3
ULBP1
SLC35F1
APOLD1
CCNE2
HIST1H1B
GUCY1B3
BLM
ARRB2
BRCA2
TICRR
SGOL1
HIST1H3G
FAM72D
HIST1H2BH
TYMS
MASTL
STC1
HIST1H3F
SERPINB9
CCNA2
SKA1
FBXO43
HIST2H3A
HIST2H3A
MKI67
PCNA
FAM111B
PLPP1
CDC25C
PBK

Assignment
NM_001195683 // RefSeq // Homo sapiens transforming growth factor, beta
receptor III (T
NM_025218 // RefSeq // Homo sapiens UL16 binding protein 1 (ULBP1), mRNA.
// chr6 // 10
NM_001029858 // RefSeq // Homo sapiens solute carrier family 35, member F1
(SLC35F1), m
ENST00000534843 // ENSEMBL // apolipoprotein L domain containing 1
[gene_biotype:protei
NM_057749 // RefSeq // Homo sapiens cyclin E2 (CCNE2), mRNA. // chr8 // 100
// 67 // 18
NM_005322 // RefSeq // Homo sapiens histone cluster 1, H1b (HIST1H1B),
mRNA. // chr6 //
NM_000857 // RefSeq // Homo sapiens guanylate cyclase 1, soluble, beta 3
(GUCY1B3), tra
NM_000057 // RefSeq // Homo sapiens Bloom syndrome, RecQ helicase-like
(BLM), transcrip
NM_001257328 // RefSeq // Homo sapiens arrestin, beta 2 (ARRB2), transcript
variant 3,
NM_000059 // RefSeq // Homo sapiens breast cancer 2, early onset (BRCA2),
mRNA. // chr1
NM_001308025 // RefSeq // Homo sapiens TOPBP1-interacting checkpoint and
replication re
NM_001012409 // RefSeq // Homo sapiens shugoshin-like 1 (S. pombe) (SGOL1),
transcript
NM_003534 // RefSeq // Homo sapiens histone cluster 1, H3g (HIST1H3G),
mRNA. // chr6 //
NM_207418 // RefSeq // Homo sapiens family with sequence similarity 72,
member D (FAM72
NM_003524 // RefSeq // Homo sapiens histone cluster 1, H2bh (HIST1H2BH),
mRNA. // chr6
NM_001071 // RefSeq // Homo sapiens thymidylate synthetase (TYMS), mRNA.
// chr18 // 10
NM_001172303 // RefSeq // Homo sapiens microtubule associated
serine/threonine kinase-l
NM_003155 // RefSeq // Homo sapiens stanniocalcin 1 (STC1), mRNA. // chr8 //
100 // 86
NM_021018 // RefSeq // Homo sapiens histone cluster 1, H3f (HIST1H3F),
mRNA. // chr6 //
NM_004155 // RefSeq // Homo sapiens serpin peptidase inhibitor, clade B
(ovalbumin), me
NM_001237 // RefSeq // Homo sapiens cyclin A2 (CCNA2), mRNA. // chr4 // 100
// 100 // 2
NM_001039535 // RefSeq // Homo sapiens spindle and kinetochore associated
complex subun
NM_001029860 // RefSeq // Homo sapiens F-box protein 43 (FBXO43), transcript
variant 2,
NM_001005464 // RefSeq // Homo sapiens histone cluster 2, H3a (HIST2H3A),
mRNA. // chr1
NM_001005464 // RefSeq // Homo sapiens histone cluster 2, H3a (HIST2H3A),
mRNA. // chr1
NM_001145966 // RefSeq // Homo sapiens marker of proliferation Ki-67
(MKI67), transcrip
NM_002592 // RefSeq // Homo sapiens proliferating cell nuclear antigen (PCNA),
transcri
NM_001142703 // RefSeq // Homo sapiens family with sequence similarity 111,
member B (F
NM_003711 // RefSeq // Homo sapiens phospholipid phosphatase 1 (PLPP1),
transcript vari
NM_001287582 // RefSeq // Homo sapiens cell division cycle 25C (CDC25C),
transcript var
NM_001278945 // RefSeq // Homo sapiens PDZ binding kinase (PBK), transcript
variant 2,

Average
Fold-Change

-7.6191
-4.62948
-4.51595
-3.9413
-3.82031
-3.77962
-3.73332
-3.56194
-3.53547
-3.4322
-3.23973
-3.23506
-3.22531
-3.18314
-3.17553
-3.14754
-3.10531
-3.09791
-3.0844
-3.04552
-3.00154
-2.98977
-2.94798
-2.93141
-2.93141
-2.87658
-2.87572
-2.87548
-2.86974
-2.85109
-2.85087
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HIST1H3E
RNF10
XRCC2
SGMS2
MYBL2
SLC7A11
ATAD5
POLQ
PPDPF
TSPAN6
KIF15
ENPP1
KIF24
MARCKS
EME1
ASNS
NSA2
MNS1
CKAP2L
HIST1H2AM
CDT1
NEIL3
HIST1H3J
FANCI
CENPQ
DLGAP5
BRCA1
CENPF
MKNK2
CCNB2
SRRM2
YBX2
TSPAN13
C5

NM_003532 // RefSeq // Homo sapiens histone cluster 1, H3e (HIST1H3E),
mRNA. // chr6 //
NM_014868 // RefSeq // Homo sapiens ring finger protein 10 (RNF10), mRNA. //
chr12 // 1
NM_005431 // RefSeq // Homo sapiens X-ray repair complementing defective
repair in Chin
NM_001136257 // RefSeq // Homo sapiens sphingomyelin synthase 2 (SGMS2),
transcript var
NM_001278610 // RefSeq // Homo sapiens v-myb avian myeloblastosis viral
oncogene homolo
NM_014331 // RefSeq // Homo sapiens solute carrier family 7 (anionic amino acid
transpo
NM_024857 // RefSeq // Homo sapiens ATPase family, AAA domain containing 5
(ATAD5), mRN
NM_199420 // RefSeq // Homo sapiens polymerase (DNA directed), theta
(POLQ), mRNA. // c
NM_024299 // RefSeq // Homo sapiens pancreatic progenitor cell differentiation
and prol
NM_001278740 // RefSeq // Homo sapiens tetraspanin 6 (TSPAN6), transcript
variant 2, mR
NM_020242 // RefSeq // Homo sapiens kinesin family member 15 (KIF15),
mRNA. // chr3 //
NM_006208 // RefSeq // Homo sapiens ectonucleotide
pyrophosphatase/phosphodiesterase 1
NM_194313 // RefSeq // Homo sapiens kinesin family member 24 (KIF24),
mRNA. // chr9 //
NM_002356 // RefSeq // Homo sapiens myristoylated alanine-rich protein kinase
C substra
NM_001166131 // RefSeq // Homo sapiens essential meiotic structure-specific
endonucleas
NM_001178075 // RefSeq // Homo sapiens asparagine synthetase (glutaminehydrolyzing) (A
NM_001271665 // RefSeq // Homo sapiens NSA2 ribosome biogenesis homolog
(NSA2), transcr
NM_018365 // RefSeq // Homo sapiens meiosis-specific nuclear structural 1
(MNS1), mRNA.
NM_001304361 // RefSeq // Homo sapiens cytoskeleton associated protein 2-like
(CKAP2L),
NM_003514 // RefSeq // Homo sapiens histone cluster 1, H2am (HIST1H2AM),
mRNA. // chr6
NM_030928 // RefSeq // Homo sapiens chromatin licensing and DNA replication
factor 1 (C
NM_018248 // RefSeq // Homo sapiens nei-like DNA glycosylase 3 (NEIL3),
mRNA. // chr4 /
ENST00000479986 // ENSEMBL // histone cluster 1, H3j
[gene_biotype:protein_coding trans
NM_001113378 // RefSeq // Homo sapiens Fanconi anemia, complementation
group I (FANCI),
NM_018132 // RefSeq // Homo sapiens centromere protein Q (CENPQ), mRNA. //
chr6 // 100
NM_001146015 // RefSeq // Homo sapiens discs, large (Drosophila) homologassociated pro
NM_007294 // RefSeq // Homo sapiens breast cancer 1, early onset (BRCA1),
transcript va
NM_016343 // RefSeq // Homo sapiens centromere protein F, 350/400kDa
(CENPF), mRNA. //
NM_017572 // RefSeq // Homo sapiens MAP kinase interacting serine/threonine
kinase 2 (M
NM_004701 // RefSeq // Homo sapiens cyclin B2 (CCNB2), mRNA. // chr15 //
100 // 79 // 2
NM_016333 // RefSeq // Homo sapiens serine/arginine repetitive matrix 2
(SRRM2), mRNA.
NM_015982 // RefSeq // Homo sapiens Y box binding protein 2 (YBX2), mRNA.
// chr17 // 1
NM_014399 // RefSeq // Homo sapiens tetraspanin 13 (TSPAN13), mRNA. // chr7
// 100 // 7
NM_001735 // RefSeq // Homo sapiens complement component 5 (C5), mRNA. //
chr9 // 100 /

-2.81285
-2.80049
-2.79875
-2.7831
-2.78231
-2.77462
-2.75198
-2.73644
-2.7147
-2.71416
-2.7103
-2.70423
-2.70389
-2.66908
-2.66487
-2.652
-2.64196
-2.63135
-2.59652
-2.58476
-2.58378
-2.58248
-2.58117
-2.57447
-2.57397
-2.57062
-2.54913
-2.54742
-2.53381
-2.52602
-2.51062
-2.50458
-2.49473
-2.49208
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TPM4
HORMAD1
FADS1
PHGDH
FANCA
EXO1
TRIM6
RAD51
FAM64A
CENPK
HTR1D
GINS2
HIST1H2BI
E2F7
KIF20A
COMMD8
KIF18B
SLC7A5
HIST1H2AB
GPR19
MCM10
KIF11
KNTC1
ARID3B
MIF4GD
TNFRSF9
HIST1H3B
DTL
CDCA8
DEPDC1
ZIK1
NTAN1
SPAG5
CDKN3

NM_001145160 // RefSeq // Homo sapiens tropomyosin 4 (TPM4), transcript
variant Tpm4.1,
NM_001199829 // RefSeq // Homo sapiens HORMA domain containing 1
(HORMAD1), transcript
NM_013402 // RefSeq // Homo sapiens fatty acid desaturase 1 (FADS1), mRNA.
// chr11 //
NM_006623 // RefSeq // Homo sapiens phosphoglycerate dehydrogenase
(PHGDH), mRNA. // ch
NM_000135 // RefSeq // Homo sapiens Fanconi anemia, complementation group
A (FANCA), tr
NM_003686 // RefSeq // Homo sapiens exonuclease 1 (EXO1), transcript variant
3, mRNA. /
NM_001003818 // RefSeq // Homo sapiens tripartite motif containing 6 (TRIM6),
transcrip
NM_001164269 // RefSeq // Homo sapiens RAD51 recombinase (RAD51),
transcript variant 4,
NM_001195228 // RefSeq // Homo sapiens family with sequence similarity 64,
member A (FA
NM_001267038 // RefSeq // Homo sapiens centromere protein K (CENPK),
transcript variant
NM_000864 // RefSeq // Homo sapiens 5-hydroxytryptamine (serotonin) receptor
1D, G prot
NM_016095 // RefSeq // Homo sapiens GINS complex subunit 2 (Psf2 homolog)
(GINS2), mRNA
NM_003525 // RefSeq // Homo sapiens histone cluster 1, H2bi (HIST1H2BI),
mRNA. // chr6
NM_203394 // RefSeq // Homo sapiens E2F transcription factor 7 (E2F7), mRNA.
// chr12 /
NM_005733 // RefSeq // Homo sapiens kinesin family member 20A (KIF20A),
mRNA. // chr5 /
NM_017845 // RefSeq // Homo sapiens COMM domain containing 8 (COMMD8),
mRNA. // chr4 //
NM_001264573 // RefSeq // Homo sapiens kinesin family member 18B (KIF18B),
transcript v
NM_003486 // RefSeq // Homo sapiens solute carrier family 7 (amino acid
transporter lig
NM_003513 // RefSeq // Homo sapiens histone cluster 1, H2ab (HIST1H2AB),
mRNA. // chr6
NM_006143 // RefSeq // Homo sapiens G protein-coupled receptor 19 (GPR19),
mRNA. // chr
NM_018518 // RefSeq // Homo sapiens minichromosome maintenance 10
replication initiatio
NM_004523 // RefSeq // Homo sapiens kinesin family member 11 (KIF11),
mRNA. // chr10 //
NM_014708 // RefSeq // Homo sapiens kinetochore associated 1 (KNTC1),
mRNA. // chr12 //
NM_001307939 // RefSeq // Homo sapiens AT rich interactive domain 3B
(BRIGHT-like) (ARI
NM_001242498 // RefSeq // Homo sapiens MIF4G domain containing (MIF4GD),
transcript var
NM_001561 // RefSeq // Homo sapiens tumor necrosis factor receptor
superfamily, member
NM_003537 // RefSeq // Homo sapiens histone cluster 1, H3b (HIST1H3B),
mRNA. // chr6 //
NM_001286229 // RefSeq // Homo sapiens denticleless E3 ubiquitin protein ligase
homolog
NM_001256875 // RefSeq // Homo sapiens cell division cycle associated 8
(CDCA8), transc
NM_001114120 // RefSeq // Homo sapiens DEP domain containing 1 (DEPDC1),
transcript var
NM_001010879 // RefSeq // Homo sapiens zinc finger protein interacting with K
protein 1
NM_001270766 // RefSeq // Homo sapiens N-terminal asparagine amidase
(NTAN1), transcrip
NM_006461 // RefSeq // Homo sapiens sperm associated antigen 5 (SPAG5),
mRNA. // chr17
NM_001130851 // RefSeq // Homo sapiens cyclin-dependent kinase inhibitor 3
(CDKN3), tra

-2.49028
-2.48965
-2.48957
-2.48909
-2.48745
-2.48328
-2.48296
-2.48137
-2.48059
-2.47994
-2.4733
-2.46952
-2.46158
-2.46125
-2.4581
-2.45305
-2.44763
-2.44165
-2.4379
-2.43532
-2.42739
-2.41916
-2.41799
-2.4156
-2.4132
-2.41134
-2.4016
-2.39383
-2.39189
-2.39187
-2.37509
-2.37377
-2.36951
-2.36825
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GSG2
TOB2P1
STAG3
ASPM
ORC1
NDC80
MIR634
SPC25
LRRCC1
CBX1
ARL17A
PTTG1
TOP2A
RPL23AP53
NCAPH
PLK4
SYNE2
GINS4
AUNIP
SKA3
HIST1H1E
ARSB
SLC1A5
RAD54L
TTK
MTBP
MXRA8
ALDH1L2
TIMM21
HMGB2
C1orf112
NET1
LOC105374104
QIQN5815

NM_031965 // RefSeq // Homo sapiens germ cell associated 2 (haspin) (GSG2),
mRNA. // ch
NR_002936 // RefSeq // Homo sapiens transducer of ERBB2, 2 pseudogene 1
(TOB2P1), non-c
NM_001282716 // RefSeq // Homo sapiens stromal antigen 3 (STAG3), transcript
variant 2,
NM_001206846 // RefSeq // Homo sapiens abnormal spindle microtubule
assembly (ASPM), tr
NM_001190818 // RefSeq // Homo sapiens origin recognition complex, subunit 1
(ORC1), tr
NM_006101 // RefSeq // Homo sapiens NDC80 kinetochore complex component
(NDC80), mRNA.
NR_030364 // RefSeq // Homo sapiens microRNA 634 (MIR634), microRNA. //
chr17 // 100 //
NM_020675 // RefSeq // Homo sapiens SPC25, NDC80 kinetochore complex
component (SPC25),
NM_033402 // RefSeq // Homo sapiens leucine rich repeat and coiled-coil
centrosomal pro
NM_001127228 // RefSeq // Homo sapiens chromobox homolog 1 (CBX1),
transcript variant 2
uc010wwt.2 // UCSC Genes // Homo sapiens ADP-ribosylation factor-like 17A
(ARL17A), tra
NM_001282382 // RefSeq // Homo sapiens pituitary tumor-transforming 1
(PTTG1), transcri
NM_001067 // RefSeq // Homo sapiens topoisomerase (DNA) II alpha 170kDa
(TOP2A), mRNA.
NR_003572 // RefSeq // Homo sapiens ribosomal protein L23a pseudogene 53
(RPL23AP53), n
NM_001281710 // RefSeq // Homo sapiens non-SMC condensin I complex,
subunit H (NCAPH),
NM_001190799 // RefSeq // Homo sapiens polo-like kinase 4 (PLK4), transcript
variant 2,
NM_015180 // RefSeq // Homo sapiens spectrin repeat containing, nuclear
envelope 2 (SYN
NM_032336 // RefSeq // Homo sapiens GINS complex subunit 4 (Sld5 homolog)
(GINS4), mRNA
NM_001287490 // RefSeq // Homo sapiens aurora kinase A and ninein interacting
protein (
NM_001166017 // RefSeq // Homo sapiens spindle and kinetochore associated
complex subun
NM_005321 // RefSeq // Homo sapiens histone cluster 1, H1e (HIST1H1E),
mRNA. // chr6 //
NM_000046 // RefSeq // Homo sapiens arylsulfatase B (ARSB), transcript variant
1, mRNA.
NM_001145144 // RefSeq // Homo sapiens solute carrier family 1 (neutral amino
acid tran
NM_001142548 // RefSeq // Homo sapiens RAD54-like (S. cerevisiae)
(RAD54L), transcript
NM_001166691 // RefSeq // Homo sapiens TTK protein kinase (TTK), transcript
variant 2,
NM_022045 // RefSeq // Homo sapiens MDM2 binding protein (MTBP), mRNA.
// chr8 // 100 /
NM_001282582 // RefSeq // Homo sapiens matrix-remodelling associated 8
(MXRA8), transcr
NM_001034173 // RefSeq // Homo sapiens aldehyde dehydrogenase 1 family,
member L2 (ALDH
NM_014177 // RefSeq // Homo sapiens translocase of inner mitochondrial
membrane 21 homo
NM_001130688 // RefSeq // Homo sapiens high mobility group box 2 (HMGB2),
transcript va
NM_018186 // RefSeq // Homo sapiens chromosome 1 open reading frame 112
(C1orf112), mRN
NM_001047160 // RefSeq // Homo sapiens neuroepithelial cell transforming 1
(NET1), tran
XR_924474 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105374104 (LOC1053741
AY358807 // GenBank // Homo sapiens clone DNA129580 QIQN5815
(UNQ5815) mRNA, complete c

-2.36041
-2.35917
-2.3581
-2.34388
-2.34261
-2.33825
-2.33724
-2.3364
-2.33023
-2.32889
-2.32815
-2.32531
-2.31916
-2.31843
-2.31523
-2.31308
-2.30654
-2.30582
-2.30536
-2.29483
-2.29437
-2.28673
-2.28431
-2.28079
-2.28067
-2.28056
-2.27993
-2.27302
-2.26865
-2.26709
-2.25193
-2.24356
-2.24206
-2.24121
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HIST1H2AJ
ESCO2
CDC45
SLC25A40
MELK
NUF2
FBN1
RNASEH2A
HMMR
FLJ36000
LOC729732
CDK1
FANCD2
RRM2
DMC1
PRIM1
HIST1H1C
HIST1H2BM
LOC389831
TK1
TXNDC16
CDCA2
CEP128
ZNF318
PRC1
CLSPN
CENPE
LOC105376944
CHAC1
KIFC1
BIRC5
NUSAP1
ARHGAP11B
MCM8

NM_021066 // RefSeq // Homo sapiens histone cluster 1, H2aj (HIST1H2AJ),
mRNA. // chr6
NM_001017420 // RefSeq // Homo sapiens establishment of sister chromatid
cohesion N-ace
NM_001178010 // RefSeq // Homo sapiens cell division cycle 45 (CDC45),
transcript varia
NM_018843 // RefSeq // Homo sapiens solute carrier family 25, member 40
(SLC25A40), mRN
NM_001256685 // RefSeq // Homo sapiens maternal embryonic leucine zipper
kinase (MELK),
NM_031423 // RefSeq // Homo sapiens NUF2, NDC80 kinetochore complex
component (NUF2), t
NM_000138 // RefSeq // Homo sapiens fibrillin 1 (FBN1), mRNA. // chr15 // 100
// 92 //
NM_006397 // RefSeq // Homo sapiens ribonuclease H2, subunit A
(RNASEH2A), mRNA. // chr
NM_001142556 // RefSeq // Homo sapiens hyaluronan-mediated motility receptor
(RHAMM) (H
NR_027084 // RefSeq // Homo sapiens uncharacterized FLJ36000 (FLJ36000),
long non-codin
NR_047662 // RefSeq // Homo sapiens uncharacterized LOC729732
(LOC729732), long non-cod
NM_001170406 // RefSeq // Homo sapiens cyclin-dependent kinase 1 (CDK1),
transcript var
NM_001018115 // RefSeq // Homo sapiens Fanconi anemia, complementation
group D2 (FANCD2
NM_001034 // RefSeq // Homo sapiens ribonucleotide reductase M2 (RRM2),
transcript vari
NM_001278208 // RefSeq // Homo sapiens DNA meiotic recombinase 1 (DMC1),
transcript var
NM_000946 // RefSeq // Homo sapiens primase, DNA, polypeptide 1 (49kDa)
(PRIM1), mRNA.
NM_005319 // RefSeq // Homo sapiens histone cluster 1, H1c (HIST1H1C),
mRNA. // chr6 //
NM_003521 // RefSeq // Homo sapiens histone cluster 1, H2bm (HIST1H2BM),
mRNA. // chr6
NM_001242480 // RefSeq // Homo sapiens uncharacterized LOC389831
(LOC389831), mRNA. //
NM_003258 // RefSeq // Homo sapiens thymidine kinase 1, soluble (TK1),
mRNA. // chr17 /
NM_001160047 // RefSeq // Homo sapiens thioredoxin domain containing 16
(TXNDC16), tran
NM_152562 // RefSeq // Homo sapiens cell division cycle associated 2 (CDCA2),
mRNA. //
NM_152446 // RefSeq // Homo sapiens centrosomal protein 128kDa (CEP128),
mRNA. // chr14
NM_014345 // RefSeq // Homo sapiens zinc finger protein 318 (ZNF318), mRNA.
// chr6 //
NM_001267580 // RefSeq // Homo sapiens protein regulator of cytokinesis 1
(PRC1), trans
NM_001190481 // RefSeq // Homo sapiens claspin (CLSPN), transcript variant 2,
mRNA. //
NM_001286734 // RefSeq // Homo sapiens centromere protein E, 312kDa
(CENPE), transcript
XR_936590 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105376944 (LOC1053769
NM_001142776 // RefSeq // Homo sapiens ChaC glutathione-specific gammaglutamylcyclotra
NM_002263 // RefSeq // Homo sapiens kinesin family member C1 (KIFC1),
mRNA. // chr6 //
NM_001012270 // RefSeq // Homo sapiens baculoviral IAP repeat containing 5
(BIRC5), tra
NM_001243142 // RefSeq // Homo sapiens nucleolar and spindle associated
protein 1 (NUSA
OTTHUMT00000430733 // Havana transcript // Rho GTPase activating protein
11B[gene_bioty
NM_001281520 // RefSeq // Homo sapiens minichromosome maintenance 8
homologous recombin

-2.24093
-2.23819
-2.22858
-2.22491
-2.2229
-2.21993
-2.21078
-2.21014
-2.2026
-2.20157
-2.20116
-2.20087
-2.19693
-2.19325
-2.19226
-2.19159
-2.19158
-2.19058
-2.18987
-2.18966
-2.18921
-2.18685
-2.18442
-2.18214
-2.17532
-2.17491
-2.17471
-2.17244
-2.17196
-2.16841
-2.16823
-2.15713
-2.15201
-2.15079
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EIF4EBP1
ZNF257
BORA
ZNF362
HIST1H4B
PLK1
PDS5B
ASF1B
PSMG2
MAP1B
MMD
LMNB2
C7orf60
NCAPG
FAM222B
XK
CLMP
CDK14
DSCC1
ZNF732
TEX15
FOPNL
LOC105370623
MDC1
NFATC3
ECT2
STIL
MYL9
CDC6
ZBED8
KIF14
ETV4
LINC01096
RTKN2

NM_004095 // RefSeq // Homo sapiens eukaryotic translation initiation factor 4E
binding
NM_033468 // RefSeq // Homo sapiens zinc finger protein 257 (ZNF257), mRNA.
// chr19 //
NM_001286746 // RefSeq // Homo sapiens bora, aurora kinase A activator
(BORA), transcri
NM_152493 // RefSeq // Homo sapiens zinc finger protein 362 (ZNF362), mRNA.
// chr1 //
NM_003544 // RefSeq // Homo sapiens histone cluster 1, H4b (HIST1H4B),
mRNA. // chr6 //
NM_005030 // RefSeq // Homo sapiens polo-like kinase 1 (PLK1), mRNA. //
chr16 // 100 //
NM_015032 // RefSeq // Homo sapiens PDS5 cohesin associated factor B
(PDS5B), mRNA. //
NM_018154 // RefSeq // Homo sapiens anti-silencing function 1B histone
chaperone (ASF1B
NM_020232 // RefSeq // Homo sapiens proteasome (prosome, macropain)
assembly chaperone
NM_005909 // RefSeq // Homo sapiens microtubule-associated protein 1B
(MAP1B), mRNA. //
NM_012329 // RefSeq // Homo sapiens monocyte to macrophage differentiationassociated (
NM_032737 // RefSeq // Homo sapiens lamin B2 (LMNB2), mRNA. // chr19 //
100 // 94 // 29
NM_152556 // RefSeq // Homo sapiens chromosome 7 open reading frame 60
(C7orf60), mRNA.
NM_022346 // RefSeq // Homo sapiens non-SMC condensin I complex, subunit G
(NCAPG), tra
NM_001077498 // RefSeq // Homo sapiens family with sequence similarity 222,
member B (F
NM_021083 // RefSeq // Homo sapiens X-linked Kx blood group (XK), mRNA. //
chrX // 100
NM_024769 // RefSeq // Homo sapiens CXADR-like membrane protein (CLMP),
mRNA. // chr11
NM_001287135 // RefSeq // Homo sapiens cyclin-dependent kinase 14 (CDK14),
transcript v
NM_024094 // RefSeq // Homo sapiens DNA replication and sister chromatid
cohesion 1 (DS
NM_001137608 // RefSeq // Homo sapiens zinc finger protein 732 (ZNF732),
mRNA. // chr4
NM_031271 // RefSeq // Homo sapiens testis expressed 15 (TEX15), mRNA. //
chr8 // 100 /
NM_001304497 // RefSeq // Homo sapiens FGFR1OP N-terminal like (FOPNL),
transcript vari
XR_915902 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105370623 (LOC1053706
NM_014641 // RefSeq // Homo sapiens mediator of DNA-damage checkpoint 1
(MDC1), mRNA. /
NM_004555 // RefSeq // Homo sapiens nuclear factor of activated T-cells,
cytoplasmic, c
NM_001258315 // RefSeq // Homo sapiens epithelial cell transforming 2 (ECT2),
transcrip
NM_001048166 // RefSeq // Homo sapiens SCL/TAL1 interrupting locus (STIL),
transcript v
NM_006097 // RefSeq // Homo sapiens myosin, light chain 9, regulatory (MYL9),
transcrip
NM_001254 // RefSeq // Homo sapiens cell division cycle 6 (CDC6), mRNA. //
chr17 // 100
NM_001303251 // RefSeq // Homo sapiens zinc finger, BED-type containing 8
(ZBED8), tran
NM_001305792 // RefSeq // Homo sapiens kinesin family member 14 (KIF14),
transcript var
NM_001079675 // RefSeq // Homo sapiens ets variant 4 (ETV4), transcript variant
2, mRNA
NR_015450 // RefSeq // Homo sapiens long intergenic non-protein coding RNA
1096 (LINC01
NM_001282941 // RefSeq // Homo sapiens rhotekin 2 (RTKN2), transcript variant
2, mRNA.

-2.14859
-2.14772
-2.14507
-2.13866
-2.13846
-2.13694
-2.12941
-2.12772
-2.12637
-2.11948
-2.11831
-2.11778
-2.11543
-2.11229
-2.11169
-2.0995
-2.08887
-2.08755
-2.08379
-2.07746
-2.07638
-2.07263
-2.06905
-2.06881
-2.06809
-2.06422
-2.06414
-2.06385
-2.05956
-2.05872
-2.05825
-2.05774
-2.05319
-2.0494
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DIAPH3
HIST1H2AI
LOC105373133
MEAT6
CKAP2
LOC257396
MCM5
CENPU
C9orf84
EFEMP1
DEPDC1B
OIP5
PKMYT1
ZWINT
RPL39L
TBC1D22AAS1
CEP55
EZR
RBL1
TRO
RFC3
SUZ12
EBAG9
DDIAS
KIF5C
CENPA
ZWILCH
FOXM1
IQGAP3
LOC101926892
MCM3
CENPN
BUB1

NM_001042517 // RefSeq // Homo sapiens diaphanous-related formin 3
(DIAPH3), transcript
NM_003509 // RefSeq // Homo sapiens histone cluster 1, H2ai (HIST1H2AI),
mRNA. // chr6
XM_011508982 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105373133 (LOC1053
NR_131926 // RefSeq // Homo sapiens melanoma-associated transcript 6
(MEAT6), long nonNM_001098525 // RefSeq // Homo sapiens cytoskeleton associated protein 2
(CKAP2), trans
NR_034107 // RefSeq // Homo sapiens uncharacterized LOC257396
(LOC257396), transcript v
NM_006739 // RefSeq // Homo sapiens minichromosome maintenance complex
component 5 (MCM
NM_024629 // RefSeq // Homo sapiens centromere protein U (CENPU), transcript
variant 1,
NM_001080551 // RefSeq // Homo sapiens chromosome 9 open reading frame 84
(C9orf84), tr
NM_001039348 // RefSeq // Homo sapiens EGF containing fibulin-like
extracellular matrix
NM_001145208 // RefSeq // Homo sapiens DEP domain containing 1B
(DEPDC1B), transcript v
NM_007280 // RefSeq // Homo sapiens Opa interacting protein 5 (OIP5), mRNA.
// chr15 //
NM_001258450 // RefSeq // Homo sapiens protein kinase, membrane associated
tyrosine/thr
NM_001005413 // RefSeq // Homo sapiens ZW10 interacting kinetochore protein
(ZWINT), tr
NM_052969 // RefSeq // Homo sapiens ribosomal protein L39-like (RPL39L),
mRNA. // chr3
NR_122047 // RefSeq // Homo sapiens TBC1D22A antisense RNA 1
(TBC1D22A-AS1), long non-c
NM_001127182 // RefSeq // Homo sapiens centrosomal protein 55kDa (CEP55),
transcript va
NM_001111077 // RefSeq // Homo sapiens ezrin (EZR), transcript variant 2,
mRNA. // chr6
NM_002895 // RefSeq // Homo sapiens retinoblastoma-like 1 (RBL1), transcript
variant 1,
NM_001039705 // RefSeq // Homo sapiens trophinin (TRO), transcript variant 6,
mRNA. //
NM_002915 // RefSeq // Homo sapiens replication factor C (activator 1) 3, 38kDa
(RFC3),
NM_015355 // RefSeq // Homo sapiens SUZ12 polycomb repressive complex 2
subunit (SUZ12)
NM_001278938 // RefSeq // Homo sapiens estrogen receptor binding site
associated, antig
NM_145018 // RefSeq // Homo sapiens DNA damage-induced apoptosis
suppressor (DDIAS), mR
NM_004522 // RefSeq // Homo sapiens kinesin family member 5C (KIF5C),
transcript varian
NM_001042426 // RefSeq // Homo sapiens centromere protein A (CENPA),
transcript variant
NM_001287821 // RefSeq // Homo sapiens zwilch kinetochore protein (ZWILCH),
transcript
NM_001243088 // RefSeq // Homo sapiens forkhead box M1 (FOXM1), transcript
variant 4, m
NM_178229 // RefSeq // Homo sapiens IQ motif containing GTPase activating
protein 3 (IQ
NR_110653 // RefSeq // Homo sapiens uncharacterized LOC101926892
(LOC101926892), long n
NM_001270472 // RefSeq // Homo sapiens minichromosome maintenance
complex component 3 (
NM_001100624 // RefSeq // Homo sapiens centromere protein N (CENPN),
transcript variant
NM_001278616 // RefSeq // Homo sapiens BUB1 mitotic checkpoint
serine/threonine kinase

-2.04876
-2.04656
-2.04589
-2.04357
-2.03953
-2.03846
-2.03843
-2.03755
-2.03306
-2.02715
-2.02609
-2.02582
-2.02559
-2.0218
-2.01873
-2.0186
-2.01809
-2.01395
-2.01384
-2.01381
-2.01231
-2.00955
-2.00784
-2.0062
-2.00381
-2.00203
-1.99939
-1.99913
-1.9938
-1.99268
-1.9913
-1.989
-1.98889

117

LOC105370496
FANCB
EML1
STOX1
LRR1
KIF20B
CCNE1
AKT3
DNA2
SIMC1
CDC20
DUSP3
CEP57
UBL7-AS1
RMND5A
ITGB3BP
DSN1
AURKB
KNSTRN
MIR130B
AGBL2
ZNF680
HIST1H4K
LAMP3
MEIOB
TTF2
HADH
FAM225A
PRR14
RAD51AP1
LOC729088
MCM7
KIF2C
LIG3

XR_915613 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105370496 (LOC1053704
NM_001018113 // RefSeq // Homo sapiens Fanconi anemia, complementation
group B (FANCB),
NM_001008707 // RefSeq // Homo sapiens echinoderm microtubule associated
protein like 1
NM_001130159 // RefSeq // Homo sapiens storkhead box 1 (STOX1), transcript
variant 3, m
NM_152329 // RefSeq // Homo sapiens leucine rich repeat protein 1 (LRR1),
transcript va
NM_001284259 // RefSeq // Homo sapiens kinesin family member 20B (KIF20B),
transcript v
NM_001238 // RefSeq // Homo sapiens cyclin E1 (CCNE1), mRNA. // chr19 //
100 // 100 //
NM_001206729 // RefSeq // Homo sapiens v-akt murine thymoma viral oncogene
homolog 3 (A
NM_001080449 // RefSeq // Homo sapiens DNA replication helicase/nuclease 2
(DNA2), tran
NM_001308195 // RefSeq // Homo sapiens SUMO-interacting motifs containing 1
(SIMC1), tr
NM_001255 // RefSeq // Homo sapiens cell division cycle 20 (CDC20), mRNA. //
chr1 // 10
NM_004090 // RefSeq // Homo sapiens dual specificity phosphatase 3 (DUSP3),
mRNA. // ch
NM_001243776 // RefSeq // Homo sapiens centrosomal protein 57kDa (CEP57),
transcript va
NR_038448 // RefSeq // Homo sapiens UBL7 antisense RNA 1 (head to head)
(UBL7-AS1), tra
NM_022780 // RefSeq // Homo sapiens required for meiotic nuclear division 5
homolog A (
NM_001206739 // RefSeq // Homo sapiens integrin beta 3 binding protein (beta3endonexin
NM_001145315 // RefSeq // Homo sapiens DSN1 homolog, MIS12 kinetochore
complex componen
NM_001256834 // RefSeq // Homo sapiens aurora kinase B (AURKB), transcript
variant 2, m
NM_001142761 // RefSeq // Homo sapiens kinetochore-localized astrin/SPAG5
binding prote
NR_029845 // RefSeq // Homo sapiens microRNA 130b (MIR130B), microRNA.
// chr22 // 100
NM_024783 // RefSeq // Homo sapiens ATP/GTP binding protein-like 2
(AGBL2), mRNA. // ch
NM_001130022 // RefSeq // Homo sapiens zinc finger protein 680 (ZNF680),
transcript var
NM_003541 // RefSeq // Homo sapiens histone cluster 1, H4k (HIST1H4K),
mRNA. // chr6 //
NM_014398 // RefSeq // Homo sapiens lysosomal-associated membrane protein 3
(LAMP3), mR
NM_001163560 // RefSeq // Homo sapiens meiosis specific with OB domains
(MEIOB), transc
NM_003594 // RefSeq // Homo sapiens transcription termination factor, RNA
polymerase II
NM_001184705 // RefSeq // Homo sapiens hydroxyacyl-CoA dehydrogenase
(HADH), transcript
NR_024366 // RefSeq // Homo sapiens family with sequence similarity 225,
member A (nonNM_024031 // RefSeq // Homo sapiens proline rich 14 (PRR14), mRNA. // chr16
// 96 // 10
NM_001130862 // RefSeq // Homo sapiens RAD51 associated protein 1
(RAD51AP1), transcrip
XR_951689 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC729088 (LOC729088), m
NM_001278595 // RefSeq // Homo sapiens minichromosome maintenance
complex component 7 (
NM_001297655 // RefSeq // Homo sapiens kinesin family member 2C (KIF2C),
transcript var
ENST00000378526 // ENSEMBL // ligase III, DNA, ATP-dependent
[gene_biotype:protein_codi

-1.98868
-1.98421
-1.98099
-1.98062
-1.97781
-1.97745
-1.97705
-1.97689
-1.97594
-1.97594
-1.97374
-1.97355
-1.97149
-1.96607
-1.96548
-1.96401
-1.96374
-1.96293
-1.96223
-1.96164
-1.95597
-1.95506
-1.95383
-1.95296
-1.95292
-1.95057
-1.9487
-1.94812
-1.94609
-1.94598
-1.94595
-1.94178
-1.94093
-1.94081
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SOBP
LCLAT1
CEP162
SMC4
HJURP
NDRG1
TROAP
GINS1
POLA2
SGOL2
USP1
EMP2
PTENP1
CENPI
ATP11A
FAM65A
MCM2
MUC1
SHCBP1
UBE2C
PROSER1
TGOLN2
HIST1H4C
GAS2L3
MTFR2
PDCD4
BRIP1
TMPO-AS1
ANLN
ORC6
DOCK11
LOC101927978
LOC101929475
TAS2R30

NM_018013 // RefSeq // Homo sapiens sine oculis binding protein homolog
(SOBP), mRNA. /
NM_001002257 // RefSeq // Homo sapiens lysocardiolipin acyltransferase 1
(LCLAT1), tran
NM_001286206 // RefSeq // Homo sapiens centrosomal protein 162kDa
(CEP162), transcript
NM_001002800 // RefSeq // Homo sapiens structural maintenance of
chromosomes 4 (SMC4),
NM_001282962 // RefSeq // Homo sapiens Holliday junction recognition protein
(HJURP), t
NM_001135242 // RefSeq // Homo sapiens N-myc downstream regulated 1
(NDRG1), transcript
NM_001100620 // RefSeq // Homo sapiens trophinin associated protein (TROAP),
transcript
NM_021067 // RefSeq // Homo sapiens GINS complex subunit 1 (Psf1 homolog)
(GINS1), mRNA
NM_002689 // RefSeq // Homo sapiens polymerase (DNA directed), alpha 2,
accessory subun
NM_001160033 // RefSeq // Homo sapiens shugoshin-like 2 (S. pombe) (SGOL2),
transcript
NM_001017415 // RefSeq // Homo sapiens ubiquitin specific peptidase 1 (USP1),
transcrip
NM_001424 // RefSeq // Homo sapiens epithelial membrane protein 2 (EMP2),
mRNA. // chr1
NR_023917 // RefSeq // Homo sapiens phosphatase and tensin homolog
pseudogene 1 (functi
NM_006733 // RefSeq // Homo sapiens centromere protein I (CENPI), mRNA. //
chrX // 100
NM_015205 // RefSeq // Homo sapiens ATPase, class VI, type 11A (ATP11A),
transcript var
NM_001193522 // RefSeq // Homo sapiens family with sequence similarity 65,
member A (FA
NM_004526 // RefSeq // Homo sapiens minichromosome maintenance complex
component 2 (MCM
NM_001018016 // RefSeq // Homo sapiens mucin 1, cell surface associated
(MUC1), transcr
NM_024745 // RefSeq // Homo sapiens SHC SH2-domain binding protein 1
(SHCBP1), mRNA. //
NM_001281741 // RefSeq // Homo sapiens ubiquitin-conjugating enzyme E2C
(UBE2C), transc
NM_025138 // RefSeq // Homo sapiens proline and serine rich 1 (PROSER1),
mRNA. // chr13
NM_001206840 // RefSeq // Homo sapiens trans-golgi network protein 2
(TGOLN2), transcri
NM_003542 // RefSeq // Homo sapiens histone cluster 1, H4c (HIST1H4C),
mRNA. // chr6 //
NM_001303130 // RefSeq // Homo sapiens growth arrest-specific 2 like 3
(GAS2L3), transc
NM_001099286 // RefSeq // Homo sapiens mitochondrial fission regulator 2
(MTFR2), trans
NM_001199492 // RefSeq // Homo sapiens programmed cell death 4 (neoplastic
transformati
NM_032043 // RefSeq // Homo sapiens BRCA1 interacting protein C-terminal
helicase 1 (BR
NR_027157 // RefSeq // Homo sapiens TMPO antisense RNA 1 (TMPO-AS1),
long non-coding RN
NM_001284301 // RefSeq // Homo sapiens anillin actin binding protein (ANLN),
transcript
NM_014321 // RefSeq // Homo sapiens origin recognition complex, subunit 6
(ORC6), trans
NM_144658 // RefSeq // Homo sapiens dedicator of cytokinesis 11 (DOCK11),
mRNA. // chrX
XR_429768 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC101927978 (LOC1019279
XR_242755 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC101929475 (LOC1019294
ENST00000539585 // ENSEMBL // taste receptor, type 2, member 30
[gene_biotype:protein_c

-1.9385
-1.93616
-1.93355
-1.9333
-1.93232
-1.9301
-1.92979
-1.92743
-1.92498
-1.92472
-1.92398
-1.92346
-1.92251
-1.92228
-1.92057
-1.91896
-1.91833
-1.91794
-1.91675
-1.91653
-1.91487
-1.91374
-1.91322
-1.90984
-1.90928
-1.90912
-1.90746
-1.90716
-1.90631
-1.90481
-1.90208
-1.90171
-1.89932
-1.8989
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CSTF3-AS1
MIR644A
LOC729987
NPR2
BASP1
POLE
FAM161A
POLE2
MDM1
LOC728755
SCML2
MCM4
LOC101929140
ARHGAP11A
RPGRIP1L
RAD54B
WDHD1
MGME1
KIF5A
SFXN2
AMOT
GGH
PARPBP
CABYR
SLC1A4
TAS2R31
NUP54
KIAA1524
HOXD4
FANCG
PLCB4
TRIP13
ARID2
GLI1

NR_034027 // RefSeq // Homo sapiens CSTF3 antisense RNA 1 (head to head)
(CSTF3-AS1), l
NR_030374 // RefSeq // Homo sapiens microRNA 644a (MIR644A), microRNA.
// chr20 // 100
NR_046088 // RefSeq // Homo sapiens uncharacterized LOC729987
(LOC729987), long non-cod
NM_003995 // RefSeq // Homo sapiens natriuretic peptide receptor 2 (NPR2),
mRNA. // chr
NM_001271606 // RefSeq // Homo sapiens brain abundant, membrane attached
signal protein
NM_006231 // RefSeq // Homo sapiens polymerase (DNA directed), epsilon,
catalytic subun
NM_001201543 // RefSeq // Homo sapiens family with sequence similarity 161,
member A (F
NM_001197330 // RefSeq // Homo sapiens polymerase (DNA directed), epsilon 2,
accessory
NM_001205028 // RefSeq // Homo sapiens Mdm1 nuclear protein (MDM1),
transcript variant
XR_110268 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC728755 (LOC728755), t
NM_006089 // RefSeq // Homo sapiens sex comb on midleg-like 2 (Drosophila)
(SCML2), tra
NM_005914 // RefSeq // Homo sapiens minichromosome maintenance complex
component 4 (MCM
NR_120423 // RefSeq // Homo sapiens uncharacterized LOC101929140
(LOC101929140), long n
NM_001286479 // RefSeq // Homo sapiens Rho GTPase activating protein 11A
(ARHGAP11A), t
NM_001127897 // RefSeq // Homo sapiens RPGRIP1-like (RPGRIP1L), transcript
variant 2, m
NM_001205262 // RefSeq // Homo sapiens RAD54 homolog B (S. cerevisiae)
(RAD54B), transc
NM_001008396 // RefSeq // Homo sapiens WD repeat and HMG-box DNA
binding protein 1 (WDH
NM_001310338 // RefSeq // Homo sapiens mitochondrial genome maintenance
exonuclease 1 (
NM_004984 // RefSeq // Homo sapiens kinesin family member 5A (KIF5A),
mRNA. // chr12 //
NM_178858 // RefSeq // Homo sapiens sideroflexin 2 (SFXN2), mRNA. // chr10 //
100 // 83
NM_001113490 // RefSeq // Homo sapiens angiomotin (AMOT), transcript variant
1, mRNA. /
NM_003878 // RefSeq // Homo sapiens gamma-glutamyl hydrolase (conjugase,
folylpolygamma
NM_017915 // RefSeq // Homo sapiens PARP1 binding protein (PARPBP),
mRNA. // chr12 // 1
NM_001308231 // RefSeq // Homo sapiens calcium binding tyrosine-(Y)phosphorylation reg
NM_001193493 // RefSeq // Homo sapiens solute carrier family 1
(glutamate/neutral amino
NM_176885 // RefSeq // Homo sapiens taste receptor, type 2, member 31
(TAS2R31), mRNA.
NM_001278603 // RefSeq // Homo sapiens nucleoporin 54kDa (NUP54),
transcript variant 2,
NM_020890 // RefSeq // Homo sapiens KIAA1524 (KIAA1524), mRNA. // chr3 //
100 // 88 //
NM_014621 // RefSeq // Homo sapiens homeobox D4 (HOXD4), mRNA. // chr2 //
100 // 58 //
NM_004629 // RefSeq // Homo sapiens Fanconi anemia, complementation group
G (FANCG), mR
NM_000933 // RefSeq // Homo sapiens phospholipase C, beta 4 (PLCB4),
transcript variant
NM_001166260 // RefSeq // Homo sapiens thyroid hormone receptor interactor 13
(TRIP13),
NM_152641 // RefSeq // Homo sapiens AT rich interactive domain 2 (ARID,
RFX-like) (ARID
NM_001160045 // RefSeq // Homo sapiens GLI family zinc finger 1 (GLI1),
transcript vari

-1.89843
-1.89717
-1.89649
-1.89617
-1.89362
-1.89189
-1.89113
-1.89109
-1.89068
-1.89014
-1.88981
-1.88922
-1.88758
-1.88685
-1.88681
-1.88542
-1.88414
-1.88245
-1.8816
-1.87955
-1.87808
-1.87685
-1.87651
-1.87627
-1.87597
-1.87416
-1.87409
-1.87288
-1.86893
-1.86851
-1.86727
-1.86307
-1.86176
-1.86078

120

CASC5
SLC6A8
GADD45B
DHFR
CENPW
MIR548O2
GTSE1
UBE2T
FAM46D
CCDC18
CEP295
GEN1
CHAF1A
ZNF681
CT47B1
CEP152
SGOL1-AS1
EXOSC1
COL12A1
HEG1
FEN1
ERCC6L
REEP4
ZNF100
SLC7A1
PIGP
RASA4B
ZNF492
FOSL1
RNASEH2B
KIF4A
LOC101929787
SLC16A10
RFC5

NM_144508 // RefSeq // Homo sapiens cancer susceptibility candidate 5
(CASC5), transcri
NM_001142805 // RefSeq // Homo sapiens solute carrier family 6
(neurotransmitter transp
NM_015675 // RefSeq // Homo sapiens growth arrest and DNA-damage-inducible,
beta (GADD4
NM_000791 // RefSeq // Homo sapiens dihydrofolate reductase (DHFR), transcript
variant
NM_001012507 // RefSeq // Homo sapiens centromere protein W (CENPW),
transcript variant
NR_039605 // RefSeq // Homo sapiens microRNA 548o-2 (MIR548O2),
microRNA. // chr20 // 1
NM_016426 // RefSeq // Homo sapiens G-2 and S-phase expressed 1 (GTSE1),
mRNA. // chr22
NM_001310326 // RefSeq // Homo sapiens ubiquitin-conjugating enzyme E2T
(UBE2T), transc
NM_001170574 // RefSeq // Homo sapiens family with sequence similarity 46,
member D (FA
NM_001306076 // RefSeq // Homo sapiens coiled-coil domain containing 18
(CCDC18), trans
NM_033395 // RefSeq // Homo sapiens centrosomal protein 295kDa (CEP295),
mRNA. // chr11
NM_001130009 // RefSeq // Homo sapiens GEN1 Holliday junction 5 flap
endonuclease (GEN1
NM_005483 // RefSeq // Homo sapiens chromatin assembly factor 1, subunit A
(p150) (CHAF
NM_138286 // RefSeq // Homo sapiens zinc finger protein 681 (ZNF681), mRNA.
// chr19 //
NM_001145718 // RefSeq // Homo sapiens cancer/testis antigen family 47,
member B1 (CT47
NM_001194998 // RefSeq // Homo sapiens centrosomal protein 152kDa
(CEP152), transcript
NR_132785 // RefSeq // Homo sapiens SGOL1 antisense RNA 1 (SGOL1-AS1),
long non-coding
NM_016046 // RefSeq // Homo sapiens exosome component 1 (EXOSC1),
mRNA. // chr10 // 100
NM_004370 // RefSeq // Homo sapiens collagen, type XII, alpha 1 (COL12A1),
transcript v
NM_020733 // RefSeq // Homo sapiens heart development protein with EGF-like
domains 1 (
NM_004111 // RefSeq // Homo sapiens flap structure-specific endonuclease 1
(FEN1), mRNA
NM_017669 // RefSeq // Homo sapiens excision repair cross-complementation
group 6-like
NM_025232 // RefSeq // Homo sapiens receptor accessory protein 4 (REEP4),
mRNA. // chr8
NM_173531 // RefSeq // Homo sapiens zinc finger protein 100 (ZNF100), mRNA.
// chr19 //
NM_003045 // RefSeq // Homo sapiens solute carrier family 7 (cationic amino acid
transp
NM_153681 // RefSeq // Homo sapiens phosphatidylinositol glycan anchor
biosynthesis, cl
ENST00000488284 // ENSEMBL // RAS p21 protein activator 4B
[gene_biotype:protein_coding
NM_020855 // RefSeq // Homo sapiens zinc finger protein 492 (ZNF492), mRNA.
// chr19 //
NM_001300844 // RefSeq // Homo sapiens FOS-like antigen 1 (FOSL1), transcript
variant 2
NM_001142279 // RefSeq // Homo sapiens ribonuclease H2, subunit B
(RNASEH2B), transcrip
NM_012310 // RefSeq // Homo sapiens kinesin family member 4A (KIF4A),
mRNA. // chrX //
XR_917210 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC101929787 (LOC1019297
NM_018593 // RefSeq // Homo sapiens solute carrier family 16 (aromatic amino
acid trans
NM_001130112 // RefSeq // Homo sapiens replication factor C (activator 1) 5,
36.5kDa (R

-1.86076
-1.85991
-1.85935
-1.85934
-1.859
-1.85846
-1.85696
-1.85677
-1.85511
-1.85401
-1.85271
-1.84863
-1.84837
-1.84784
-1.84425
-1.84363
-1.84356
-1.84285
-1.84184
-1.8418
-1.83949
-1.83925
-1.83588
-1.83552
-1.83206
-1.83136
-1.82887
-1.82851
-1.82848
-1.82733
-1.82716
-1.82688
-1.82569
-1.82462

121

NEMP1
RPS6KA3
C16orf58
SNORD114-31
MERTK
CDCA3
PABPC4
E2F8
CTGF
NCAPD2
FERMT2
ZEB2
LOC105379280
DUSP19
LOC105372906
SPC24
ARHGAP11B
SMC2
SMC1B
PCNA-AS1
MPV17L2
FBXL7
MMS22L
SGCB
TMPO
ZNF594
HM13-AS1
PLOD1
EMB
FANCM
PRKAA2
GNPDA1
DPYSL5
TACR3

NM_001130963 // RefSeq // Homo sapiens nuclear envelope integral membrane
protein 1 (NE
NM_004586 // RefSeq // Homo sapiens ribosomal protein S6 kinase, 90kDa,
polypeptide 3 (
NM_022744 // RefSeq // Homo sapiens chromosome 16 open reading frame 58
(C16orf58), mRN
NR_003224 // RefSeq // Homo sapiens small nucleolar RNA, C/D box 114-31
(SNORD114-31),
NM_006343 // RefSeq // Homo sapiens MER proto-oncogene, tyrosine kinase
(MERTK), mRNA.
NM_001297602 // RefSeq // Homo sapiens cell division cycle associated 3
(CDCA3), transc
NM_001135653 // RefSeq // Homo sapiens poly(A) binding protein, cytoplasmic 4
(inducibl
NM_001256371 // RefSeq // Homo sapiens E2F transcription factor 8 (E2F8),
transcript va
NM_001901 // RefSeq // Homo sapiens connective tissue growth factor (CTGF),
mRNA. // ch
NM_014865 // RefSeq // Homo sapiens non-SMC condensin I complex, subunit
D2 (NCAPD2), m
NM_001134999 // RefSeq // Homo sapiens fermitin family member 2 (FERMT2),
transcript va
NM_001171653 // RefSeq // Homo sapiens zinc finger E-box binding homeobox 2
(ZEB2), tra
XR_949107 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105379280 (LOC1053792
NM_001142314 // RefSeq // Homo sapiens dual specificity phosphatase 19
(DUSP19), transc
XR_920756 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105372906 (LOC1053729
NM_182513 // RefSeq // Homo sapiens SPC24, NDC80 kinetochore complex
component (SPC24),
NM_001039841 // RefSeq // Homo sapiens Rho GTPase activating protein 11B
(ARHGAP11B), m
NM_001042550 // RefSeq // Homo sapiens structural maintenance of
chromosomes 2 (SMC2),
NM_001291501 // RefSeq // Homo sapiens structural maintenance of
chromosomes 1B (SMC1B)
NR_028370 // RefSeq // Homo sapiens PCNA antisense RNA 1 (PCNA-AS1),
long non-coding RN
NM_032683 // RefSeq // Homo sapiens MPV17 mitochondrial membrane proteinlike 2 (MPV17L
NM_001278317 // RefSeq // Homo sapiens F-box and leucine-rich repeat protein 7
(FBXL7),
NM_198468 // RefSeq // Homo sapiens MMS22-like, DNA repair protein
(MMS22L), mRNA. // c
NM_000232 // RefSeq // Homo sapiens sarcoglycan, beta (43kDa dystrophinassociated glyc
NM_001032283 // RefSeq // Homo sapiens thymopoietin (TMPO), transcript
variant 2, mRNA.
NM_032530 // RefSeq // Homo sapiens zinc finger protein 594 (ZNF594), mRNA.
// chr17 //
NR_046853 // RefSeq // Homo sapiens HM13 antisense RNA 1 (HM13-AS1),
long non-coding RN
NM_000302 // RefSeq // Homo sapiens procollagen-lysine, 2-oxoglutarate 5dioxygenase 1
NM_198449 // RefSeq // Homo sapiens embigin (EMB), mRNA. // chr5 // 100 //
53 // 8 // 8
NM_001308133 // RefSeq // Homo sapiens Fanconi anemia, complementation
group M (FANCM),
NM_006252 // RefSeq // Homo sapiens protein kinase, AMP-activated, alpha 2
catalytic su
NM_005471 // RefSeq // Homo sapiens glucosamine-6-phosphate deaminase 1
(GNPDA1), mRNA.
NM_001253723 // RefSeq // Homo sapiens dihydropyrimidinase-like 5 (DPYSL5),
transcript
NM_001059 // RefSeq // Homo sapiens tachykinin receptor 3 (TACR3), mRNA. //
chr4 // 100

-1.82227
-1.82142
-1.82101
-1.82069
-1.81997
-1.81946
-1.81677
-1.81673
-1.81624
-1.8158
-1.81567
-1.81486
-1.81384
-1.81264
-1.80893
-1.80884
-1.80219
-1.79989
-1.79916
-1.79718
-1.7964
-1.79537
-1.79497
-1.79416
-1.79356
-1.79018
-1.7893
-1.78928
-1.7879
-1.78702
-1.78693
-1.78423
-1.78283
-1.78228
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GMNN
KIF23
LRCH2
ATAD2
PHF19
GPLD1
HIST2H2AB
ZP3
SLC25A35
LYRM4-AS1
ZNF75D
STC2
TRAJ5
KIAA0101
C17orf53
PROCR
HIST2H2BB
LOC105375974
POLD2
ESPL1
MYPN
CENPP
SNRPN
PMP22
PPP4R4
SLC35G5
ADAM23
ZNF480
PLEKHH2
SCOC-AS1
VBP1
THAP9
ASRGL1
MBNL3

NM_001251989 // RefSeq // Homo sapiens geminin, DNA replication inhibitor
(GMNN), trans
NM_001281301 // RefSeq // Homo sapiens kinesin family member 23 (KIF23),
transcript var
NM_001243963 // RefSeq // Homo sapiens leucine-rich repeats and calponin
homology (CH)
NM_014109 // RefSeq // Homo sapiens ATPase family, AAA domain containing 2
(ATAD2), mRN
NM_001009936 // RefSeq // Homo sapiens PHD finger protein 19 (PHF19),
transcript varian
NM_001503 // RefSeq // Homo sapiens glycosylphosphatidylinositol specific
phospholipase
NM_175065 // RefSeq // Homo sapiens histone cluster 2, H2ab (HIST2H2AB),
mRNA. // chr1
NM_001110354 // RefSeq // Homo sapiens zona pellucida glycoprotein 3 (sperm
receptor) (
NM_201520 // RefSeq // Homo sapiens solute carrier family 25, member 35
(SLC25A35), mRN
NR_126016 // RefSeq // Homo sapiens LYRM4 antisense RNA 1 (LYRM4-AS1),
transcript varia
NM_001185063 // RefSeq // Homo sapiens zinc finger protein 75D (ZNF75D),
transcript var
NM_003714 // RefSeq // Homo sapiens stanniocalcin 2 (STC2), mRNA. // chr5 //
100 // 71
OTTHUMT00000410993 // Havana transcript // T cell receptor alpha joining
5[gene_biotype
NM_001029989 // RefSeq // Homo sapiens KIAA0101 (KIAA0101), transcript
variant 2, mRNA.
NM_001171251 // RefSeq // Homo sapiens chromosome 17 open reading frame 53
(C17orf53),
NM_006404 // RefSeq // Homo sapiens protein C receptor, endothelial (PROCR),
mRNA. // c
OTTHUMT00000098433 // Havana transcript // histone cluster 2, H2bb
(pseudogene)[gene_bi
XR_929476 // RefSeq // PREDICTED: Homo sapiens uncharacterized
LOC105375974 (LOC1053759
NM_001127218 // RefSeq // Homo sapiens polymerase (DNA directed), delta 2,
accessory su
NM_012291 // RefSeq // Homo sapiens extra spindle pole bodies like 1, separase
(ESPL1),
NM_001256267 // RefSeq // Homo sapiens myopalladin (MYPN), transcript
variant 4, mRNA.
NM_001012267 // RefSeq // Homo sapiens centromere protein P (CENPP),
transcript variant
AF400486 // GenBank // Homo sapiens clone kid4 SNURF-SNRPN mRNA,
downstream untranslate
NM_000304 // RefSeq // Homo sapiens peripheral myelin protein 22 (PMP22),
transcript va
NM_020958 // RefSeq // Homo sapiens protein phosphatase 4, regulatory subunit 4
(PPP4R4
OTTHUMT00000207313 // Havana transcript // solute carrier family 35, member
G5[gene_bio
NM_003812 // RefSeq // Homo sapiens ADAM metallopeptidase domain 23
(ADAM23), mRNA. //
NM_001297624 // RefSeq // Homo sapiens zinc finger protein 480 (ZNF480),
transcript var
NM_172069 // RefSeq // Homo sapiens pleckstrin homology domain containing,
family H (wi
NR_033939 // RefSeq // Homo sapiens SCOC antisense RNA 1 (SCOC-AS1),
long non-coding RN
NM_001303543 // RefSeq // Homo sapiens von Hippel-Lindau binding protein 1
(VBP1), tran
NM_024672 // RefSeq // Homo sapiens THAP domain containing 9 (THAP9),
mRNA. // chr4 //
NM_001083926 // RefSeq // Homo sapiens asparaginase like 1 (ASRGL1),
transcript variant
NM_001170701 // RefSeq // Homo sapiens muscleblind-like splicing regulator 3
(MBNL3), t

-1.78099
-1.77925
-1.7786
-1.77827
-1.77812
-1.77769
-1.77599
-1.7751
-1.77356
-1.77335
-1.77287
-1.77274
-1.77194
-1.76817
-1.76815
-1.76695
-1.76424
-1.76331
-1.76292
-1.76247
-1.76247
-1.76236
-1.76199
-1.76135
-1.76088
-1.76033
-1.75982
-1.75973
-1.7586
-1.75854
-1.75736
-1.7554
-1.75434
-1.75387
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NCAPD3
SLC47A1
CCNJ

NM_015261 // RefSeq // Homo sapiens non-SMC condensin II complex, subunit
D3 (NCAPD3),
NM_018242 // RefSeq // Homo sapiens solute carrier family 47 (multidrug and
toxin extru
NM_001134375 // RefSeq // Homo sapiens cyclin J (CCNJ), transcript variant 1,
mRNA. //

-1.75143
-1.75051
-1.75014

Appendix Table 3 Expression of MMP1 or MMP14 microRNAs in microarray
Gene Symbol

Target

MIR9-1

MMP14

MIR146A

MMP1

MIR22HG

MMP14

MIR133A1

MMP14

MIR34A

MMP1

MIR222

MMP1

Assignment
NR_029691 // RefSeq // Homo sapiens microRNA 9-1 (MIR9-1),
microRNA. // chr1 // 100 //
NR_029701 // RefSeq // Homo sapiens microRNA 146a (MIR146A),
microRNA. // chr5 // 100 /
NR_028502 // RefSeq // Homo sapiens MIR22 host gene (MIR22HG),
transcript variant 1, lo
NR_029675 // RefSeq // Homo sapiens microRNA 133a-1
(MIR133A1), microRNA. // chr18 // 1
NR_029610 // RefSeq // Homo sapiens microRNA 34a (MIR34A),
microRNA. // chr1 // 100 //
NR_029636 // RefSeq // Homo sapiens microRNA 222 (MIR222),
microRNA. // chrX // 100 //

Average
Fold-Change

1.44411
1.15373
1.1216
-1.04109
-1.13227
-1.65699

Appendix Table 4 Expression of MMP activity regulators in microarray
Gene Symbol

Assignment

TIMP2

NM_003255 // RefSeq // Homo sapiens TIMP metallopeptidase inhibitor 2 (TIMP2),
mRNA. //
NM_003254 // RefSeq // Homo sapiens TIMP metallopeptidase inhibitor 1 (TIMP1),
mRNA. //
NM_003256 // RefSeq // Homo sapiens TIMP metallopeptidase inhibitor 4 (TIMP4),
mRNA. //
NM_000362 // RefSeq // Homo sapiens TIMP metallopeptidase inhibitor 3 (TIMP3),
mRNA. //
NM_001289823 // RefSeq // Homo sapiens furin (paired basic amino acid cleaving
enzyme)
NM_000301 // RefSeq // Homo sapiens plasminogen (PLG), transcript variant 1,
mRNA. // c

TIMP1
TIMP4
TIMP3
FURIN
PLG

Average FoldChange

1.25805
1.13388
1.09581
-1.0215333
-1.07985
-1.10423

Appendix Table 5 Expression of EMT regulating microRNAs microarray
Gene Symbol

Target

MIR30A

SNAIL

MIR101-1

CDH1

MIR200B

ZEB1/2

MIR200C

ZEB1/2

MIR22HG

SNAIL

MIR200A

ZEB1/2

MIR429

ZEB1/2

MIR205HG

ZEB1/2

MIR141

ZEB1/2

MIR9-3

CDH1

Assignment
NR_029504 // RefSeq // Homo sapiens microRNA 30a (MIR30A),
microRNA. // chr6 // 100 //
NR_029516 // RefSeq // Homo sapiens microRNA 101-1 (MIR101-1),
microRNA. // chr1 // 100
NR_029639 // RefSeq // Homo sapiens microRNA 200b (MIR200B),
microRNA. // chr1 // 100 /
NR_029779 // RefSeq // Homo sapiens microRNA 200c (MIR200C),
microRNA. // chr12 // 100
NR_028502 // RefSeq // Homo sapiens MIR22 host gene (MIR22HG),
transcript variant 1, lo
NR_029834 // RefSeq // Homo sapiens microRNA 200a (MIR200A),
microRNA. // chr1 // 100 /
NR_029957 // RefSeq // Homo sapiens microRNA 429 (MIR429),
microRNA. // chr1 // 100 //
NM_001104548 // RefSeq // Homo sapiens MIR205 host gene
(MIR205HG), mRNA. // chr1 // 10
NR_029682 // RefSeq // Homo sapiens microRNA 141 (MIR141),
microRNA. // chr12 // 100 //
NR_029692 // RefSeq // Homo sapiens microRNA 9-3 (MIR9-3),
microRNA. // chr15 // 100 //

Average
Fold-Change

1.6762
1.53542
1.22807
1.18659
1.1216
1.07458
1.01476
-1.11731
-1.25733
-1.52468
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